

WEST Search History

DATE: Wednesday, September 15, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L15	L14 AND cyclin	54
<input type="checkbox"/>	L14	L13 AND fusion protein	214
<input type="checkbox"/>	L13	L12 AND SV40	249
<input type="checkbox"/>	L12	VP22	521
<input type="checkbox"/>	L11	L10 AND VP22	79
<input type="checkbox"/>	L10	530/300,350.CCLS.	16925
<input type="checkbox"/>	L9	L7 AND SV40	54
<input type="checkbox"/>	L8	L7 AND cyclin	18
<input type="checkbox"/>	L7	L6 AND VP22	70
<input type="checkbox"/>	L6	435/69.1.CCLS.	19087
<input type="checkbox"/>	L5	Cardoso.IN.	395
<input type="checkbox"/>	L4	Cardoso-M.IN.	4
<input type="checkbox"/>	L3	Leonhardt.IN.	998
<input type="checkbox"/>	L2	Leonhardt-H.IN.	46
<input type="checkbox"/>	L1	(Leonhardt-Heinrich.IN.)	2

END OF SEARCH HISTORY

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 70 of 70 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 70

File: PGPB

Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 2. Document ID: US 20040142892 A1

L7: Entry 2 of 70

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040142892 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 514/44; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for

h e b b g e e f e h e e f b e

expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040132088 A1

L7: Entry 3 of 70

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040132033 A1

L7: Entry 4 of 70

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132033

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132033 A1

TITLE: Human heparanase gene regulatory sequences

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Elizabeth J.	Orinda	CA	US	
Wolffe, Alan P.	Orinda	CA	US	
Qi, Hong	Cottonwood	CA	US	

US-CL-CURRENT: 435/6; 435/200, 435/320.1, 435/325, 435/69.1, 536/21, 536/23.2

ABSTRACT:

Nucleotide sequences comprising regulatory regions of the human heparanase gene are provided. Also provided are methods and compositions for regulating heparanase expression, as well as methods and compositions for using heparanase sequences to regulate a heterologous target gene.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

5. Document ID: US 20040115770 A1

L7: Entry 5 of 70

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma

membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 6. Document ID: US 20040063907 A1

L7: Entry 6 of 70

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 7. Document ID: US 20040058881 A1

L7: Entry 7 of 70

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMI	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 8. Document ID: US 20040038338 A1

L7: Entry 8 of 70

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or

h e b b g e e f e h e e f b e

amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Publ	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 9. Document ID: US 20040034199 A1

L7: Entry 9 of 70

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040034199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040034199 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A	Bainbridge Island		GB	
Cosman, David J.	Bainbridge Island		GB	

US-CL-CURRENT: 530/358; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Publ	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 10. Document ID: US 20040002455 A1

L7: Entry 10 of 70

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	

h e b b g e e f e h e e f b e

Guo, Yong	Freshmeadows	NJ	US
Cheng, Su	Bridgewater		US

US-CL-CURRENT: [514/12](#); [435/320.1](#), [435/325](#), [435/69.1](#), [530/350](#), [536/23.2](#)

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMI	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 11. Document ID: US 20030235575 A1

L7: Entry 11 of 70

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235575

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235575 A1

TITLE: Identification of oligoadenylate synthetase-like genes

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matzuk, Martin M.	Pearland	TX	US	
Bai, Yuchen	Newtown	PA	US	
Yan, Wei	Houston	TX	US	

US-CL-CURRENT: [424/94.61](#); [435/199](#), [435/320.1](#), [435/325](#), [435/6](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMI	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 12. Document ID: US 20030229019 A1

L7: Entry 12 of 70

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229019

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229019 A1

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burke, James R.	Chapel Hill	NC	US	
Strittmatter, Warren J.	Durham	NC	US	
Nagai, Yoshitaka	Osaka		JP	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 435/7.1, 514/44, 530/324, 536/23.1

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NAME	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20030224444 A1

L7: Entry 13 of 70

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224444

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224444 A1

TITLE: Antibodies to native conformations of membrane proteins

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.1; 435/326, 435/69.1, 530/387.1

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NAME	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20030219859 A1

L7: Entry 14 of 70

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMOC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20030204069 A1

L7: Entry 15 of 70

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204069
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030204069 A1

TITLE: Segments of the human gene for telomerase reverse transcriptase

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morin, Gregg B.	Toronto	NV	CA	
Andrews, William H.	Reno		US	

US-CL-CURRENT: 536/23.2; 435/199, 435/320.1, 435/325, 435/456, 435/6, 435/69.1

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful

for treatment of diseases such as cancers.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 16. Document ID: US 20030198626 A1

L7: Entry 16 of 70

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198626

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030198626 A1

TITLE: Inhibition of Ii expression in mammalian cells

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xu, Minzhen	Northborough	MA	US	
Humphreys, Robert	Acton	MA	US	

US-CL-CURRENT: 424/93.21; 435/320.1, 435/366, 435/456, 435/69.1, 536/23.5

ABSTRACT:

The present invention is directed toward composition and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. More specifically, disclosed are compositions and methods which relate to MHC Class II molecule presentation of antigenic epitopes which, under normal circumstances, would not be presented in association with MHC Class II molecules. The invention relates to presentation in cells which normally express MHC Class II molecules, as well as cells which can be induced to express MHC Class II molecules.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 17. Document ID: US 20030194727 A1

L7: Entry 17 of 70

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	

h e b b g e e f e h e e f b e

Lee, Horim	Chungcheongnam-do	KR
Lee, Seong-Il	Yuseong-gu	KR
Yang, Hyo-Young	Yuseong-gu	KR
Lee, Yangsoon	Yuseong-gu	KR
Jang, Young-Soon	Yuseong-gu	KR

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20030175920 A1

L7: Entry 18 of 70

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175920

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030175920 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 435/184; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030171318 A1

L7: Entry 19 of 70

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171318

h e b b g e e f e h e e f b e

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030171318 A1

TITLE: Composition and method for treating viral infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 514/44; 424/186.1, 435/6, 435/69.1, 514/12

ABSTRACT:

Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 20. Document ID: US 20030170871 A1

L7: Entry 20 of 70

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170871

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170871 A1

TITLE: Alphavirus-based vectors for persistent infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dubensky, Thomas W. JR.	Piedmont	CA	US	
Polo, John M.	Hayward	CA	US	
Perri, Silvia	Castro Valley	CA	US	
Belli, Barbara	San Diego	CA	US	

US-CL-CURRENT: 435/235.1; 424/93.21, 435/325, 435/456, 435/69.1, 536/23.72

ABSTRACT:

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein 2 gene which, when operably incorporated into an alphavirus replicon particle, eukaryotic layered vector initiation system, alphavirus vector construct or RNA vector replicon, provides a noncytopathic phenotype or confers the ability to establish persistent replication. Also disclosed are RNA vector replicons, alphavirus vector constructs, alphavirus replicon particles and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules, as well as methods of using such replicons, constructs, particles and eukaryotic layered vector initiation systems for expression of recombinant proteins.

h e b b g e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 21. Document ID: US 20030166141 A1

L7: Entry 21 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 22. Document ID: US 20030166099 A1

L7: Entry 22 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166099

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166099 A1

TITLE: Minicells comprising membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	
Segall, Anca M.	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/69.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 23. Document ID: US 20030165945 A1

L7: Entry 23 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 24. Document ID: US 20030152945 A1

L7: Entry 24 of 70

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152945

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	

h e b b g e e e f e h e e f b e

Glover, David Moore	Sandy	GB
Midgley, Carol	Milton Keynes	GB

US-CL-CURRENT: [435/6](#); [435/183](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 25. Document ID: US 20030148265 A1

L7: Entry 25 of 70

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148265

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030148265 A1

TITLE: Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brooks, Timothy John Gilby	Wiltshire		GB	
Duggan, Jacqueline Marie	Wiltshire		GB	

US-CL-CURRENT: [435/5](#); [424/159.1](#), [435/235.1](#), [435/252.3](#), [435/320.1](#), [435/69.1](#), [530/388.3](#)

ABSTRACT:

A protein conjugate comprising conjugate comprising a first region comprising a factor that permits translocation of a protein across a cell membrane; and a second region comprising a single-chain antibody fragment which has affinity for a viral protein, in particular a viral protein which is necessary for replication of a virus such as a flavivirus.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 26. Document ID: US 20030143681 A1

L7: Entry 26 of 70

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030143681 A1

h e b b g e e e f e h e e f b e

TITLE: Human ataxin-1-like polypeptide IMX97018

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, Dirk M.	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/199, 435/254.2, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.

Full	Title	Classen	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	---------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 27. Document ID: US 20030119771 A1

L7: Entry 27 of 70

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 28. Document ID: US 20030118611 A1

L7: Entry 28 of 70

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Corey, Lawrence	Seattle	WA	US	

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1,
435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 29. Document ID: US 20030108886 A1

L7: Entry 29 of 70

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108886

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108886 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	

MacLachlan, Ian

Vancouver

CA

US-CL-CURRENT: [435/6](#); [435/199](#), [435/252.3](#), [435/320.1](#), [435/69.1](#), [514/44](#), [536/23.2](#)

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KBAC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 30. Document ID: US 20030108880 A1

L7: Entry 30 of 70

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: [435/6](#); [435/226](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KBAC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 31. Document ID: US 20030104526 A1

L7: Entry 31 of 70

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104526

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104526 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

h e b b g e e e f e h e e f b e

US-CL-CURRENT: [435/69.1](#); [435/226](#), [435/320.1](#), [435/325](#), [435/6](#), [536/23.2](#)

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 32. Document ID: US 20030103992 A1

L7: Entry 32 of 70

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030103992

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030103992 A1

TITLE: Clasp membrane proteins

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: [424/185.1](#); [435/226](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

The present invention relates to cell surface molecules, designated cadherin-like asymmetry proteins ("CLASPs"). In particular, it relates to CLASP polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 33. Document ID: US 20030100093 A1

L7: Entry 33 of 70

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100093

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030100093 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/199; 435/320.1, 435/325, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 34. Document ID: US 20030096344 A1

L7: Entry 34 of 70

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096344

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030096344 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche 25	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/199, 435/320.1, 435/325

ABSTRACT:

The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to

h e b b g e e e f e h e e f b e

pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Know	Draft Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 35. Document ID: US 20030087411 A1

L7: Entry 35 of 70

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Know	Draft Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 36. Document ID: US 20030077827 A1

L7: Entry 36 of 70

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077827 A1

TITLE: Surface transfection and expression procedure

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uhler, Michael D.	Ann Arbor	MI	US	

US-CL-CURRENT: 435/455; 435/325, 435/6, 435/69.1

h e b b g e e f e h e e f b e

ABSTRACT:

The present invention relates to a method of transfecting cells comprising applying cells directly onto nucleic acids which are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the nucleic acids are immobilized in an array. In another aspect of the present invention, the method further includes expression of the nucleic acids in the transfected cells. In yet another aspect of the present invention, the method further comprises detecting the expression of the nucleic acids in the transfected cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 37. Document ID: US 20030068675 A1

L7: Entry 37 of 70

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068675

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068675 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/6, 702/19

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 38. Document ID: US 20030049602 A1

L7: Entry 38 of 70

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

h e b b g e e e f e h e e f b e

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 39. Document ID: US 20030044404 A1

L7: Entry 39 of 70

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044404

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044404 A1

TITLE: Regulation of angiogenesis with zinc finger proteins

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	
Liu, Qiang	Foster City	CA	US	
Liu, Pei-Qi	Richmond	CA	US	
Wolffe, Alan	Orinda	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric	Boulder	CO	US	

US-CL-CURRENT: 424/94.63; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger

h e b b g e e e f e h e e f b e

proteins or nucleic acids encoding them are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 40. Document ID: US 20030040038 A1

L7: Entry 40 of 70

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040038

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030040038 A1

TITLE: INDUCIBLE REGULATORY SYSTEM AND USE THEREOF

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DOWDY, STEVEN F.	CLAYTON	MO	US	
JESSEE, JOEL A.	MOUNT AIRY	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455

ABSTRACT:

The present invention provides an inducible regulatory system in which transcription of a target nucleotide sequence in a host cell is activated by the introduction of a fusion protein having a transcription activator region and a protein transduction domain for entry of the fusion protein into the cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 41. Document ID: US 20030036163 A1

L7: Entry 41 of 70

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

h e b b g e e e f e h e e f b e

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBL	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 42. Document ID: US 20030008324 A1

L7: Entry 42 of 70

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBL	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 43. Document ID: US 20020177152 A1

L7: Entry 43 of 70

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

h e b b g e e e f e h e e f b e

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: [435/6](#); [435/189](#), [435/320.1](#), [435/325](#), [435/69.1](#)

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 44. Document ID: US 20020173026 A1

L7: Entry 44 of 70

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: [435/199](#); [435/226](#), [435/320.1](#), [435/325](#), [435/69.1](#)

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 45. Document ID: US 20020169283 A1

L7: Entry 45 of 70

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283

h e b b g e e e f e h e e f b e

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 46. Document ID: US 20020168683 A1

L7: Entry 46 of 70

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 47. Document ID: US 20020155432 A1

L7: Entry 47 of 70

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: 435/5; 424/199.1, 424/205.1, 424/229.1, 435/320.1, 435/69.1

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one additional pharmacological agent or surgical procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	WMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 48. Document ID: US 20020146788 A1

L7: Entry 48 of 70

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146788
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146788 A1

TITLE: Artificial endonuclease

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franklin, Sonya	Iowa City	IA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention provides artificial endonucleases and methods to prepare and

h e b b g e e f e h e e f b e

use those endonucleases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 49. Document ID: US 20020106676 A1

L7: Entry 49 of 70

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106676

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106676 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 50. Document ID: US 20020102267 A1

L7: Entry 50 of 70

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102267

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102267 A1

TITLE: CLASP-5 transmembrane protein

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	

h e b b g e e f e h e e f b e

Candia, Albert F. III Menlo Park CA US

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-5 ("CLASP-5"). In particular, it relates to CLASP-5 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-5 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 51. Document ID: US 20020086382 A1

L7: Entry 51 of 70

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086382

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086382 A1

TITLE: Clasp-3 transmembrane protein

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-3 ("CLASP-3"). In particular, it relates to CLASP-3 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-3 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 52. Document ID: US 20020086361 A1

L7: Entry 52 of 70

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

h e b b g e e e f e he ef b e

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 53. Document ID: US 20020061296 A1

L7: Entry 53 of 70

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061296

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061296 A1

TITLE: Delivery method for the tumor specific apoptosis inducing activity of apoptin

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Noteborn, Mathieu H.M.	Leiderdrop		NL	
Voorhoeve, Pieter M.	Amsterdam		NL	
Zhang, Ying-Hui	Leiden		NL	
Leliveld, Sirik R.	Leiden		NL	

US-CL-CURRENT: 424/93.21; 424/94.63, 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, auto-immune-derived cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

54. Document ID: US 20020039765 A1

L7: Entry 54 of 70

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	AMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

55. Document ID: US 20020001805 A1

L7: Entry 55 of 70

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-

h e b b g e e f e h e e f b e

dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 56. Document ID: US 6780986 B1

L7: Entry 56 of 70

File: USPT

Aug 24, 2004

US-PAT-NO: 6780986

DOCUMENT-IDENTIFIER: US 6780986 B1

TITLE: RIP60 nucleic acid and polypeptide sequences and uses therefor

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heintz; Nicholas H.	Jericho	VT		
Houchens; Christopher R.	Baltimore	MD		

US-CL-CURRENT: 536/23.5; 435/455, 435/69.1, 435/71.1, 435/91.4, 536/23.1

ABSTRACT:

The invention relates to nucleic acids and encoded polypeptides from the human zinc finger protein RIP60. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, fragments of the foregoing including functional fragments and variants. Kits containing the foregoing molecules additionally are provided.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 57. Document ID: US 6777185 B2

L7: Entry 57 of 70

File: USPT

Aug 17, 2004

US-PAT-NO: 6777185

DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

h e b b g e e e f e h e e f b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Class	Front	Review	Classification	Date	Reference			Claims	KWC	Drawing Desc
------	-------	-------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------------

☐ 58. Document ID: US 6723512 B2

L7: Entry 58 of 70

File: USPT

Apr 20, 2004

US-PAT-NO: 6723512

DOCUMENT-IDENTIFIER: US 6723512 B2

TITLE: METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS THAT FACILITATE INTERNALIZATION AND TRANSGENE EXPRESSION AND CELLS OR TISSUES COMPETENT FOR THE SAME AND METHODS FOR EVOLVING GENE DELIVERY VECTORS

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larocca; David	Encinitas	CA		
Kassner; Paul	San Mateo	CA		
Baird; Andrew	San Diego	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/5, 435/69.1, 435/DIG.14, 435/DIG.15, 435/DIG.2, 435/DIG.35, 435/DIG.4, 536/23.1

ABSTRACT:

A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, transduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the

nucleus, endosome, chloroplast, mitochondria, etc.

33 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	AmC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 59. Document ID: US 6703487 B2

L7: Entry 59 of 70

File: USPT

Mar 9, 2004

US-PAT-NO: 6703487

DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324,
530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	AmC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 60. Document ID: US 6660259 B2

L7: Entry 60 of 70

File: USPT

Dec 9, 2003

US-PAT-NO: 6660259

DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

h e b b g e e f e h e e f b e

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIND	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 61. Document ID: US 6653102 B2

L7: Entry 61 of 70

File: USPT

Nov 25, 2003

US-PAT-NO: 6653102

DOCUMENT-IDENTIFIER: US 6653102 B2

TITLE: Nucleic acid encoding a phosphatase 2C that interacts with Fe 65

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roch; Jean-Marc	Salt Lake City	UT		
Bartel; Paul L.	Salt Lake City	UT		
Heichman; Karen	Salt Lake City	UT		
Mauck; Kimberly	Sandy	UT		
Dufford; Max	Salt Lake City	UT		

US-CL-CURRENT: 435/69.1; 435/183, 435/252.3, 435/254.11, 435/254.2, 435/320.1,
435/325, 536/23.5

ABSTRACT:

The present invention relates to the discovery of protein--protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

4 Claims, 0 Drawing figures

Exemplary Claim Number: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIND	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 62. Document ID: US 6649158 B1

L7: Entry 62 of 70

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158

DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Drawing Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------------

☐ 63. Document ID: US 6635244 B2

L7: Entry 63 of 70

File: USPT

Oct 21, 2003

US-PAT-NO: 6635244

DOCUMENT-IDENTIFIER: US 6635244 B2

TITLE: Adenovirus E1B-55K single amino acid mutants and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shen; Yuqiao	Richmond	CA		
Nye; Julie	Berkeley	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.6, 435/235.1, 435/320.1, 435/455, 435/456, 435/69.1, 435/91.4, 435/91.41, 536/23.1

h e b b g e e f e h e e f b e

ABSTRACT:

Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.

7 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	-----------

☐ 64. Document ID: US 6485977 B1

L7: Entry 64 of 70

File: USPT

Nov 26, 2002

US-PAT-NO: 6485977

DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	-----------

☐ 65. Document ID: US 6475789 B1

L7: Entry 65 of 70

File: USPT

Nov 5, 2002

US-PAT-NO: 6475789

DOCUMENT-IDENTIFIER: US 6475789 B1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cech; Thomas R.	Boulder	CO		
Lingner; Joachim	Epalinges			CH
Nakamura; Toru	Boulder	CO		
Chapman; Karen B.	Sausalito	CA		
Morin; Gregg B.	Palo Alto	CA		
Harley; Calvin B.	Palo Alto	CA		
Andrews; William H.	Richmond	CA		

US-CL-CURRENT: 435/366; 424/94.1, 435/320.1, 435/69.1, 536/23.2

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

8 Claims, 40 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

Pub	Title	Citation	Front	Review	Classification	Date	Reference			Claims	AMC	Draw Desc
-----	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 66. Document ID: US 6472176 B2

L7: Entry 66 of 70

File: USPT

Oct 29, 2002

US-PAT-NO: 6472176

DOCUMENT-IDENTIFIER: US 6472176 B2

TITLE: Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kovesdi; Imre	Rockville	MD		
Bruder; Joseph T.	Ijamsville	MD		

h e b b g e e f e h e e f b e

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 435/69.7, 435/69.8, 536/23.1, 536/23.2, 536/23.4, 536/23.5, 536/23.7, 536/24.1

ABSTRACT:

The invention pertains to a polynucleotide encoding a chimeric protein comprising an endoplasmic reticulum localization signal peptide, a transport moiety, and a moiety of interest, wherein the endoplasmic reticulum localization signal peptide, the transport moiety, and the moiety of interest are operably linked with each other, a vector comprising the polynucleotide, a cell comprising such a vector, and a method of expressing a protein comprising the transport moiety and the moiety of interest.

25 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KARC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 67. Document ID: US 6451579 B1

L7: Entry 67 of 70

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KARC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 68. Document ID: US 6413518 B1

L7: Entry 68 of 70

File: USPT

Jul 2, 2002

h e b b g e e e f e h e e f b e

US-PAT-NO: 6413518

DOCUMENT-IDENTIFIER: US 6413518 B1

**** See image for Certificate of Correction ****

TITLE: Immunologically significant herpes simplex virus antigens and methods for identifying and using same

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Chen; Hongbo	Shoreline	WA		
Corey; Lawrence	Mercer Island	WA		
Hosken; Nancy Ann	Seattle	WA		
McGowan; Patrick	Seattle	WA		
Fling; Steven P.	Bainbridge Island	WA		
Posavad; Christine M.	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/184.1, 424/192.1, 424/231.1, 435/69.1, 435/69.3, 435/91.1, 435/91.4, 536/23.5

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

12 Claims, 56 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	----------

☐ 69. Document ID: US 6350572 B1

L7: Entry 69 of 70

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572

DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL

h e b b g e e e f e h e e f b e

Record List Display

Zwijssen; Renate

Utrecht

NL

US-CL-CURRENT: 435/4; 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2,
435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Publ	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 70. Document ID: US 6313269 B1

L7: Entry 70 of 70

File: USPT

Nov 6, 2001

US-PAT-NO: 6313269

DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures

Exemplary Claim Number: 1

h e b b g e e e f e h e e f b e

Full	Title	Citation	Print	Review	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L6 AND VP22	70

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 18 of 18 returned.

☐ 1. Document ID: US 20040002455 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 18

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full	Title	Citation	Front	****	Classification	Date	Reference	Sequences	Attachments	Claims	INOC	Draw Des.
------	-------	----------	-------	------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 2. Document ID: US 20030194727 A1

L8: Entry 2 of 18

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	
Lee, Horim	Chungcheongnam-do		KR	

Lee, Seong-Il	Yuseong-gu	KR
Yang, Hyo-Young	Yuseong-gu	KR
Lee, Yangsoon	Yuseong-gu	KR
Jang, Young-Soon	Yuseong-gu	KR

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20030166141 A1

L8: Entry 3 of 18

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20030152945 A1

L8: Entry 4 of 18

File: PGPB

Aug 14, 2003

h e b b g e e e f e h e e f b e

PGPUB-DOCUMENT-NUMBER: 20030152945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	
Glover, David Moore	Sandy		GB	
Midgley, Carol	Milton Keynes		GB	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 5. Document ID: US 20030108880 A1

L8: Entry 5 of 18

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 6. Document ID: US 20030087411 A1

h e b b g e e e f e h e e f b e

L8: Entry 6 of 18

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	MMAC	Draw Des
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20030049602 A1

L8: Entry 7 of 18

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

h e b b g e e e f e h e e f b e

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	PubC	Draw Des
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20030036163 A1

L8: Entry 8 of 18

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	PubC	Draw Des
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20030008324 A1

L8: Entry 9 of 18

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	Keywords	Drawings
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	----------	----------

☐ 10. Document ID: US 20020177152 A1

L8: Entry 10 of 18

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	Keywords	Drawings
------	-------	----------	-------	----------------	------	-----------	-----------	-------------	--------	----------	----------

☐ 11. Document ID: US 20020173026 A1

L8: Entry 11 of 18

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: [435/199](#); [435/226](#), [435/320.1](#), [435/325](#), [435/69.1](#)

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLCL1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	RWD	Draw Desc
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 12. Document ID: US 20020155432 A1

L8: Entry 12 of 18

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: [435/5](#); [424/199.1](#), [424/205.1](#), [424/229.1](#), [435/320.1](#), [435/69.1](#)

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one additional pharmacological agent or surgical procedure.

Full	Title	Citation	Front	Classification	Date	Reference	Sequences	Attachments	Claims	RWD	Draw Desc
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

13. Document ID: US 6777185 B2

L8: Entry 13 of 18

File: USPT

Aug 17, 2004

US-PAT-NO: 6777185

DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Classen	Front	****	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	---------	-------	------	----------------	------	-----------	--	--	--------	-----	-----------

14. Document ID: US 6660259 B2

L8: Entry 14 of 18

File: USPT

Dec 9, 2003

US-PAT-NO: 6660259

DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells.

h e b b g e e f e h e e f b e

Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Classification	Date	Reference	Claims	KeyC	Draw Desc
------	-------	----------	-------	----------------	------	-----------	--------	------	-----------

☐ 15. Document ID: US 6649158 B1

L8: Entry 15 of 18

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Classification	Date	Reference	Claims	KeyC	Draw Desc
------	-------	----------	-------	----------------	------	-----------	--------	------	-----------

☐ 16. Document ID: US 6485977 B1

L8: Entry 16 of 18

File: USPT

Nov 26, 2002

US-PAT-NO: 6485977
DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

h e b b g e e f e h e e f b e

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Class	Classification	Date	Reference	Claims	KBAC	Draw. Desc.
------	-------	----------	-------	-------	----------------	------	-----------	--------	------	-------------

17. Document ID: US 6451579 B1

L8: Entry 17 of 18

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and

subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	****	Classification	Date	Reference			Claims	KeyC	Draw Desc
------	-------	----------	-------	------	----------------	------	-----------	--	--	--------	------	-----------

☐ 18. Document ID: US 6350572 B1

L8: Entry 18 of 18

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572

DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijssen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4, 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	****	Classification	Date	Reference			Claims	KeyC	Draw Desc
------	-------	----------	-------	------	----------------	------	-----------	--	--	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L7 AND cyclin	18

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 54 of 54 returned.

☐ 1. Document ID: US 20040142892 A1

Using default format because multiple data bases are involved.

L9: Entry 1 of 54

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040142892 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 514/44; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIID	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040132088 A1

L9: Entry 2 of 54

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

h e b b g e e e f e h e e f b e

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040132033 A1

L9: Entry 3 of 54

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132033

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132033 A1

TITLE: Human heparanase gene regulatory sequences

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Elizabeth J.	Orinda	CA	US	
Wolffe, Alan P.	Orinda	CA	US	
Qi, Hong	Cottonwood	CA	US	

US-CL-CURRENT: 435/6; 435/200, 435/320.1, 435/325, 435/69.1, 536/21, 536/23.2

ABSTRACT:

Nucleotide sequences comprising regulatory regions of the human heparanase gene are provided. Also provided are methods and compositions for regulating heparanase expression, as well as methods and compositions for using heparanase sequences to regulate a heterologous target gene.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040115770 A1

L9: Entry 4 of 54

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

h e b b g e e f e h e e f b e

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KDD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 5. Document ID: US 20040063907 A1

L9: Entry 5 of 54

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

h e b b g e e e f e h e e f b e

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBL	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 6. Document ID: US 20040034199 A1

L9: Entry 6 of 54

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040034199

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040034199 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A	Bainbridge Island		GB	
Cosman, David J.	Bainbridge Island		GB	

US-CL-CURRENT: 530/358; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBL	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 7. Document ID: US 20040002455 A1

L9: Entry 7 of 54

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20030235575 A1

L9: Entry 8 of 54

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235575

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235575 A1

TITLE: Identification of oligoadenylate synthetase-like genes

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matzuk, Martin M.	Pearland	TX	US	
Bai, Yuchen	Newtown	PA	US	
Yan, Wei	Houston	TX	US	

US-CL-CURRENT: 424/94.61; 435/199, 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20030224444 A1

L9: Entry 9 of 54

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224444

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224444 A1

TITLE: Antibodies to native conformations of membrane proteins

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.1; 435/326, 435/69.1, 530/387.1

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Draw	Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 10. Document ID: US 20030219859 A1

L9: Entry 10 of 54

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

h e b b g e e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 11. Document ID: US 20030204069 A1

L9: Entry 11 of 54

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204069

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030204069 A1

TITLE: Segments of the human gene for telomerase reverse transcriptase

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morin, Gregg B.	Toronto	NV	CA	
Andrews, William H.	Reno		US	

US-CL-CURRENT: 536/23.2; 435/199, 435/320.1, 435/325, 435/456, 435/6, 435/69.1

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 12. Document ID: US 20030194727 A1

L9: Entry 12 of 54

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	
Lee, Horim	Chungcheongnam-do		KR	

Lee, Seong-Il	Yuseong-gu	KR
Yang, Hyo-Young	Yuseong-gu	KR
Lee, Yangsoon	Yuseong-gu	KR
Jang, Young-Soon	Yuseong-gu	KR

US-CL-CURRENT: [435/6](#); [435/219](#), [435/252.3](#), [435/254.2](#), [435/320.1](#), [435/325](#), [435/69.1](#), [435/7.2](#)

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMI	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 13. Document ID: US 20030171318 A1

L9: Entry 13 of 54

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171318

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030171318 A1

TITLE: Composition and method for treating viral infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: [514/44](#); [424/186.1](#), [435/6](#), [435/69.1](#), [514/12](#)

ABSTRACT:

Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMI	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 14. Document ID: US 20030170871 A1

L9: Entry 14 of 54

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170871

PGPUB-FILING-TYPE: new

h e b b g e e f e h e e f b e

DOCUMENT-IDENTIFIER: US 20030170871 A1

TITLE: Alphavirus-based vectors for persistent infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dubensky, Thomas W. JR.	Piedmont	CA	US	
Polo, John M.	Hayward	CA	US	
Perri, Silvia	Castro Valley	CA	US	
Belli, Barbara	San Diego	CA	US	

US-CL-CURRENT: 435/235.1; 424/93.21, 435/325, 435/456, 435/69.1, 536/23.72

ABSTRACT:

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein 2 gene which, when operably incorporated into an alphavirus replicon particle, eukaryotic layered vector initiation system, alphavirus vector construct or RNA vector replicon, provides a noncytopathic phenotype or confers the ability to establish persistent replication. Also disclosed are RNA vector replicons, alphavirus vector constructs, alphavirus replicon particles and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules, as well as methods of using such replicons, constructs, particles and eukaryotic layered vector initiation systems for expression of recombinant proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20030166141 A1

L9: Entry 15 of 54

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous

h e b b g e e e f e h e e f b e

cellular genes using engineered zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 16. Document ID: US 20030166099 A1

L9: Entry 16 of 54

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166099

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166099 A1

TITLE: Minicells comprising membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Surber, Mark W.	Coronado	CA	US	
Berkley, Neil	San Diego	CA	US	
Segall, Anca M.	San Diego	CA	US	
Klepper, Robert	San Diego	CA	US	

US-CL-CURRENT: 435/69.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 17. Document ID: US 20030165945 A1

L9: Entry 17 of 54

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: [435/6](#); [435/320.1](#), [435/325](#), [435/69.1](#), [435/7.1](#), [530/350](#), [536/23.5](#)

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 18. Document ID: US 20030143681 A1

L9: Entry 18 of 54

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030143681 A1

TITLE: Human ataxin-1-like polypeptide IMX97018

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, Dirk M.	Seattle	WA	US	

US-CL-CURRENT: [435/69.1](#); [435/199](#), [435/254.2](#), [435/320.1](#), [435/325](#), [435/6](#), [536/23.2](#)

ABSTRACT:

This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 19. Document ID: US 20030119771 A1

L9: Entry 19 of 54

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	

h e b b g e e e f e h e e f b e

Tomme, Peter Herwig Maria	Gent	BE
Klaassen, Hubertus Johannes Matheus	Herent	BE

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-------------

☐ 20. Document ID: US 20030108886 A1

L9: Entry 20 of 54

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108886

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108886 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 435/6; 435/199, 435/252.3, 435/320.1, 435/69.1, 514/44, 536/23.2

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-------------

☐ 21. Document ID: US 20030108880 A1

L9: Entry 21 of 54

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

22. Document ID: US 20030104526 A1

L9: Entry 22 of 54

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104526
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104526 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 23. Document ID: US 20030103992 A1

L9: Entry 23 of 54

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030103992

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030103992 A1

TITLE: Clasp membrane proteins

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: [424/185.1](#); [435/226](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

The present invention relates to cell surface molecules, designated cadherin-like asymmetry proteins ("CLASPs"). In particular, it relates to CLASP polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 24. Document ID: US 20030100093 A1

L9: Entry 24 of 54

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100093

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030100093 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: [435/199](#); [435/320.1](#), [435/325](#), [435/368](#), [435/69.1](#), [536/23.2](#)

h e b b g e e e f e h e e f b e

ABSTRACT:

The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

Full	Title	Distion	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	---------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 25. Document ID: US 20030096344 A1

L9: Entry 25 of 54

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096344

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030096344 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	PI. Croix-Blanche 25	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/199, 435/320.1, 435/325

ABSTRACT:

The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Full	Title	Distion	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	---------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 26. Document ID: US 20030087411 A1

L9: Entry 26 of 54

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 27. Document ID: US 20030077827 A1

L9: Entry 27 of 54

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077827 A1

TITLE: Surface transfection and expression procedure

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uhler, Michael D.	Ann Arbor	MI	US	

US-CL-CURRENT: 435/455; 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention relates to a method of transfecting cells comprising applying cells directly onto nucleic acids which are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the nucleic acids are immobilized in an array. In another aspect of the present invention, the method further includes expression of the nucleic acids in the transfected cells. In yet another aspect of the present invention, the method further comprises detecting the expression of the nucleic acids in the transfected cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 28. Document ID: US 20030068675 A1

L9: Entry 28 of 54

File: PGPB

Apr 10, 2003

h e b b g e e f e h e e f b e

PGPUB-DOCUMENT-NUMBER: 20030068675
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030068675 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/6, 702/19

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Renew	Classification	Date	Reference	Sequences	Attachments	Claims	KMO	Draw Des
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 29. Document ID: US 20030049602 A1

L9: Entry 29 of 54

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of

h e b b g e e f e h e e f b e

the inhibitors

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 30. Document ID: US 20030044404 A1

L9: Entry 30 of 54

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044404

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044404 A1

TITLE: Regulation of angiogenesis with zinc finger proteins

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	
Liu, Qiang	Foster City	CA	US	
Liu, Pei-Qi	Richmond	CA	US	
Wolffe, Alan	Orinda	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric	Boulder	CO	US	

US-CL-CURRENT: 424/94.63; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 31. Document ID: US 20030040038 A1

L9: Entry 31 of 54

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040038

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030040038 A1

TITLE: INDUCIBLE REGULATORY SYSTEM AND USE THEREOF

h e b b g e e e f e h e e f b e

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DOWDY, STEVEN F.	CLAYTON	MO	US	
JESSEE, JOEL A.	MOUNT AIRY	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455

ABSTRACT:

The present invention provides an inducible regulatory system in which transcription of a target nucleotide sequence in a host cell is activated by the introduction of a fusion protein having a transcription activator region and a protein transduction domain for entry of the fusion protein into the cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 32. Document ID: US 20030036163 A1

L9: Entry 32 of 54

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 33. Document ID: US 20030008324 A1

L9: Entry 33 of 54

File: PGPB

Jan 9, 2003

h e b b g e e f e h e e f b e

PGPUB-DOCUMENT-NUMBER: 20030008324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 34. Document ID: US 20020177152 A1

L9: Entry 34 of 54

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Pub	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 35. Document ID: US 20020173026 A1

L9: Entry 35 of 54

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLCL1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Pub	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 36. Document ID: US 20020169283 A1

L9: Entry 36 of 54

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 37. Document ID: US 20020168683 A1

L9: Entry 37 of 54

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 38. Document ID: US 20020155432 A1

L9: Entry 38 of 54

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	

h e b b g e e e f e h e e f b e

Weichselbaum, Ralph R.	Chicago	IL	US
Roizman, Bernard	Chicago	IL	US

US-CL-CURRENT: [435/5](#); [424/199.1](#), [424/205.1](#), [424/229.1](#), [435/320.1](#), [435/69.1](#)

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one additional pharmacological agent or surgical procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 39. Document ID: US 20020102267 A1

L9: Entry 39 of 54

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102267
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102267 A1

TITLE: CLASP-5 transmembrane protein

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: [424/185.1](#); [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-5 ("CLASP-5"). In particular, it relates to CLASP-5 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-5 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 40. Document ID: US 20020086382 A1

L9: Entry 40 of 54

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086382

h e b b g e e e f e h e e f b e

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086382 A1

TITLE: Clasp-3 transmembrane protein

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-3 ("CLASP-3"). In particular, it relates to CLASP-3 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-3 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 41. Document ID: US 20020061296 A1

L9: Entry 41 of 54

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061296
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061296 A1

TITLE: Delivery method for the tumor specific apoptosis inducing activity of apoptin

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Noteborn, Mathieu H.M.	Leiderdrop		NL	
Voorhoeve, Pieter M.	Amsterdam		NL	
Zhang, Ying-Hui	Leiden		NL	
Leliveld, Sirik R.	Leiden		NL	

US-CL-CURRENT: 424/93.21; 424/94.63, 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, auto-immune-derived cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Dram Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 42. Document ID: US 20020039765 A1

L9: Entry 42 of 54

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Dram Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 43. Document ID: US 20020001805 A1

L9: Entry 43 of 54

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 44. Document ID: US 6780986 B1

L9: Entry 44 of 54

File: USPT

Aug 24, 2004

US-PAT-NO: 6780986

DOCUMENT-IDENTIFIER: US 6780986 B1

TITLE: RIP60 nucleic acid and polypeptide sequences and uses therefor

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heintz; Nicholas H.	Jericho	VT		
Houchens; Christopher R.	Baltimore	MD		

US-CL-CURRENT: 536/23.5; 435/455, 435/69.1, 435/71.1, 435/91.4, 536/23.1

ABSTRACT:

The invention relates to nucleic acids and encoded polypeptides from the human zinc finger protein RIP60. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, fragments of the foregoing including functional fragments and variants. Kits containing the foregoing molecules additionally are provided.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 45. Document ID: US 6777185 B2

L9: Entry 45 of 54

File: USPT

Aug 17, 2004

US-PAT-NO: 6777185

DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

h e b b g e e e f e h e e f b e

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	ABDC	Drawing Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 46. Document ID: US 6723512 B2

L9: Entry 46 of 54

File: USPT

Apr 20, 2004

US-PAT-NO: 6723512

DOCUMENT-IDENTIFIER: US 6723512 B2

TITLE: METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS THAT FACILITATE INTERNALIZATION AND TRANSGENE EXPRESSION AND CELLS OR TISSUES COMPETENT FOR THE SAME AND METHODS FOR EVOLVING GENE DELIVERY VECTORS

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larocca; David	Encinitas	CA		
Kassner; Paul	San Mateo	CA		
Baird; Andrew	San Diego	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/5, 435/69.1, 435/DIG.14, 435/DIG.15, 435/DIG.2, 435/DIG.35, 435/DIG.4, 536/23.1

ABSTRACT:

A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, transduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene

h e b b g e e e f e h e e f b e

delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the nucleus, endosome, chloroplast, mitochondria, etc.

33 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NOTE	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 47. Document ID: US 6703487 B2

L9: Entry 47 of 54

File: USPT

Mar 9, 2004

US-PAT-NO: 6703487

DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324, 530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NOTE	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 48. Document ID: US 6660259 B2

L9: Entry 48 of 54

File: USPT

Dec 9, 2003

US-PAT-NO: 6660259

DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

h e b b g e e e f e h e e f b e

Laquerre; Sylvie Walnut Creek CA
Hermiston; Terry Corte Madera CA

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 49. Document ID: US 6649158 B1

L9: Entry 49 of 54

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158

DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 50. Document ID: US 6475789 B1

L9: Entry 50 of 54

File: USPT

Nov 5, 2002

US-PAT-NO: 6475789

DOCUMENT-IDENTIFIER: US 6475789 B1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cech; Thomas R.	Boulder	CO		
Lingner; Joachim	Epalinges			CH
Nakamura; Toru	Boulder	CO		
Chapman; Karen B.	Sausalito	CA		
Morin; Gregg B.	Palo Alto	CA		
Harley; Calvin B.	Palo Alto	CA		
Andrews; William H.	Richmond	CA		

US-CL-CURRENT: 435/366; 424/94.1, 435/320.1, 435/69.1, 536/23.2

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

8 Claims, 40 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Publ	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 51. Document ID: US 6472176 B2

L9: Entry 51 of 54

File: USPT

Oct 29, 2002

US-PAT-NO: 6472176

DOCUMENT-IDENTIFIER: US 6472176 B2

TITLE: Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kovesdi; Imre	Rockville	MD		

Bruder; Joseph T.

Ijamsville

MD

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 435/69.7, 435/69.8, 536/23.1,
536/23.2, 536/23.4, 536/23.5, 536/23.7, 536/24.1

ABSTRACT:

The invention pertains to a polynucleotide encoding a chimeric protein comprising an endoplasmic reticulum localization signal peptide, a transport moiety, and a moiety of interest, wherein the endoplasmic reticulum localization signal peptide, the transport moiety, and the moiety of interest are operably linked with each other, a vector comprising the polynucleotide, a cell comprising such a vector, and a method of expressing a protein comprising the transport moiety and the moiety of interest.

25 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	ICMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 52. Document ID: US 6451579 B1

L9: Entry 52 of 54

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6,
435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	ICMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 53. Document ID: US 6350572 B1

L9: Entry 53 of 54

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572

DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijzen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4; 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FORM	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 54. Document ID: US 6313269 B1

L9: Entry 54 of 54

File: USPT

Nov 6, 2001

US-PAT-NO: 6313269

DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L7 AND SV40	54

Display Format: [Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 79 of 79 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L11: Entry 1 of 79

File: PGPB

Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: [514/12](#); [435/320.1](#), [435/325](#), [435/69.1](#), [530/350](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 2. Document ID: US 20040151739 A1

L11: Entry 2 of 79

File: PGPB

Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151739

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040151739 A1

TITLE: Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Monnier, Philippe P.	Tubingen		DE	
Mueller, Bernhard K.	Tubingen		DE	
Schwab, Jan	Tubingen		DE	

US-CL-CURRENT: [424/239.1](#); [514/12](#), [530/350](#)

h e b b g e e e f e h e e f b e

ABSTRACT:

The invention relates to the use of a composition, comprising a fusion protein and at least one transporter for the in-vivo inhibition of scar tissue formation, the in-vivo reduction of secondary damage and/or the in-vivo accumulation of macrophages. The fusion protein contains at least one binding domain for the transporter and at least one modulation domain for the covalent modification of small GTP-binding proteins. The transporter permits the uptake of the fusion protein in a target cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040132969 A1

L11: Entry 3 of 79

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132969

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132969 A1

TITLE: Antibodies, peptides, analogs and uses thereof

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Melvin, William Thomas	Aberdeen		GB	
Thompson, William Douglas	Inverurie		GB	
Stirk, Christina Maureen	Stonghaven		GB	

US-CL-CURRENT: 530/350

ABSTRACT:

Fibrin degradation products stimulate cell proliferation and angiogenesis. The present invention provides peptides, analogs and antibodies which are useful in the modulation of fibrin fragment E activities such as modulation of cell proliferation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040132088 A1

L11: Entry 4 of 79

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

h e b b g e e e f e h e e f b e

Record List Display

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-------------

☐ 5. Document ID: US 20040115770 A1

L11: Entry 5 of 79

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or

h e b b g e e e f e h e e f b e

recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 6. Document ID: US 20040072270 A1

L11: Entry 6 of 79

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072270

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072270 A1

TITLE: Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fernandez-Salas, Ester	Fullerton	CA	US	
Steward, Lance E.	Irvine	CA	US	
Aoki, Kei Roger	Coto de Caza	CA	US	

US-CL-CURRENT: 435/7.32; 435/23, 530/350

ABSTRACT:

The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 7. Document ID: US 20040063907 A1

L11: Entry 7 of 79

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907

h e b b g e e f e h e e f b e

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20040058881 A1

L11: Entry 8 of 79

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

h e b b g e e f e h e e f b e

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20040038338 A1

L11: Entry 9 of 79

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: US 20040038303 A1

L11: Entry 10 of 79

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038303

h e b b g e e e f e h e e f b e

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040038303 A1

TITLE: Biologic modulations with nanoparticles

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unger, Gretchen M.	Chaska	MN	US	

US-CL-CURRENT: 435/7.1; 530/350, 530/387.1, 530/396, 536/123

ABSTRACT:

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 11. Document ID: US 20040002455 A1

L11: Entry 11 of 79

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

h e b b g e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 12. Document ID: US 20030235594 A1

L11: Entry 12 of 79

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235594

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235594 A1

TITLE: Ii-Key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 424/192.1; 435/320.1, 435/325, 435/69.3, 530/350, 536/23.5

ABSTRACT:

Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20030229202 A1

L11: Entry 13 of 79

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	WNC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 14. Document ID: US 20030228634 A1

L11: Entry 14 of 79

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228634

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030228634 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/7.2; 435/320.1, 530/350

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a

method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 15. Document ID: US 20030220480 A1

L11: Entry 15 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220480

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220480 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 16. Document ID: US 20030220474 A1

L11: Entry 16 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220474

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220474 A1

TITLE: Conjugate of biodegradable aliphatic polyester with Tat49-57 peptide or peptide chain containing Tat49-57 peptide and nanoparticle manufactured using the same

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Park, Ju Young	Yongin-si		KR	
Nam, Yoon Sung	Yongin-si		KR	
Han, Sang Hoon	Suwon-si		KR	
Chang, Ih Seop	Yongin-si		KR	

US-CL-CURRENT: 530/350; 436/518, 436/531

ABSTRACT:

Conjugates of a biodegradable aliphatic polyester-based polymer with Tat.sub.49-57 peptide or a peptide chain containing the Tat.sub.49-57 peptide, and nanoparticles manufactured using the same. Intracellular permeability of the Tat.sub.49-57 peptide can be enhanced by exposing Tat peptide moieties to the surface of the nanoparticles.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 17. Document ID: US 20030220264 A1

L11: Entry 17 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220264
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220264 A1

TITLE: Reversible modification of membrane interaction

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rozema, David B.	Madison	WI	US	
Wakefield, Darren	Madison	WI	US	
Wolff, Jon A.	Madison	WI	US	
Ekena, Kirk	Madison	WI	US	
Hagstrom, James E.	Middleton	WI	US	

US-CL-CURRENT: 514/12; 530/350, 530/406

ABSTRACT:

An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOG	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 18. Document ID: US 20030219859 A1

L11: Entry 18 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

h e b b g e e e f e h e e f b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030219378 A1

L11: Entry 19 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219378 A1

TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Piwnicka-Worms, David	Ladue	MO	US	

US-CL-CURRENT: 424/1.69; 424/188.1, 424/9.34, 424/9.6, 530/350

ABSTRACT:

Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 20. Document ID: US 20030190324 A1

L11: Entry 20 of 79

File: PGPB

Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190324 A1

h e b b g e e f e h e e f b e

TITLE: Immunologically significant herpes simplex virus antigens and methods for using same

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Hosken, Nancy A.	Seattle	WA	US	
Posavad, Christine M.	Seattle	WA	US	
Chen, Hongbo	Shoreline	WA	US	
McGowan, Patrick	Seattle	WA	US	

US-CL-CURRENT: 424/186.1; 435/235.1, 435/320.1, 435/325, 435/5, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 21. Document ID: US 20030175807 A1

L11: Entry 21 of 79

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175807

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030175807 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca²⁺ at the single cell level

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Kansas City	MO	US	
Le Mouellic, Herve	Paris		FR	
Brulet, Philippe	Paris		FR	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.2

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy

h e b b g e e e f e h e e f b e

by Chemiluminescence Resonance Energy Transfer (CRET).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 22. Document ID: US 20030170826 A1

L11: Entry 22 of 79

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170826
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170826 A1

TITLE: Peptides for facilitating composite receptor expression and translocation of macromolecules

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rabinovich, Peter	Madison	CT	US	
Bray-Ward, Patricia	Madison	CT	US	
Ward, David C.	Madison	CT	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/7.5, 530/350, 536/23.5

ABSTRACT:

The invention relates to compositions and methods for expressing a composite receptor on the cell surface. The composite receptor can be integrated into a cell membrane via a fusion peptide which includes a cell penetrating domain linked to a transmembrane domain. In a preferred embodiment, the composite receptor further comprises a ligand binding domain. In yet another embodiment the invention relates to compositions and methods for translocating a nucleic acid or other molecule across the cell membrane into the cell. In a preferred embodiment, the nucleic acid or other molecule is linked to a fusion peptide comprising an adapter domain which is linked to a cell penetrating domain.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 23. Document ID: US 20030166160 A1

L11: Entry 23 of 79

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166160
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166160 A1

TITLE: Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
h e b b g e e f	e	he	ef	b e

Hawley, Stephen B.	San Diego	CA	US
Chapin, Steven	San Diego	CA	US
Sheridan, Philip L.	San Diego	CA	US
Houston, L. L.	Del Mar	CA	US
Glynn, Jacqueline M.	San Diego	CA	US

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from the properties of monomers, complexes and compounds having only one targeting element directed to a paracellular and/or transcytotic ligand. The complexes and compounds of the invention undergo endocytosis, transcytosis and exocytosis; following endocytosis, the complexes or compounds may be transported into the cytosol or an organelle of a cell. In polarized cells, transcytosis can proceed in a "forward" or "reverse" direction. Reverse transcytosis is used for the non-invasive delivery of biologically active agents from the lumen of, e.g., the gastrointestinal tract or the airways of lungs, to the circulatory system. The complexes and compounds are incorporated in various compositions and medical devices suitable for medicinal or veterinary use.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 24. Document ID: US 20030165945 A1

L11: Entry 24 of 79

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 25. Document ID: US 20030119771 A1

L11: Entry 25 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350,
536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 26. Document ID: US 20030118611 A1

L11: Entry 26 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	

h e b b g e e f e h e e f b e

Corey, Lawrence

Seattle

WA

US

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1,
435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 27. Document ID: US 20030118600 A1

L11: Entry 27 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118600

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030118600 A1

TITLE: Transfer compounds, production and use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerdes, Johannes	Feldhorst		DE	
Scholzen, Thomas	Neritz		DE	
Wohlenberg, Claudia	Hamburg		DE	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.3, 514/44, 530/350, 536/23.2

ABSTRACT:

The invention relates to the use of a carboxy-terminal fragment of the Ki-67 protein or of an active part, fragment or homologue thereof as a compound that can be used for intracellular transfer and for the introduction in and the release by the cells. The invention further relates to transfer compounds that contain the above-mentioned Ki-67 protein and to the vectors encoding the same. The invention also relates to corresponding pharmaceutical compositions and to the use of the transfer protein as an excipient or active agent in the treatment of diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 28. Document ID: US 20030105277 A1

h e b g e e e f e h e e f b e

L11: Entry 28 of 79

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030105277
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030105277 A1

TITLE: Compositions and therapeutic methods for viral infection

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 530/300; 424/186.1, 530/350

ABSTRACT:

Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the infected host cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Keywords	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	----------	----------

☐ 29. Document ID: US 20030066095 A1

L11: Entry 29 of 79

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030066095
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030066095 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Paris		FR	
LeMouellic, Herve	Paris		FR	
Brulet, Philippe	Paris		FR	

US-CL-CURRENT: 800/3; 424/9.6, 435/4, 530/350, 536/23.5

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 30. Document ID: US 20030055219 A1

L11: Entry 30 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055219
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030055219 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/7.1, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 31. Document ID: US 20030054409 A1

L11: Entry 31 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	

h e b b g e e e f e h e e f b e

Mueller, Rolf

Marburg

DE

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350,
530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 32. Document ID: US 20030054000 A1

L11: Entry 32 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 33. Document ID: US 20030044427 A1

h e b b g e e e f e h e e f b e

L11: Entry 33 of 79

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044427
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044427 A1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howley, Peter M.	Wellesley	MA	US	
Benson, John	Brookline	MA	US	
Kasukawa, Hiroaki	Princeton	NJ	US	

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4,
536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Pub	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NAME	Draw Desc
-----	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 34. Document ID: US 20030036163 A1

L11: Entry 34 of 79

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological

h e b b g e e e f e h e e f b e

Record List Display

processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 35. Document ID: US 20030032592 A1

L11: Entry 35 of 79

File: PGPB

Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032592
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030032592 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 435/7.1, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 36. Document ID: US 20030017174 A1

L11: Entry 36 of 79

File: PGPB

Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030017174
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030017174 A1

TITLE: HERPES SIMPLEX VIRUS VP22 VACCINES AND METHODS OF USE

Record List Display

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BURKE, RAE LYNN	SAN FRANCISCO	CA	US	
TIGGES, MICHAEL A.	OAKLAND	CA	US	

US-CL-CURRENT: 424/231.1; 424/204.1, 530/300, 530/350, 530/826

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 37. Document ID: US 20020177692 A1

L11: Entry 37 of 79

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 38. Document ID: US 20020169283 A1

L11: Entry 38 of 79

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283

h e b b g e e e f e h e e f b e

Record List Display

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 39. Document ID: US 20020168683 A1

L11: Entry 39 of 79

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 40. Document ID: US 20020165352 A1

L11: Entry 40 of 79

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165352
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165352 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	References	Sequences	Attachments	Claims	Draw	Draw Desc
------	-------	----------	-------	--------	----------------	------	------------	-----------	-------------	--------	------	-----------

☐ 41. Document ID: US 20020164666 A1

L11: Entry 41 of 79

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164666
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164666 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.23; 435/183, 530/350, 530/388.1

h e b b g e e e f e h e e f b e

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 42. Document ID: US 20020147306 A1

L11: Entry 42 of 79

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147306
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147306 A1

TITLE: Peptides that modulate the interaction of B class ephrins and PDZ domains

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lin, Danny	Scarborough		CA	
Pawson, Anthony	Toronto		CA	
Gish, Gerald	East York		CA	

US-CL-CURRENT: 530/350; 530/324

ABSTRACT:

The invention relates to complexes comprising a B class ephrin and a PDZ domain containing protein; peptides that interfere with the interaction of a B class ephrin with a PDZ domain binding site, and a PDZ domain containing protein; and, uses of the peptides and complexes. Methods for modulating the interaction of a B class ephrin and a PDZ domain containing protein, and methods for evaluating compounds for their ability to modulate the interaction are also described.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 43. Document ID: US 20020115607 A1

L11: Entry 43 of 79

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115607
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115607 A1

h e b b g e e e f e h e e f b e

Record List Display

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 424/146.1, 435/194, 435/226, 530/350

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	DOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

44. Document ID: US 20020106378 A1

L11: Entry 44 of 79

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106378

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106378 A1

TITLE: Materials and methods for intracellular transport and their uses

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Oxted		GB	
Elliott, Gillian Daphne	Oxted		GB	

US-CL-CURRENT: 424/186.1; 530/350

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

h e b b g e e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 45. Document ID: US 20020086361 A1

L11: Entry 45 of 79

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 46. Document ID: US 20020068302 A1

L11: Entry 46 of 79

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068302

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068302 A1

TITLE: Clasp-4 transmembrane protein

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

h e b b g e e e f e h e e f b e

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-4 ("CLASP-4"). In particular, it relates to CLASP-4 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-4 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

L11: Entry 47 of 79

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350,
536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KnowC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

L11: Entry 48 of 79

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020032154
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020032154 A1

TITLE: Interferon-suppressing placental lactogen peptides

PUBLICATION-DATE: March 14, 2002

Record List Display

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Peyman, John A.	New Haven	CT	US	

US-CL-CURRENT: 514/12; 435/184, 530/350

ABSTRACT:

Interferon-Suppressing Placental Lactogen Peptides (ISPLP) are disclosed which block actions of the human cytokine interferon-gamma. In addition, methods are disclosed for the treatment with ISPLP of certain disorders associated with increased expression of interferon-gamma-stimulated major histocompatibility complex antigens, such as autoimmune diseases, inflammatory diseases, and transplant rejection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 49. Document ID: US 20020001805 A1

L11: Entry 49 of 79

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 50. Document ID: US 20010044417 A1

L11: Entry 50 of 79

File: PGPB

Nov 22, 2001

h e b b g e e e f e h e e f b e

PGPUB-DOCUMENT-NUMBER: 20010044417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010044417 A1

TITLE: Compound containing a labile disulfide bond

PUBLICATION-DATE: November 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolff, Jon A.	Madison	WI	US	
Monahan, Sean D.	Madison	WI	US	
Budker, Vladimir G.	Middleton	WI	US	
Slattum, Paul M.	Madison	WI	US	
Rozema, David B.	Madison	WI	US	

US-CL-CURRENT: 514/44; 514/2, 530/350, 536/23.1

ABSTRACT:

A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 51. Document ID: US 6787326 B1

L11: Entry 51 of 79

File: USPT

Sep 7, 2004

US-PAT-NO: 6787326
DOCUMENT-IDENTIFIER: US 6787326 B1

TITLE: Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ratcliffe; Peter John	Oxford			GB
Maxwell; Patrick Henry	Oxford			GB
Pugh; Christopher William	Oxford			GB

US-CL-CURRENT: 435/14; 435/6, 435/7.1, 435/8, 530/350

ABSTRACT:

The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor .alpha. subunits, by targeting HIF .alpha. for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF .alpha. subunit sequence which may modulate this interaction.

Record List Display

16 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 52. Document ID: US 6780970 B2

L11: Entry 52 of 79

File: USPT

Aug 24, 2004

US-PAT-NO: 6780970
DOCUMENT-IDENTIFIER: US 6780970 B2

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/324; 530/300, 530/325, 530/326, 530/332

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

13 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 53. Document ID: US 6773920 B1

L11: Entry 53 of 79

File: USPT

Aug 10, 2004

US-PAT-NO: 6773920
DOCUMENT-IDENTIFIER: US 6773920 B1

TITLE: Delivery of functional protein sequences by translocating polypeptides

DATE-ISSUED: August 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dalby; Brian	Carlsbad	CA		
Bennett; Robert P.	Encinitas	CA		

US-CL-CURRENT: 435/462; 435/455, 435/468, 435/471, 530/300, 530/350

ABSTRACT:

h e b b g e e e f e h e e f b e

The invention provides methods for modulating a cellular process by contacting a cell in culture with a cell process-modifying molecule attached to a translocating polypeptide. For example, in one embodiment, a cell in culture is transfected with a target gene by contacting the cell in culture with a polynucleotide (that contains the target gene) attached to a translocating polypeptide. In another embodiment, expression of a target gene product in a cell in culture that contains a target gene under control of one or more regulatory elements is modulated by contacting the cell in culture with one or more regulatory agents attached to a translocating polypeptide. The one or more regulatory agents are translocated into the cell in culture and interact therein with the one or more regulatory elements to modulate expression of the target gene product by the cell.

37 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 54. Document ID: US 6740524 B1

L11: Entry 54 of 79

File: USPT

May 25, 2004

US-PAT-NO: 6740524

DOCUMENT-IDENTIFIER: US 6740524 B1

TITLE: Nucleic acid transfer phage

DATE-ISSUED: May 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akuta; Teruo	Kumamoto			JP
Yokoi; Haruhiko	Tokyo			JP
Okuyama; Hajime	Hyogo			JP
Takeda; Katsuo	late of Tokyo			JP
Hasegawa; Mamoru	Ibaraki			JP
Nakanishi; Mahito	Osaka			JP

US-CL-CURRENT: 435/456; 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/69.7,
435/975, 530/350, 536/23.4

ABSTRACT:

The present invention provides a novel phage expressing in its head a bi-functional protein that has nuclear translocation and cell adhesion activities. The phage is used to package a foreign substance such as a gene. As a bi-functional protein, TAT protein of HIV can be used. The phage is useful in gene therapy.

18 Claims, 8 Drawing figures

Exemplary Claim Number: 1,15

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 55. Document ID: US 6734167 B2

L11: Entry 55 of 79

File: USPT

May 11, 2004

US-PAT-NO: 6734167

DOCUMENT-IDENTIFIER: US 6734167 B2

TITLE: Uses of transport proteins

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Surry			GB
Normand; Nadia Michelle	Boulogne-Billancourt			FR
Brewis; Neil Douglas	Surry			GB
Phelan; Anne	Kent			GB

US-CL-CURRENT: 514/12; 424/204.1, 424/231.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

11 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NAME	Origin Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 56. Document ID: US 6703487 B2

L11: Entry 56 of 79

File: USPT

Mar 9, 2004

US-PAT-NO: 6703487

DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324, 530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides

h e b b g e e f e h e e f b e

Record List Display

as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 57. Document ID: US 6683048 B1

L11: Entry 57 of 79

File: USPT

Jan 27, 2004

US-PAT-NO: 6683048

DOCUMENT-IDENTIFIER: US 6683048 B1

TITLE: Compounds and methods for stimulating gene expression and cellular differentiation

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Gour; Barbara J.	Montreal			CA

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/9,
530/300, 530/326, 530/328, 530/329 , 530/330

ABSTRACT:

Modulating agents for inhibiting an interaction between .alpha.-catenin and .beta.-catenin are provided. The modulating agents comprise one or more of: (a) a .beta.-catenin HAV motif; (b) a peptide analogue or mimetic of a .beta.-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a .beta.-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.

16 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 58. Document ID: US 6677116 B1

L11: Entry 58 of 79

File: USPT

Jan 13, 2004

US-PAT-NO: 6677116

DOCUMENT-IDENTIFIER: US 6677116 B1

TITLE: Methods for treating cancer by modulating .beta.-catenin mediated gene expression

DATE-ISSUED: January 13, 2004

Record List Display

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Byers; Stephen	Washington	DC		
Gour; Barbara J.	Kemptville			CA

US-CL-CURRENT: 435/6; 514/14, 514/2, 514/9, 530/300, 536/22.1

ABSTRACT:

Modulating agents for inhibiting .beta.-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating .beta.-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.

13 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	RMK	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	----------

59. Document ID: US 6673354 B2

L11: Entry 59 of 79

File: USPT

Jan 6, 2004

US-PAT-NO: 6673354

DOCUMENT-IDENTIFIER: US 6673354 B2

TITLE: Compositions and methods for treating papillomavirus-infected cells

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		
Benson; John	Brookline	MA		
Kasukawa; Hiroaki	Princeton	NJ		

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

17 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

h e b b g e e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 60. Document ID: US 6669951 B2

L11: Entry 60 of 79

File: USPT

Dec 30, 2003

US-PAT-NO: 6669951

DOCUMENT-IDENTIFIER: US 6669951 B2

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 424/436; 514/11, 514/16, 514/169, 514/2, 514/634, 514/636, 530/300, 530/329, 564/236, 564/243

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

88 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 61. Document ID: US 6664040 B2

L11: Entry 61 of 79

File: USPT

Dec 16, 2003

US-PAT-NO: 6664040

DOCUMENT-IDENTIFIER: US 6664040 B2

TITLE: Compositions and methods for delivery of a molecule into a cell

h e b b g e e e f e h e e f b e

Record List Display

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherman; Michael P.	San Francisco	CA		
Greene; Warner C.	San Francisco	CA		
de Noronha; Carlos M.C.	San Francisco	CA		
Schubert; Ulrich	Bethesda	MA		
Henklein; Peter	Berlin			GB

US-CL-CURRENT: 435/5; 435/29, 435/325, 435/41, 530/300, 530/350, 530/395

ABSTRACT:

Provided is a composition comprising a Vpr polypeptide conjugated to a therapeutic molecule. Preferably, the Vpr comprises synthetic Vpr. The therapeutic molecule can comprise any molecule capable of being conjugated to Vpr or a fragment thereof, including a polypeptide, a polynucleotide, and/or a toxin. The invention additionally provides a method for delivering a molecule into a cell. The method comprises contacting the cell with a conjugate comprising a Vpr polypeptide conjugated to the molecule. The invention further provides a method for modulating the expression of a transgene in a cell, a method for killing a target cell population in a subject, a method for increasing the sensitivity of cells to radiation therapy, and a method for inhibiting cell proliferation.

14 Claims, 83 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 29

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	NOTE	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 62. Document ID: US 6635258 B2

L11: Entry 62 of 79

File: USPT

Oct 21, 2003

US-PAT-NO: 6635258

DOCUMENT-IDENTIFIER: US 6635258 B2

TITLE: Herpes simplex virus VP22 vaccines and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; Rae Lyn	San Francisco	CA		
Tigges; Michael A.	Oakland	CA		

US-CL-CURRENT: 424/231.1; 424/185.1, 424/204.1, 424/229.1, 530/350

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

h e b b g e e e f e h e e f b e

Record List Display

24 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	----------

☐ 63. Document ID: US 6632616 B2

L11: Entry 63 of 79

File: USPT

Oct 14, 2003

US-PAT-NO: 6632616

DOCUMENT-IDENTIFIER: US 6632616 B2

**** See image for Certificate of Correction ****

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; James R.	Chapel Hill	NC		
Strittmatter; Warren J.	Durham	NC		
Nagai; Yoshitaka	Osaka			JP

US-CL-CURRENT: 435/7.1; 435/4, 435/6, 530/350

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

6 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keywords	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	----------

☐ 64. Document ID: US 6610820 B1

L11: Entry 64 of 79

File: USPT

Aug 26, 2003

US-PAT-NO: 6610820

DOCUMENT-IDENTIFIER: US 6610820 B1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

h e b b g e e e f e h e e f b e

Record List Display

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/300; 530/324, 530/326, 530/328

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

20 Claims, 17 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 65. Document ID: US 6610542 B1

L11: Entry 65 of 79

File: USPT

Aug 26, 2003

US-PAT-NO: 6610542

DOCUMENT-IDENTIFIER: US 6610542 B1

**** See image for Certificate of Correction ****

TITLE: Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bell; David N.	Oakville			CA
Rosenthal; Kenneth Lee	Ancaster			CA

US-CL-CURRENT: 435/377; 424/93.2, 424/93.21, 435/320.1, 435/325, 435/455, 514/44, 530/350, 530/351

ABSTRACT:

Methods for the expansion of CD4, CD8, and DP T-cells from HIV infected patients are disclosed which allow the maintenance of low levels of HIV. The invention further discloses methods for the inhibition of HIV gene expression. Also disclosed are methods for the rapid and efficient screening of cells derived from HIV-infected patients to assess the suitability of various antiviral treatments. The invention further provides a means for the generation of cell banks for use in immune reconstitution and means of treating or modifying expanded cell populations prior to infusion to enhance or modulate therapeutic effectiveness.

33 Claims, 4 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 66. Document ID: US 6593292 B1

L11: Entry 66 of 79

File: USPT

Jul 15, 2003

US-PAT-NO: 6593292

DOCUMENT-IDENTIFIER: US 6593292 B1

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/15, 514/159, 514/16, 514/169, 514/17, 514/254.07, 514/263.31, 514/291, 514/423, 514/456, 514/458, 514/634, 514/635, 514/636, 530/300, 530/321, 530/328, 530/329, 530/330, 544/366

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

134 Claims, 41 Drawing figures

Exemplary Claim Number: 61

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Knowl	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	-----------

☐ 67. Document ID: US 6461822 B2

L11: Entry 67 of 79

File: USPT

Oct 8, 2002

US-PAT-NO: 6461822

DOCUMENT-IDENTIFIER: US 6461822 B2

TITLE: Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

h e b b g e e e f e h e e f b e

Record List Display

Gabel; Christopher A.	Ledyard	CT
Griffiths; Richard J.	East Lyme	CT
Eggler; James F.	Stonington	CT
Dombroski; Mark A.	Waterford	CT
Geoghegan; Kieran	Mystic	CT

US-CL-CURRENT: 435/7.2; 435/7.1, 530/350, 536/23.5, 564/305

ABSTRACT:

The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1.beta..

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

68. Document ID: US 6451601 B1

L11: Entry 68 of 79

File: USPT

Sep 17, 2002

US-PAT-NO: 6451601

DOCUMENT-IDENTIFIER: US 6451601 B1

TITLE: Transiently immortalized cells for use in gene therapy

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Verona	WI		
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/366; 435/377, 435/405, 530/350, 536/23.4

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e h e e f b e

Number of Drawing Sheets: 8

Full	Title	Edison	Front	Review	Classification	Date	Reference			Claims	KMOC	Draw Des
------	-------	--------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 69. Document ID: US 6451579 B1

L11: Entry 69 of 79

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6,
435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Edison	Front	Review	Classification	Date	Reference			Claims	KMOC	Draw Des
------	-------	--------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 70. Document ID: US 6399075 B1

L11: Entry 70 of 79

File: USPT

Jun 4, 2002

US-PAT-NO: 6399075

DOCUMENT-IDENTIFIER: US 6399075 B1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		

h e b b g e e e f e h e e f b e

Record List Display

Benson; John	Brookline	MA
Kasukawa; Hiroaki	Princeton	NJ

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

32 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Publ	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 71. Document ID: US 6375952 B1

L11: Entry 71 of 79

File: USPT

Apr 23, 2002

US-PAT-NO: 6375952

DOCUMENT-IDENTIFIER: US 6375952 B1

**** See image for Certificate of Correction ****

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Corey; Lawrence	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/192.1, 424/199.1, 424/231.1, 435/235.1, 435/252.3, 435/320.1, 435/325, 435/69.3, 435/69.7 , 530/350, 536/23.4, 536/23.7

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

39 Claims, 7 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e he ef b e

Record List Display

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 72. Document ID: US 6358739 B1

L11: Entry 72 of 79

File: USPT

Mar 19, 2002

US-PAT-NO: 6358739

DOCUMENT-IDENTIFIER: US 6358739 B1

**** See image for Certificate of Correction ****

TITLE: Transiently immortalized cells

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Lausanne			CH
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/377; 530/350

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 73. Document ID: US 6316252 B1

L11: Entry 73 of 79

File: USPT

Nov 13, 2001

US-PAT-NO: 6316252

DOCUMENT-IDENTIFIER: US 6316252 B1

TITLE: Biotherapeutic delivery system

DATE-ISSUED: November 13, 2001

h e b b g e e e f e h e e f b e

Record List Display

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Harms; Jerome S.	Madison	WI		
Splitter; Gary A.	Brooklyn	WI		

US-CL-CURRENT: 435/320.1; 435/69.7, 530/350, 530/826, 536/23.4, 536/23.72

ABSTRACT:

Disclosed herein are fusion proteins, nucleotide sequences for creating them, and vectors containing the nucleotide sequences. The fusion proteins have a bovine herpesvirus protein linked to a biotherapeutic protein or reporter protein. They rapidly spread biotherapeutic or reporter protein throughout mammalian cells.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Info	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 74. Document ID: US 6313269 B1

L11: Entry 74 of 79

File: USPT

Nov 6, 2001

US-PAT-NO: 6313269

DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e he ef b e

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KBAC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 75. Document ID: US 6251398 B1

L11: Entry 75 of 79

File: USPT

Jun 26, 2001

US-PAT-NO: 6251398

DOCUMENT-IDENTIFIER: US 6251398 B1

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxtd			GB
Elliott; Gillian Daphne	Oxtd			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1,
435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an amino acid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KBAC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 76. Document ID: US 6200577 B1

L11: Entry 76 of 79

File: USPT

Mar 13, 2001

US-PAT-NO: 6200577

DOCUMENT-IDENTIFIER: US 6200577 B1

TITLE: Anti-herpesviral agents and assays therefor

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

h e b b g e e e f e h e e f b e

Record List Display

NAME	CITY	STATE	ZIP CODE	COUNTRY
McLauchlan; John	Glasgow			GB
McGeoch; Duncan James	Glasgow			GB
Hope; Ralph Graham	Glasgow			GB
Rixon; Helen Winton McLaren	Strathblane			GB

US-CL-CURRENT: 424/229.1; 424/204.1, 424/231.1, 435/5, 435/7.93, 435/975, 530/300,
536/23.72

ABSTRACT:

There is described an antiviral agent capable of disrupting the association of two viral structural proteins required for maturation, replication and infection of herpesviruses. The agents are based upon VP22 and disrupt the normal association of that protein with VP16 and/or gB. Suitable agents are peptides having the amino acid sequences TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLW or ITTIRVTVCCEGKNLLQRANE. The agents are suitable for combatting infection of herpesviruses and thus for the treatment of cold sores, genital herpes, chickenpox and shingles. An assay to test for agents able to disrupt VP22/VP16 and/or VP22/gB association is also described.

13 Claims, 16 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 77. Document ID: US 6184038 B1

L11: Entry 77 of 79

File: USPT

Feb 6, 2001

US-PAT-NO: 6184038

DOCUMENT-IDENTIFIER: US 6184038 B1

**** See image for Certificate of Correction ****

TITLE: Transport proteins and their uses

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/455; 435/468, 435/471, 530/300, 530/350

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

8 Claims, 10 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 8

h e b b g e e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 78. Document ID: US 6086900 A

L11: Entry 78 of 79

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900

DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 79. Document ID: US 6017735 A

L11: Entry 79 of 79

File: USPT

Jan 25, 2000

US-PAT-NO: 6017735

DOCUMENT-IDENTIFIER: US 6017735 A

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.4, 536/23.5

h e b b g e e e f e h e e f b e

Record List Display

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMAC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L10 AND VP22	79

Display Format:

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 54 of 54 returned.

☐ 1. Document ID: US 20040137622 A1

Using default format because multiple data bases are involved.

L15: Entry 1 of 54

File: PGPB

Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137622
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137622 A1

TITLE: Modular transfection systems

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schmidt, Hanns-Martin	Koln		DE	
Altrogge, Ludger	Pulheim		DE	
Lenz, Dietmar	Koln		DE	
Riemen, Gudula	Langenfeld		DE	
Brosterhus, Helmut	Kirchhunden		DE	
Lorbach, Elke	Koln		DE	
Helfrich, Juliana	Koln		DE	
Hein, Katharina	Koln		DE	
Gremse, Marion	Koln		DE	
Males, Tarjana	Hilden		DE	
Christine, Rainer	Koln		DE	
Siebenkotten, Gregor	Freehen-Konigsdorf		DE	
Ortmann, Bodo	Koln		DE	
Klacs, Andrea	Koln		DE	

US-CL-CURRENT: 435/455

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	...	KMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-----	------	-----------

☐ 2. Document ID: US 20040072319 A1

L15: Entry 2 of 54

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072319
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072319 A1

TITLE: Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

h e b b g e e e f e h e e f b e

Record List Display

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nash, Piers	Ontario		CA	
Pawson, Anthony	Ontario		CA	
Tang, Xiaojing	Ontario		CA	
Tyers, Michael	Ontario		CA	

US-CL-CURRENT: 435/226; 435/320.1, 435/325

ABSTRACT:

The invention relates to methods for identifying compounds that modulate ubiquitin-dependent proteolysis, and compounds identified using the methods. The invention also relates to a novel peptide motif referred to as the "CPD motif", molecules derived from the CPD motif, and uses of the CPD motif and molecules.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	~~~~~	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 3. Document ID: US 20040028693 A1

L15: Entry 3 of 54

File: PGPB

Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040028693

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040028693 A1

TITLE: Molecular vaccine linking intercellular spreading protein to an antigen

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wu, Tzyy Choou	Brookeville	MD	US	
Hung, Chien-Fu	Baltimore	MD	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K000	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 4. Document ID: US 20040022769 A1

L15: Entry 4 of 54

File: PGPB

Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040022769
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040022769 A1

TITLE: Methods and compositions to induce antitumor response

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFace, Drake M.	San Diego	CA	US	

US-CL-CURRENT: 424/93.2; 435/235.1, 435/320.1, 435/456

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K000	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 5. Document ID: US 20040002455 A1

L15: Entry 5 of 54

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	

h e b b g e e e f e h e e f b e

Guo, Yong	Freshmeadows	NJ	US
Cheng, Su	Bridgewater		US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-----	-----------

☐ 6. Document ID: US 20030232781 A1

L15: Entry 6 of 54

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232781
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232781 A1

TITLE: Modulation of gene expression using insulator binding proteins

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.			US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 514/44; 424/94.61, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions including insulator domains for targeted regulation of a gene or transgene are provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-----	-----------

☐ 7. Document ID: US 20030229202 A1

L15: Entry 7 of 54

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

h e b b g e e e f e h e e f b e

Record List Display

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	-----	HOME	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 8. Document ID: US 20030194727 A1

L15: Entry 8 of 54

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	
Lee, Horim	Chungcheongnam-do		KR	
Lee, Seong-Il	Yuseong-gu		KR	
Yang, Hyo-Young	Yuseong-gu		KR	
Lee, Yangsoon	Yuseong-gu		KR	
Jang, Young-Soon	Yuseong-gu		KR	

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance,

h e b b g e e e f e h e e f b e

Record List Display

altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	------------

☐ 9. Document ID: US 20030180777 A1

L15: Entry 9 of 54

File: PGPB

Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180777

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030180777 A1

TITLE: Rapid identification of transcriptional regulatory domains

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartsevich, Victor	Albany	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/7.2

ABSTRACT:

Compositions and methods for high-throughput assay for transcriptional regulatory domains in mammalian cells are provided. In certain embodiments, libraries of random amino acid sequences are assayed for transcriptional regulatory activity. In additional embodiments, cDNA libraries are assayed. Libraries are fused to a DNA-binding domain that is targeted to a reporter gene, and modulation of expression of the reporter gene is assayed. Accordingly, regulatory domains having both positive and negative transcriptional regulatory activity can be identified.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	------------

☐ 10. Document ID: US 20030166141 A1

L15: Entry 10 of 54

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

h e b b g e e e f e h e e f b e

ABSTRACT:

[illegible]

☐ 11. Document ID: US 20030148973 A1

L15: Entry 11 of 54

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148973
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148973 A1

TITLE: MAGE-A1 peptides for treating or preventing cancer

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

INVENTOR-INFORMATION:				
NAME	CITY	STATE	COUNTRY	RULE-47
Emtage, Peter	Boston	MA	US	
Karunakaran, Liza	Toronto	NY	CA	
Pedyczak, Arthur	Toronto		CA	
Barber, Brian H.	Hawthorne		US	

US-CL-CURRENT: 514/44; 424/185.1, 424/93.2, 536/23.1

ABSTRACT:

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KOMC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 12. Document ID: US 20030113919 A1

L15: Entry 12 of 54

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113919
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113919 A1

TITLE: Immunogenic targets for melanoma

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

INVENTOR-INFORMATION.				
NAME	CITY	STATE	COUNTRY	RULE-47

h e b b g e e e f e he ef b e

Record List Display

Emtage, Peter	Sunnyvale	CA	US
Karunakaran, Liza	Thornhill	NY	CA
Pedyczak, Artur	Pickering		CA
Barber, Brian	White Plains		US

US-CL-CURRENT: 435/456; 435/235.1, 435/320.1

ABSTRACT:

The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-------	-----------

☐ 13. Document ID: US 20030108880 A1

L15: Entry 13 of 54

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-------	-----------

☐ 14. Document ID: US 20030087817 A1

L15: Entry 14 of 54

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087817
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030087817 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

h e b b g e e e f e h e e f b e

Record List Display

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cox, George Norbert III	Louisville	CO	US	
Case, Casey Christopher	San Mateo	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric Edward	Boulder	CO	US	
Spratt, Sharon Kaye	Vacaville	CA	US	

US-CL-CURRENT: 514/12; 435/455

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	NAME	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 15. Document ID: US 20030087411 A1

L15: Entry 15 of 54

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	NAME	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 16. Document ID: US 20030082552 A1

L15: Entry 16 of 54

File: PGPB

May 1, 2003

h e b b g e e e f e h e e f b e

PGPUB-DOCUMENT-NUMBER: 20030082552
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082552 A1

TITLE: Modulation of gene expression using localization domains

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Berkeley	CA	US	
Raschke, Eva	San Francisco	CA	US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 435/6; 435/317.1, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions comprising localization domains, and fusions of localization domains with DNA binding domains and, optionally regulatory domains, are provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------	------	------

☐ 17. Document ID: US 20030054409 A1

L15: Entry 17 of 54

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	
Mueller, Rolf	Marburg		DE	

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350, 530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation

h e b b g e e e f e h e e f b e

Record List Display

of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 18. Document ID: US 20030054000 A1

L15: Entry 18 of 54

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 19. Document ID: US 20030049649 A1

L15: Entry 19 of 54

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049649

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049649 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

h e b b g e e e f e he ef b e

Record List Display

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	San Pablo	CA	US	
Wolffe, Elizabeth J.	Richmond	CA	US	
Collingwood, Trevor			US	
Snowden, Andrew			US	

US-CL-CURRENT: 435/6; 435/199, 435/455, 435/468

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------	-----------

☐ 20. Document ID: US 20030036163 A1

L15: Entry 20 of 54

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------	-----------

☐ 21. Document ID: US 20030022330 A1

L15: Entry 21 of 54

File: PGPB

Jan 30, 2003

h e b b g e e e f e h e e f b e

Record List Display

PGPUB-DOCUMENT-NUMBER: 20030022330
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030022330 A1

TITLE: APOA2-interacting proteins and use thereof

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/226, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Knowl	Diagn Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-------	-----------

22. Document ID: US 20030013169 A1

L15: Entry 22 of 54

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013169
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030013169 A1

TITLE: Transcription factor E2F DNA-binding domain inhibitor peptides and their use

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Muller, Rolf	Marburg		DE	
Kontermann, Roland E.	Marburg		DE	
Montigiani, Silvia	Siena		IT	

US-CL-CURRENT: 435/184; 530/330

ABSTRACT:

The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID NO:2); WHFIFW (SEQ ID NO:3); IWLSQLSRGVVVSFP (SEQ ID NO:4); and GSRILTRSGSWYAS (SEQ ID NO:5) and derivatives based upon these sequences. Compositions and the use of the peptides in inhibiting cell cycle progression, such

h e b b g e e e f e h e e f b e

Record List Display

as in uncontrolled cell proliferation, are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 23. Document ID: US 20030008373 A1

L15: Entry 23 of 54

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008373

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008373 A1

TITLE: APOA1-interacting proteins and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Szankasi, Philippe	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/226; 435/183, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA1 and one or more APOA1-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA1 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 24. Document ID: US 20030008324 A1

L15: Entry 24 of 54

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

h e b b g e e e f e h e e f b e

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	****	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-------	----------

☐ 25. Document ID: US 20020197691 A1

L15: Entry 25 of 54

File: PGPB

Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020197691
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020197691 A1

TITLE: FLT4-interacting proteins and use thereof

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/7.23

ABSTRACT:

Protein complexes are provided comprising FLT4 and one or more FLT4-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with FLT4 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	****	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-------	----------

☐ 26. Document ID: US 20020177692 A1

L15: Entry 26 of 54

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

Record List Display

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FORM	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 27. Document ID: US 20020177207 A1

L15: Entry 27 of 54

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177207

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020177207 A1

TITLE: Tsg101-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/196; 435/199, 435/226

ABSTRACT:

Protein complexes are provided comprising Tsg101 and one or more protein interactors of Tsg101. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Tsg101 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FORM	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 28. Document ID: US 20020177177 A1

L15: Entry 28 of 54

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177177

PGPUB-FILING-TYPE: new

h e b b g e e e f e h e e f b e

Record List Display

DOCUMENT-IDENTIFIER: US 20020177177 A1

TITLE: Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bernards, Rene	Alconde		NL	
Zwijzen, Renate	Utrecht		NL	

US-CL-CURRENT: 435/7.23; 514/14, 514/15, 514/16, 530/326, 530/327, 530/328

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumors, for assays for compounds useful in the prevention of tumors and compounds obtainable by such assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None	Draw Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	----	------	-----------

☐ 29. Document ID: US 20020177152 A1

L15: Entry 29 of 54

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 30. Document ID: US 20020173026 A1

L15: Entry 30 of 54

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLCL1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 31. Document ID: US 20020164575 A1

L15: Entry 31 of 54

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164575
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164575 A1

TITLE: Gene identification

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Urnov, Fyodor	Richmond	CA	US	

US-CL-CURRENT: 435/4; 435/6

ABSTRACT:

h e b b g e e e f e h e e f b e

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMID	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 32. Document ID: US 20020160940 A1

L15: Entry 32 of 54

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160940

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160940 A1

TITLE: Modulation of endogenous gene expression in cells

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Wolffe, Alan	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Richmond	CA	US	
Snowden, Andrew	Alameda	CA	US	
Tan, Siyuan	El Cerrito	CA	US	
Gregory, Philip			US	

US-CL-CURRENT: 514/6; 435/455

ABSTRACT:

Disclosed herein are methods and compositions for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMID	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 33. Document ID: US 20020150557 A1

L15: Entry 33 of 54

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150557

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150557 A1

TITLE: Selectively replicating viral vectors

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ramachandra, Muralidhara	San Diego	CA	US	
Shabram, Paul W.	Olivenhain	CA	US	

US-CL-CURRENT: 424/93.2; 424/456, 435/320.1

ABSTRACT:

The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 34. Document ID: US 20020115215 A1

L15: Entry 34 of 54

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115215

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020115215 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Orinda	CA	US	
Collingwood, Trevor	San Pablo	CA	US	

US-CL-CURRENT: 435/455; 435/468, 435/6

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	----------

☐ 35. Document ID: US 20020094529 A1

L15: Entry 35 of 54

File: PGPB

Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094529
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094529 A1

TITLE: Gene identification

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Urnov, Fyodor	Richmond	CA	US	

US-CL-CURRENT: 435/6; 435/4, 435/455

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	-----	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-----	-----------

☐ 36. Document ID: US 20020081614 A1

L15: Entry 36 of 54

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081614
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081614 A1

TITLE: Functional genomics using zinc finger proteins

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Zhang, Lei	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/7.21, 702/19

ABSTRACT:

0 The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

h e b b g e e f e h e e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 37. Document ID: US 20020068706 A1

L15: Entry 37 of 54

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068706

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068706 A1

TITLE: INHIBITORS OF CELL-CYCLE PROGRESSION AND USES RELATED THERETO

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GYURIS, JENO	WINCHESTER	MA	US	
LAMPHERE, LOU	BOSTON	MA	US	
BEACH, DAVID H.	HUNTINGTON BAY	NY	US	

US-CL-CURRENT: 514/44; 435/455, 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	------	-----------

☐ 38. Document ID: US 20020037280 A1

L15: Entry 38 of 54

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037280

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037280 A1

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lieber, Andre	Seattle	WA	US	
Steinwaerder, Dirk S.	Hamburg	WA	DE	
Carlson, Cheryl A.	Seattle	WA	US	
Mi, Jie	Seattle		US	

US-CL-CURRENT: 424/93.21; 435/235.1, 435/320.1, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	-------	-------	----------

☐ 39. Document ID: US 6780590 B2

L15: Entry 39 of 54

File: USPT

Aug 24, 2004

US-PAT-NO: 6780590

DOCUMENT-IDENTIFIER: US 6780590 B2

TITLE: Gene identification

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

30 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-------	-------	----------

☐ 40. Document ID: US 6777185 B2

L15: Entry 40 of 54

File: USPT

Aug 17, 2004

h e b b g e e e f e h e e f b e

US-PAT-NO: 6777185

DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Code	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	----------

41. Document ID: US 6686196 B2

L15: Entry 41 of 54

File: USPT

Feb 3, 2004

US-PAT-NO: 6686196

DOCUMENT-IDENTIFIER: US 6686196 B2

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

DATE-ISSUED: February 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lieber; Andre	Seattle	WA		
Steinwaerder; Dirk S.	Hamburg			DE
Carlson; Cheryl A.	Seattle	WA		
Mi; Jie	Seattle	WA		

US-CL-CURRENT: 435/320.1; 424/93.2, 435/455, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also

referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

26 Claims, 32 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference				Full	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	------	----------

☐ 42. Document ID: US 6649158 B1

L15: Entry 42 of 54

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference				Full	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	------	----------

☐ 43. Document ID: US 6645501 B2

L15: Entry 43 of 54

File: USPT

Nov 11, 2003

US-PAT-NO: 6645501
DOCUMENT-IDENTIFIER: US 6645501 B2

h e b b g e e f e h e e f b e

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: November 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/195.11, 424/196.11

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

27 Claims, 26 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference				NAME	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	------	------------

☐ 44. Document ID: US 6607882 B1

L15: Entry 44 of 54

File: USPT

Aug 19, 2003

US-PAT-NO: 6607882

DOCUMENT-IDENTIFIER: US 6607882 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George N.	Louisville	CO		
Case; Casey C.	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric E.	Boulder	CO		
Spratt; Sharon K.	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/455, 435/468, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

32 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference				RMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	-----	-----------

☐ 45. Document ID: US 6599692 B1

L15: Entry 45 of 54

File: USPT

Jul 29, 2003

US-PAT-NO: 6599692

DOCUMENT-IDENTIFIER: US 6599692 B1

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	San Francisco	CA		

US-CL-CURRENT: 435/4; 435/6, 536/23.1

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

55 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference				RMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	-----	-----------

☐ 46. Document ID: US 6534261 B1

L15: Entry 46 of 54

File: USPT

Mar 18, 2003

US-PAT-NO: 6534261

DOCUMENT-IDENTIFIER: US 6534261 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George Norbert	Louisville	CO		
Case; Casey Christopher	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric Edward	Boulder	CO		
Spratt; Sharon Kaye	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/29, 536/23.5, 536/24.1

h e b b g e e f e he ef b e

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

85 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			****	KNOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	------	-----------

☐ 47. Document ID: US 6495526 B2

L15: Entry 47 of 54

File: USPT

Dec 17, 2002

US-PAT-NO: 6495526

DOCUMENT-IDENTIFIER: US 6495526 B2

TITLE: Inhibitors of cell-cycle progression and uses related thereto

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gyuris; Jenő	Winchester	MA		
Lamphere; Lou	Boston	MA		
Beach; David H.	Huntington Bay	NY		

US-CL-CURRENT: 514/44; 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

42 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			****	KNOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	------	-----------

☐ 48. Document ID: US 6495346 B1

L15: Entry 48 of 54

File: USPT

Dec 17, 2002

US-PAT-NO: 6495346

DOCUMENT-IDENTIFIER: US 6495346 B1

TITLE: Complex-forming proteins

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

h e b b g e e e f e h e e f b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jerome; Valerie	Colbe			DE
Sedlacek; Hans-Harald	Marburg			DE
Muller; Rolf	Marburg			DE

US-CL-CURRENT: 435/69.7; 424/85.1, 424/85.2, 435/69.5, 435/69.52, 530/351, 536/23.4, 536/23.5, 536/23.51

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

12 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference				KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	-----	-----------

☐ 49. Document ID: US 6451579 B1

L15: Entry 49 of 54

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high

level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference				KMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	------	-----------

☐ 50. Document ID: US 6350572 B1

L15: Entry 50 of 54

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572
DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijssen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4, 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference				KMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	------	-----------

☐ 51. Document ID: US 6251398 B1

L15: Entry 51 of 54

File: USPT

Jun 26, 2001

US-PAT-NO: 6251398
DOCUMENT-IDENTIFIER: US 6251398 B1

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

h e b b g e e f e h e e f b e

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1,
435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference				RMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	-----	-----------

52. Document ID: US 6221355 B1

L15: Entry 52 of 54

File: USPT

Apr 24, 2001

US-PAT-NO: 6221355

DOCUMENT-IDENTIFIER: US 6221355 B1

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: April 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/204.1, 424/208.1, 530/387.3, 530/388.3, 536/23.4

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

21 Claims, 26 Drawing figures

h e b b g e e e f e h e e f b e

Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference			****	****	****	****
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	------	------	------

☐ 53. Document ID: US 6086900 A

L15: Entry 53 of 54

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900
DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3,
435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			****	****	****	****
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	------	------	------

☐ 54. Document ID: US 6017735 A

L15: Entry 54 of 54

File: USPT

Jan 25, 2000

US-PAT-NO: 6017735
DOCUMENT-IDENTIFIER: US 6017735 A

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxtd			GB
Elliott; Gillian Daphne	Oxtd			GB

h e b b g e e e f e h e e f b e

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.4, 536/23.5

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6


Full	Title	Citation	Front	Review	Classification	Date	Reference			XXXX	RMIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Blwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L14 AND cyclin	54

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for VP22 Go Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Summary

Show:

500

Sort

Send to

Text

About Entrez

Items 1 - 113 of 113

One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA, Hsieh CY.](#) Related Articles, Links



Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.

Eur J Immunol. 2004 Jul;34(7):1892-900.

PMID: 15214037 [PubMed - indexed for MEDLINE]

☐ 2: [Jarver P, Langel U.](#) Related Articles, Links



The use of cell-penetrating peptides as a tool for gene regulation.

Drug Discov Today. 2004 May 1;9(9):395-402. Review.

PMID: 15081956 [PubMed - indexed for MEDLINE]

☐ 3: [Suzuki K, Murtuza B, Brand NJ, Varela-Carver A, Fukushima S, Yacoub MH.](#) Related Articles, Links



Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport.

J Mol Cell Cardiol. 2004 Apr;36(4):603-6.

PMID: 15081320 [PubMed - in process]

☐ 4: [Qiu Z, Harms JS, Zhu J, Splitter GA.](#) Related Articles, Links



Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22.

J Virol. 2004 Apr;78(8):4224-33.

PMID: 15047837 [PubMed - indexed for MEDLINE]

☐ 5: [Falk K, Aspehaug V, Vlasak R, Endresen C.](#) Related Articles, Links



Identification and characterization of viral structural proteins of infectious salmon anemia virus.

J Virol. 2004 Mar;78(6):3063-71.

PMID: 14990725 [PubMed - indexed for MEDLINE]

☐ 6: [Brady RO.](#) Related Articles, Links



Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.

Acta Paediatr Suppl. 2003 Dec;92(443):19-24.

PMID: 14989461 [PubMed - indexed for MEDLINE]

☐ 7: [Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA, Wu TC.](#) Related Articles, Links





















Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.




















Hum Gene Ther. 2004 Feb;15(2):167-77.

PMID: 14975189 [PubMed - in process]


☐ 8: [Barbe-Tuana FM, Machado DC, Saitovitch D.](#) Related Articles, Links

Modified location of the major histocompatibility protein Kb by co-delivery

-  with VP22 protein.
Biomol Eng. 2004 Jan;21(1):27-31.
PMID: 14715317 [PubMed - indexed for MEDLINE]
-  **9:** Roeder GE, Parish JL, Stern PL, Gaston K. [Related Articles, Links](#)
 Herpes Simplex Virus VP22-Human Papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.
Biotechnol Appl Biochem. 2004 Jan 7 [Epub ahead of print]
PMID: 14709162 [PubMed - as supplied by publisher]
-  **10:** Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll JL. [Related Articles, Links](#)
 VP22-mediated and light-activated delivery of an anti-c-ras antisense oligonucleotide improves its activity after intratumoral injection in nude mice.
Mol Ther. 2003 Nov;8(5):840-5.
PMID: 14599818 [PubMed - indexed for MEDLINE]
-  **11:** Kueltzo LA, Middaugh CR. [Related Articles, Links](#)
 Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems.
J Pharm Sci. 2003 Sep;92(9):1754-72. Review.
PMID: 12949995 [PubMed - indexed for MEDLINE]
-  **12:** Stroh C, Held J, Samraj AK, Schulze-Osthoff K. [Related Articles, Links](#)
 Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the Herpes virus protein VP22.
Oncogene. 2003 Aug 14;22(34):5367-73.
PMID: 12917639 [PubMed - indexed for MEDLINE]
-  **13:** van Leeuwen H, Okuwaki M, Hong R, Chakravarti D, Nagata K, O'Hare P. [Related Articles, Links](#)
 Herpes simplex virus type 1 tegument protein VP22 interacts with TAF-I proteins and inhibits nucleosome assembly but not regulation of histone acetylation by INHAT.
J Gen Virol. 2003 Sep;84(Pt 9):2501-10.
PMID: 12917472 [PubMed - indexed for MEDLINE]
-  **14:** Kong BH, Wang WX, Liu CS, Ma DX, Qu X. [Related Articles, Links](#)
 [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo]
Zhonghua Fu Chan Ke Za Zhi. 2003 Apr;38(4):195-8. Chinese.
PMID: 12885362 [PubMed - in process]
-  **15:** Rutjes SA, Bosma PJ, Rohn JL, Noteborn MH, Wesseling JG. [Related Articles, Links](#)
 Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.
J Mol Med. 2003 Sep;81(9):558-65. Epub 2003 Jul 16.
PMID: 12879152 [PubMed - indexed for MEDLINE]
-  **16:** Lundberg M, Wikstrom S, Johansson M. [Related Articles, Links](#)
 Cell surface adherence and endocytosis of protein transduction domains.
Mol Ther. 2003 Jul;8(1):143-50.
PMID: 12842437 [PubMed - indexed for MEDLINE]
-  **17:** Kong B, Wang W, Liu C, Song L, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Wang B, Wei MQ, Yang Q. [Related Articles, Links](#)

-  **Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.**
In Vivo. 2003 Mar-Apr;17(2):153-6.
PMID: 12792977 [PubMed - indexed for MEDLINE]
-  **18:** [Namiki S, Tomida T, Tanabe M, Iino M, Hirose K.](#) [Related Articles, Links](#)
-  **Intracellular delivery of glutathione S-transferase into mammalian cells.**
Biochem Biophys Res Commun. 2003 Jun 6;305(3):592-7.
PMID: 12763035 [PubMed - indexed for MEDLINE]
-  **19:** [Kretz A, Wybranietz WA, Hermening S, Lauer UM, Isenmann S.](#) [Related Articles, Links](#)
-  **HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo.**
Mol Ther. 2003 May;7(5 Pt 1):659-69.
PMID: 12718909 [PubMed - indexed for MEDLINE]
-  **20:** [Boenicke L, Chu K, Pauls R, Tams C, Kruse ML, Kurdow R, Schniewind B, Bohle A, Kremer B, Kalthoff H.](#) [Related Articles, Links](#)
-  **Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.**
J Mol Med. 2003 Mar;81(3):205-13. Epub 2003 Mar 18.
PMID: 12682729 [PubMed - indexed for MEDLINE]
-  **21:** [Brignati MJ, Loomis JS, Wills JW, Courtney RJ.](#) [Related Articles, Links](#)
-  **Membrane association of VP22, a herpes simplex virus type 1 tegument protein.**
J Virol. 2003 Apr;77(8):4888-98.
PMID: 12663795 [PubMed - indexed for MEDLINE]
-  **22:** [Weitzman MD.](#) [Related Articles, Links](#)
-  **VP22 flips the switch on cell death.**
Mol Ther. 2003 Feb;7(2):146-7. No abstract available.
PMID: 12638542 [PubMed - indexed for MEDLINE]
-  **23:** [Walters JN, Sexton GL, McCaffery JM, Desai P.](#) [Related Articles, Links](#)
-  **Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L71 in the N terminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells.**
J Virol. 2003 Apr;77(7):4043-59.
PMID: 12634364 [PubMed - indexed for MEDLINE]
-  **24:** [Brewis ND, Phelan A, Normand N, Choolun E, O'Hare P.](#) [Related Articles, Links](#)
-  **Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis.**
Mol Ther. 2003 Feb;7(2):262-70.
PMID: 12597915 [PubMed - indexed for MEDLINE]
-  **25:** [Zavaglia D, Favrot MC, Eymin B, Tenaud C, Coll JL.](#) [Related Articles, Links](#)
-  **Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.**
Gene Ther. 2003 Feb;10(4):314-25.
PMID: 12595890 [PubMed - indexed for MEDLINE]
-  **26:** [Roy I, Holle L, Song W, Holle E, Wagner T, Yu X.](#) [Related Articles, Links](#)
-  **Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.**
Anticancer Res. 2002 Nov-Dec;22(6A):3185-9.

PMID: 12530063 [PubMed - indexed for MEDLINE]


 **27:** [Lyman MG, Demmin GL, Banfield BW.](#)

[Related Articles, Links](#)

The attenuated pseudorabies virus strain Bartha fails to package the tegument proteins Us3 and VP22.

J Virol. 2003 Jan;77(2):1403-14.

PMID: 12502856 [PubMed - indexed for MEDLINE]


 **28:** [Cashman SM, Sadowski SL, Morris DJ, Frederick J, Kumar-Singh R.](#)

[Related Articles, Links](#)

Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors--implications for gene therapy.

Mol Ther. 2002 Dec;6(6):813-23.

PMID: 12498777 [PubMed - indexed for MEDLINE]


 **29:** [Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S.](#)

[Related Articles, Links](#)

[Anti-tumor effect of lentivirus-mediated MUC1 antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice]

Zhonghua Yi Xue Za Zhi. 2002 Sep 10;82(17):1207-10. Chinese.

PMID: 12475412 [PubMed - indexed for MEDLINE]


 **30:** [Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC.](#)

[Related Articles, Links](#)

HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis.

Virology. 2002 Oct 10;302(1):95-105.

PMID: 12429519 [PubMed - indexed for MEDLINE]

 **31:** [Ye D, Xu D, Singer AU, Juliano RL.](#)

[Related Articles, Links](#)

Evaluation of strategies for the intracellular delivery of proteins.

Pharm Res. 2002 Sep;19(9):1302-9.

PMID: 12403066 [PubMed - indexed for MEDLINE]


 **32:** [Hutchinson I, Whiteley A, Browne H, Elliott G.](#)

[Related Articles, Links](#)

Sequential localization of two herpes simplex virus tegument proteins to punctate nuclear dots adjacent to ICP0 domains.

J Virol. 2002 Oct;76(20):10365-73.

PMID: 12239313 [PubMed - indexed for MEDLINE]


 **33:** [Miranda-Saksena M, Boadle RA, Armati P, Cunningham AL.](#)

[Related Articles, Links](#)

In rat dorsal root ganglion neurons, herpes simplex virus type 1 tegument forms in the cytoplasm of the cell body.

J Virol. 2002 Oct;76(19):9934-51.

PMID: 12208970 [PubMed - indexed for MEDLINE]


 **34:** [Qian C, Sangro B, Prieto J.](#)

[Related Articles, Links](#)

New strategies to enhance gene therapy efficiency.

Gastroenterology. 2002 Aug;123(2):639-42. No abstract available.

PMID: 12145817 [PubMed - indexed for MEDLINE]










 **35:** [Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S.](#)

[Related Articles, Links](#)











Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors.


Gastroenterology. 2002 Aug;123(2):608-18.

PMID: 12145813 [PubMed - indexed for MEDLINE]

-  **36:** Fuchs W, Klupp BG, Granzow H, Hengartner C, Brack A, Mundt A, Enquist I, W, Mettenleiter TC [Related Articles](#), [Links](#)
Physical interaction between envelope glycoproteins E and M of pseudorabies virus and the major tegument protein UL49.
 J Virol. 2002 Aug;76(16):8208-17.
 PMID: 12134026 [PubMed - indexed for MEDLINE]
-  **37:** Sciortino MT, Taddeo B, Poon AP, Mastino A, Roizman B. [Related Articles](#), [Links](#)
Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection.
 Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8318-23.
 PMID: 12060774 [PubMed - indexed for MEDLINE]
-  **38:** Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. [Related Articles](#), [Links](#)
VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo.
 Cancer Gene Ther. 2002 Jun;9(6):489-96.
 PMID: 12032659 [PubMed - indexed for MEDLINE]
-  **39:** Morris SJ, Smith H, Sweet C. [Related Articles](#), [Links](#)
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
 Arch Virol. 2002 May;147(5):961-79.
 PMID: 12021867 [PubMed - indexed for MEDLINE]
-  **40:** Martin A, O'Hare P, McLauchlan J, Elliott G. [Related Articles](#), [Links](#)
Herpes simplex virus tegument protein VP22 contains overlapping domains for cytoplasmic localization, microtubule interaction, and chromatin binding.
 J Virol. 2002 May;76(10):4961-70.
 PMID: 11967313 [PubMed - indexed for MEDLINE]
-  **41:** Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M, Lauer UM. [Related Articles](#), [Links](#)
Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene.
 Gene Ther. 2001 Nov;8(21):1654-64.
 PMID: 11895004 [PubMed - indexed for MEDLINE]
-  **42:** Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M. [Related Articles](#), [Links](#)
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination.
 Virology. 2002 Mar 1;294(1):47-59.
 PMID: 11886264 [PubMed - indexed for MEDLINE]
-  **43:** van Leeuwen H, Elliott G, O'Hare P. [Related Articles](#), [Links](#)
Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress.
 J Virol. 2002 Apr;76(7):3471-81.
 PMID: 11884571 [PubMed - indexed for MEDLINE]
-  **44:** Diefenbach RJ, Miranda-Saksena M, Diefenbach E, Holland DJ, Boadle RA, Armati PJ, Cunningham AL. [Related Articles](#), [Links](#)

Herpes simplex virus tegument protein US11 interacts with conventional

-  **kinesin heavy chain.**
J Virol. 2002 Apr;76(7):3282-91.
PMID: 11884553 [PubMed - indexed for MEDLINE]
-  **45: O'Donnell LA, Clemmer JA, Czymmek K, Schmidt CJ.** [Related Articles, Links](#)
Marek's disease virus VP22: subcellular localization and characterization of carboxyl terminal deletion Mutations.
Virology. 2002 Jan 20;292(2):235-40.
PMID: 11878926 [PubMed - indexed for MEDLINE]
-  **46: Soden J, Stevens A, Ray DW.** [Related Articles, Links](#)
Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation.
J Endocrinol. 2002 Mar;172(3):615-25.
PMID: 11874710 [PubMed - indexed for MEDLINE]
-  **47: Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC.** [Related Articles, Links](#)
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
Hum Gene Ther. 2002 Mar 1;13(4):553-68.
PMID: 11874633 [PubMed - indexed for MEDLINE]
-  **48: Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC.** [Related Articles, Links](#)
Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen.
J Virol. 2002 Mar;76(6):2676-82.
PMID: 11861834 [PubMed - indexed for MEDLINE]
-  **49: Lundberg M, Johansson M.** [Related Articles, Links](#)
Positively charged DNA-binding proteins cause apparent cell membrane translocation.
Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71.
PMID: 11846414 [PubMed - indexed for MEDLINE]
-  **50: Lai Z, Brady RO.** [Related Articles, Links](#)
Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector.
J Neurosci Res. 2002 Feb 1;67(3):363-71.
PMID: 11813241 [PubMed - indexed for MEDLINE]
-  **51: Marples B, Greco O, Joiner MC, Scott SD.** [Related Articles, Links](#)
Molecular approaches to chemo-radiotherapy.
Eur J Cancer. 2002 Jan;38(2):231-9. Review.
PMID: 11803140 [PubMed - indexed for MEDLINE]
-  **52: Dorange F, Fischer BK, Vautherot JF, Osterrieder N.** [Related Articles, Links](#)
Characterization of Marek's disease virus serotype 1 (MDV-1) deletion mutants that lack UL46 to UL49 genes: MDV-1 UL49, encoding VP22, is indispensable for virus growth.
J Virol. 2002 Feb;76(4):1959-70.
PMID: 11799190 [PubMed - indexed for MEDLINE]
-  **53: Bennett RP, Daiby B, Guy PM.** [Related Articles, Links](#)
Protein delivery using VP22.
Nat Biotechnol. 2002 Jan;20(1):20. No abstract available. Erratum in: Nat Biotechnol 2002 Apr;20(4):338.
PMID: 11753353 [PubMed - indexed for MEDLINE]

 **54:** [del Rio T, Werner HC, Enquist LW.](#)


[Related Articles](#), [Links](#)



The pseudorabies virus VP22 homologue (UL49) is dispensable for virus growth in vitro and has no effect on virulence and neuronal spread in rodents.

J Virol. 2002 Jan;76(2):774-82.

PMID: 11752167 [PubMed - indexed for MEDLINE]

 **55:** [Morris MC, Depollier J, Mery J, Heitz F, Divita G.](#)


[Related Articles](#), [Links](#)



A peptide carrier for the delivery of biologically active proteins into mammalian cells.

Nat Biotechnol. 2001 Dec;19(12):1173-6.

PMID: 11731788 [PubMed - indexed for MEDLINE]

 **56:** [Derer W, Easwaran HP, Leonhardt IL, Cardoso MC.](#)


[Related Articles](#), [Links](#)



A novel approach to induce cell cycle reentry in terminally differentiated muscle cells.

FASEB J. 2002 Jan;16(1):132-3. Epub 2001 Nov 29.

PMID: 11729099 [PubMed - indexed for MEDLINE]

 **57:** [Blouin A, Blaho JA.](#)


[Related Articles](#), [Links](#)



Assessment of the subcellular localization of the herpes simplex virus structural protein VP22 in the absence of other viral gene products.

Virus Res. 2001 Dec 4;81(1-2):57-68.

PMID: 11682125 [PubMed - indexed for MEDLINE]

 **58:** [Geiss BJ, Tavis JE, Metzger LM, Leib DA, Morrison LA.](#)


[Related Articles](#), [Links](#)



Temporal regulation of herpes simplex virus type 2 VP22 expression and phosphorylation.

J Virol. 2001 Nov;75(22):10721-9.

PMID: 11602713 [PubMed - indexed for MEDLINE]

 **59:** [Ren X, Harms JS, Splitter GA.](#)


[Related Articles](#), [Links](#)



Tyrosine phosphorylation of bovine herpesvirus 1 tegument protein VP22 correlates with the incorporation of VP22 into virions.

J Virol. 2001 Oct;75(19):9010-7.

PMID: 11533164 [PubMed - indexed for MEDLINE]

 **60:** [Aints A, Guven H, Gahrton G, Smith CI, Dilber MS.](#)


[Related Articles](#), [Links](#)



Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting.

Gene Ther. 2001 Jul;8(14):1051-6.

PMID: 11526452 [PubMed - indexed for MEDLINE]

 **61:** [Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE.](#)

[Related Articles](#), [Links](#)



Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.

J Virol. 2001 Sep;75(18):8733-41.

PMID: 11507218 [PubMed - indexed for MEDLINE]

 **62:** [Kotsakis A, Pomeranz LE, Blouin A, Blaho JA.](#)


[Related Articles](#), [Links](#)




Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein.

J Virol. 2001 Sep;75(18):8697-711.

PMID: 11507215 [PubMed - indexed for MEDLINE]


 **63:** [Ren X, Harms JS, Splitter GA.](#)


[Related Articles](#), [Links](#)

 **Bovine herpesvirus 1 tegument protein VP22 interacts with histones, and the carboxyl terminus of VP22 is required for nuclear localization.**
J Virol. 2001 Sep;75(17):8251-8.
PMID: 11483770 [PubMed - indexed for MEDLINE]


 **64:** [Lundberg M, Johansson M.](#)

[Related Articles](#), [Links](#)

 **Is VP22 nuclear homing an artifact?**
Nat Biotechnol. 2001 Aug;19(8):713-4. No abstract available.
PMID: 11479552 [PubMed - indexed for MEDLINE]


 **65:** [Oliveira SC, Harms JS, Afonso RR, Splitter GA.](#)

[Related Articles](#), [Links](#)

 **A genetic immunization adjuvant system based on BVP22-antigen fusion.**
Hum Gene Ther. 2001 Jul 1;12(10):1353-9.
PMID: 11440628 [PubMed - indexed for MEDLINE]


 **66:** [Ford KG, Souberbielle BE, Darling D, Farzaneh F.](#)


[Related Articles](#), [Links](#)

 **Protein transduction: an alternative to genetic intervention?**
Gene Ther. 2001 Jan;8(1):1-4. Review.
PMID: 11402295 [PubMed - indexed for MEDLINE]


 **67:** [Spengler M, Niesen N, Grose C, Ruyechan WT, Hay J.](#)


[Related Articles](#), [Links](#)

 **Interactions among structural proteins of varicella zoster virus.**
Arch Virol Suppl. 2001;(17):71-9.
PMID: 11339553 [PubMed - indexed for MEDLINE]


 **68:** [Liu CS, Kong B, Xia HH, Ellem KA, Wei MQ.](#)


[Related Articles](#), [Links](#)

 **VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.**
J Gene Med. 2001 Mar-Apr;3(2):145-52.
PMID: 11318113 [PubMed - indexed for MEDLINE]


 **69:** [Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC.](#)


[Related Articles](#), [Links](#)

 **Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen.**
J Immunol. 2001 May 1;166(9):5733-40.
PMID: 11313416 [PubMed - indexed for MEDLINE]


 **70:** [Falnes PO, Wesche J, Olsnes S.](#)


[Related Articles](#), [Links](#)

 **Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.**
Biochemistry. 2001 Apr 10;40(14):4349-58.
PMID: 11284691 [PubMed - indexed for MEDLINE]


 **71:** [Normand N, van Leeuwen H, O'Hare P.](#)


[Related Articles](#), [Links](#)

 **Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery.**
J Biol Chem. 2001 May 4;276(18):15042-50. Epub 2001 Jan 18.
PMID: 11278656 [PubMed - indexed for MEDLINE]

 **72:** [Schwartz JJ, Zhang S.](#)

[Related Articles](#), [Links](#)

 **Peptide-mediated cellular delivery.**
Curr Opin Mol Ther. 2000 Apr;2(2):162-7. Review.
PMID: 11249637 [PubMed - indexed for MEDLINE]

 **73:** [Donnelly M, Elliott G.](#)

[Related Articles](#), [Links](#)

Fluorescent tagging of herpes simplex virus tegument protein VP13/14 in

**virus infection.**

J Virol. 2001 Mar;75(6):2575-83.

PMID: 11222680 [PubMed - indexed for MEDLINE]

**74: Rajcani J, Durmanova V.**

Related Articles, Links

**Early expression of herpes simplex virus (HSV) proteins and reactivation of latent infection.**

Folia Microbiol (Praha). 2000;45(1):7-28. Review.

PMID: 11200675 [PubMed - indexed for MEDLINE]

**75: Cheng WF, Hung CH, Chai CY, Hsu KF, He L, Ling M, Wu TC.**

Related Articles, Links

**Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.**

J Virol. 2001 Mar;75(5):2368-76.

PMID: 11160740 [PubMed - indexed for MEDLINE]

**76: Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB**

Related Articles, Links

**CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.**

J Virol. 2000 Dec;74(23):11422-5.

PMID: 11070045 [PubMed - indexed for MEDLINE]

**77: Lai Z, Han L, Zirzow G, Brady RO, Reiser J.**

Related Articles, Links

**Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.**

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11297-302.

PMID: 11027330 [PubMed - indexed for MEDLINE]

**78: Pomeranz LE, Blaho JA.**

Related Articles, Links

**Assembly of infectious Herpes simplex virus type 1 virions in the absence of full-length VP22.**

J Virol. 2000 Nov;74(21):10041-54.

PMID: 11024133 [PubMed - indexed for MEDLINE]

**79: Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF.**

Related Articles, Links

**Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16.**

J Gen Virol. 2000 Sep;81(Pt 9):2219-30.

PMID: 10950980 [PubMed - indexed for MEDLINE]

**80: Kueltzo LA, Normand N, O'Hare P, Middaugh CR.**

Related Articles, Links

**Conformational lability of herpesvirus protein VP22.**

J Biol Chem. 2000 Oct 27;275(43):33213-21.

PMID: 10913125 [PubMed - indexed for MEDLINE]

**81: Aints A, Dilber MS, Smith CL.**

Related Articles, Links

**Intercellular spread of GFP-VP22.**

J Gene Med. 1999 Jul-Aug;1(4):275-9.

PMID: 10738560 [PubMed - indexed for MEDLINE]






















**82: Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M, Lauer UM.**

Related Articles, Links

**Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines.**

J Gene Med. 1999 Jul-Aug;1(4):265-74.

PMID: 10738559 [PubMed - indexed for MEDLINE]

-  **83:** [Harms JS, Ren X, Oliveira SC, Splitter GA.](#) [Related Articles, Links](#)
-  **Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations.**
J Virol. 2000 Apr;74(7):3301-12.
PMID: 10708447 [PubMed - indexed for MEDLINE]
-  **84:** [Elliott G, O'Hare P.](#) [Related Articles, Links](#)
-  **Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division.**
J Virol. 2000 Mar;74(5):2131-41.
PMID: 10666242 [PubMed - indexed for MEDLINE]
-  **85:** [Brewis N, Phelan A, Webb J, Drew J, Elliott G, O'Hare P.](#) [Related Articles, Links](#)
-  **Evaluation of VP22 spread in tissue culture.**
J Virol. 2000 Jan;74(2):1051-6.
PMID: 10623773 [PubMed - indexed for MEDLINE]
-  **86:** [Derer W, Easwaran HP, Knopf CW, Leonhardt H, Cardoso MC.](#) [Related Articles, Links](#)
-  **Direct protein transfer to terminally differentiated muscle cells.**
J Mol Med. 1999 Aug;77(8):609-13.
PMID: 10543392 [PubMed - indexed for MEDLINE]
-  **87:** [Luft FC.](#) [Related Articles, Links](#)
-  **Can VP22 resurrect gene therapy?**
J Mol Med. 1999 Aug;77(8):575-6. No abstract available.
PMID: 10543389 [PubMed - indexed for MEDLINE]
-  **88:** [Pomeranz LE, Blaho JA.](#) [Related Articles, Links](#)
-  **Modified VP22 localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection.**
J Virol. 1999 Aug;73(8):6769-81.
PMID: 10400775 [PubMed - indexed for MEDLINE]
-  **89:** [Elliott G, O'Reilly D, O'Hare P.](#) [Related Articles, Links](#)
-  **Identification of phosphorylation sites within the herpes simplex virus tegument protein VP22.**
J Virol. 1999 Jul;73(7):6203-6.
PMID: 10364384 [PubMed - indexed for MEDLINE]
-  **90:** [Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CL, O'Hare P.](#) [Related Articles, Links](#)
-  **Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.**
Gene Ther. 1999 Jan;6(1):12-21.
PMID: 10341871 [PubMed - indexed for MEDLINE]
-  **91:** [Elliott G, O'Hare P.](#) [Related Articles, Links](#)
-  **Intercellular trafficking of VP22-GFP fusion proteins.**
Gene Ther. 1999 Jan;6(1):149-51.
PMID: 10341888 [PubMed - indexed for MEDLINE]
-  **92:** [Murphy AL, Murphy SJ.](#) [Related Articles, Links](#)
-  **Catch VP22: the hitch-hiker's ride to gene therapy?**
Gene Ther. 1999 Jan;6(1):4-5. No abstract available.
PMID: 10341869 [PubMed - indexed for MEDLINE]
-  **93:** [Elliott G, O'Hare P.](#) [Related Articles, Links](#)

**Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection.**

J Virol. 1999 May;73(5):4110-9.

PMID: 10196307 [PubMed - indexed for MEDLINE]

**94:** [Fang B, Xu B, Koch P, Roth JA.](#)[Related Articles, Links](#)**Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.**

Gene Ther. 1998 Oct;5(10):1420-4.

PMID: 9930348 [PubMed - indexed for MEDLINE]

**95:** [Morrison EE, Stevenson AJ, Wang YF, Meredith DM.](#)[Related Articles, Links](#)**Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells.**

J Gen Virol. 1998 Oct;79 (Pt 10):2517-28.

PMID: 9780059 [PubMed - indexed for MEDLINE]

**96:** [Koelle DM, Frank JM, Johnson ML, Kwok WW.](#)[Related Articles, Links](#)**Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.**

J Virol. 1998 Sep;72(9):7476-83.

PMID: 9696844 [PubMed - indexed for MEDLINE]

**97:** [Morrison EE, Wang YF, Meredith DM.](#)[Related Articles, Links](#)**Phosphorylation of structural components promotes dissociation of the herpes simplex virus type 1 tegument.**

J Virol. 1998 Sep;72(9):7108-14.

PMID: 9696804 [PubMed - indexed for MEDLINE]

**98:** [Elliott G, O'Hare P.](#)[Related Articles, Links](#)**Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules.**

J Virol. 1998 Aug;72(8):6448-55.

PMID: 9658087 [PubMed - indexed for MEDLINE]

**99:** [Phelan A, Elliott G, O'Hare P.](#)[Related Articles, Links](#)**Intercellular delivery of functional p53 by the herpesvirus protein VP22.**

Nat Biotechnol. 1998 May;16(5):440-3.

PMID: 9592391 [PubMed - indexed for MEDLINE]

**100:** [Liang X, Chow B, Babiuk LA.](#)[Related Articles, Links](#)**Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cattle.**

Vaccine. 1997 Jul;15(10):1057-64.

PMID: 9269047 [PubMed - indexed for MEDLINE]

**101:** [Elliott G, O'Hare P.](#)[Related Articles, Links](#)**Intercellular trafficking and protein delivery by a herpesvirus structural protein.**


Cell. 1997 Jan 24;88(2):223-33.

PMID: 9008163 [PubMed - indexed for MEDLINE]

**102:** [McLauchlan J.](#)[Related Articles, Links](#)**The abundance of the herpes simplex virus type 1 UL37 tegument protein in virus particles is closely controlled.**

J Gen Virol. 1997 Jan;78 (Pt 1):189-94.

PMID: 9010303 [PubMed - indexed for MEDLINE]

 **103:** [Elliott G, O'Reilly D, O'Hare P.](#)


Related Articles, Links



Phosphorylation of the herpes simplex virus type 1 tegument protein VP22.

Virology. 1996 Dec 1;226(1):140-5.

PMID: 8941333 [PubMed - indexed for MEDLINE]

 **104:** [Leslie J, Rixon FJ, McLauchlan J.](#)

Related Articles, Links



Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles.

Virology. 1996 Jun 1;220(1):60-8.

PMID: 8659129 [PubMed - indexed for MEDLINE]

 **105:** [Elliott G, Mouzakis G, O'Hare P.](#)

Related Articles, Links



VP16 interacts via its activation domain with VP22, a tegument protein of herpes simplex virus, and is relocated to a novel macromolecular assembly in coexpressing cells.

J Virol. 1995 Dec;69(12):7932-41.

PMID: 7494306 [PubMed - indexed for MEDLINE]

 **106:** [Dargatzis DJ, Patel AH, Subak-Sharpe JH.](#)


Related Articles, Links



PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked.

J Virol. 1995 Aug;69(8):4924-32.

PMID: 7609061 [PubMed - indexed for MEDLINE]

 **107:** [Liang X, Chow B, Li Y, Raggo C, Yoo D, Attah-Poku S, Babiuk LA.](#)


Related Articles, Links



Characterization of bovine herpesvirus 1 UL49 homolog gene and product: bovine herpesvirus 1 UL49 homolog is dispensable for virus growth.

J Virol. 1995 Jun;69(6):3863-7.

PMID: 7745736 [PubMed - indexed for MEDLINE]

 **108:** [Koptidesova D, Kopacek J, Zelnik V, Ross NL, Pastorekova S, Pastorek J.](#)

Related Articles, Links



Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of alpha-transinducing factor (VP16) of HSV-1.

Arch Virol. 1995;140(2):355-62.

PMID: 7710361 [PubMed - indexed for MEDLINE]

 **109:** [Coulter LJ, Moss HW, Lang J, McGeoch DJ.](#)

Related Articles, Links



A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted.

J Gen Virol. 1993 Mar;74 (Pt 3):387-95.

PMID: 8383174 [PubMed - indexed for MEDLINE]

 **110:** [Elliott GD, Meredith DM.](#)


Related Articles, Links



The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49.

J Gen Virol. 1992 Mar;73 (Pt 3):723-6.

PMID: 1312128 [PubMed - indexed for MEDLINE]


 **111:** [Meredith DM, Lindsay JA, Halliburton IW, Whittaker GR.](#)

Related Articles, Links



Post-translational modification of the tegument proteins (VP13 and VP14) of herpes simplex virus type 1 by glycosylation and phosphorylation.

J Gen Virol. 1991 Nov;72 (Pt 11):2771-5.
PMID: 1658203 [PubMed - indexed for MEDLINE]

 **112:** [Baker TS, Newcomb WW, Booy FP, Brown JC, Steven AC.](#)

[Related Articles, Links](#)



Three-dimensional structures of maturable and abortive capsids of equine herpesvirus 1 from cryoelectron microscopy.

J Virol. 1990 Feb;64(2):563-73.

PMID: 2153224 [PubMed - indexed for MEDLINE]

 **113:** [Knopf KW, Kaerner HC.](#)

[Related Articles, Links](#)



Virus-specific basic phosphoproteins associated with herpes simplex virus type a (HSV-1) particles and the chromatin of HSV-1-infected cells.

J Gen Virol. 1980 Feb;46(2):405-14.

PMID: 6247428 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** **Sort** **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 10 2004 06:30:44



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for VP22 AND SV40 Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 2 of 2

One page.

Text Version

1: Roeder GE, Parish JL, Stern PL, Gaston K.

Related Articles, Links



Herpes Simplex Virus VP22-Human Papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.

Biotechnol Appl Biochem. 2004 Jan 7 [Epub ahead of print]
PMID: 14709162 [PubMed - as supplied by publisher]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

2: Derer W, Saswaran HP, Leonhardt H, Cardoso MC.

Related Articles, Links



A novel approach to induce cell cycle reentry in terminally differentiated muscle cells.

FASEB J. 2002 Jan;16(1):132-3. Epub 2001 Nov 29.
PMID: 11729099 [PubMed - indexed for MEDLINE]

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 10 2004 06:30:44



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for VP22 AND cyclin Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 3 of 3

One page.

Text Version

☐ 1: [Zavaglia D, Favrot MC, Eymin B, Tenaud C, Coll JL.](#)

[Related Articles, Links](#)



Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.

Gene Ther. 2003 Feb;10(4):314-25.

PMID: 12595890 [PubMed - indexed for MEDLINE]

☐ 2: [Roy I, Holle L, Song W, Holle E, Wagner T, Yu X.](#)

[Related Articles, Links](#)



Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.

Anticancer Res. 2002 Nov-Dec;22(6A):3185-9.

PMID: 12530063 [PubMed - indexed for MEDLINE]

☐ 3: [Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE.](#)

[Related Articles, Links](#)



Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.

J Virol. 2001 Sep;75(18):8733-41.

PMID: 11507218 [PubMed - indexed for MEDLINE]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 10 2004 06:30:44

Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:32:53 ON 15 SEP 2004

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:33:12 ON 15 SEP 2004

FILE 'AQUALINE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:33:12 ON 15 SEP 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:33:12 ON 15 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:33:12 ON 15 SEP 2004

FILE 'CAPLUS' ENTERED AT 16:33:12 ON 15 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:33:12 ON 15 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:33:12 ON 15 SEP 2004

FILE 'CROPU' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:33:12 ON 15 SEP 2004

FILE 'FOMAD' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:33:12 ON 15 SEP 2004

FILE 'HEALSAFE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetic Chemists

FILE 'LIFESCI' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'NIOSHTIC' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:33:12 ON 15 SEP 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 16:33:12 ON 15 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:33:12 ON 15 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:33:12 ON 15 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:33:12 ON 15 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 16:33:12 ON 15 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:33:12 ON 15 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 16:33:12 ON 15 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

```

=> S VP22
    51 FILES SEARCHED...
L1      2494 VP22

=> S SV40 OR cyclin OR cyclin K OR cyclin V
    18 FILES SEARCHED...
    43 FILES SEARCHED...
    66 FILES SEARCHED...
L2      345179 SV40 OR CYCLIN OR CYCLIN K OR CYCLIN V

=> S L1 AND L2
    55 FILES SEARCHED...
L3      354 L1 AND L2

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4      297 DUP REM L3 (57 DUPLICATES REMOVED)

=> D L4 1-297

L4      ANSWER 1 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
        DUPLICATE 1
AN      2004-15941 BIOTECHDS
TI      Delivering a small interfering RNA (siRNA) to a cell comprises contacting
        the cell with conjugate of siRNA and a delivery peptide or with a mixture
        of siRNA and a dendrimer;
        for use in disorder therapy
AU      RANA T M
PA      UNIV MASSACHUSETTS
PI      WO 2004048545 10 Jun 2004
AI      WO 2003-US37886 24 Nov 2003
PRAI    US 2002-430520 26 Nov 2002; US 2002-430520 26 Nov 2002
DT      Patent
LA      English
OS      WPI: 2004-450364 [42]

L4      ANSWER 2 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 2
AN      10635673 IFIPAT;IFIUDB;IFICDB
TI      USES OF TRANSPORT PROTEINS
IN      Brewis Neil Douglas (GB); Normand Nadia Michelle (GB); O'Hare Peter
        Francis Joseph (GB); Phelan Anne (GB)
PA      Phogen Ltd GB (59743)
PI      US 2004142900 A1 20040722
AI      US 2004-789113 20040226
RLI     US 2000-747772 20001220 CONTINUATION 6734167
PRAI    GB 1999-305195 19991224
FI      US 2004142900 20040722
        US 6734167
DT      Utility; Patent Application - First Publication
FS      CHEMICAL
        APPLICATION
CLMN    15

L4      ANSWER 3 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
AN      10541162 IFIPAT;IFIUDB;IFICDB
TI      CHIMERIC VECTORS AND THEIR USE FOR HETEROLOGOUS GENES TRANSFER
IN      Di Giovine Monica (IT); Saggio Isabella (IT); Salone Barbara (IT); Yuri
        Martina (IT)
PA      Unassigned Or Assigned To Individual (68000)
PI      US 2004048380 A1 20040311
AI      US 2003-381182 20031020
        WO 2001-IB1742 20010921
        20031020 PCT 371 date
        20031020 PCT 102(e) date
FI      US 2004048380 20040311
DT      Utility; Patent Application - First Publication
FS      CHEMICAL
        APPLICATION
CLMN    30
GI      6 Figure(s).

```

Integrins were immobilized on a plate and incubated with Pb phage (4 x 10¹² particles/well), with Delta Pb phage (1 x 10¹² particles/well), or with control phage (4 x 10¹² particles/well). The bound phages were detected with a primary anti-M13 antibody and with a secondary anti-pVIII-HRP antibody. Data are shown as average OD values from tests carried out in two series. Standard deviation (SD) is also shown.

FIG. 2. Electron microscopy for the detection of the binding of chimeric phages to HeLa cells. 10⁵ HeLa cells are incubated at 4 degrees C. with 3 x 10¹² and 9 x 10¹² particles of Delta Pb phage (B, C) and Pb phage (A), respectively. After incubation the cells are treated as for analysis by electron microscope. Original enlargement: A, 15500 x ; B, 5200 x ; C, 11500 x .

FIG. 3. Internalization of chimeric phages into eukaryotic cells, detected by immunofluorescence. 2.5 x 10⁵ HeLa cells are incubated with chimeric phage particles. Panel C, control phage (3 x 10¹² particles/well); panels B, D and E: Delta Pb phage (3 x 10¹² particles/well); panel A: Pb phage (9 x 10¹² particles/well). Panels A, B e C: incubation for 1 hour at 4 degrees C., followed by 1 hour at 37 degrees C.; panels D and E: incubation for only 1 hour at 4 degrees C. to inhibit internalization due to the receptor. The cells are observed with a fluorescence microscope with a 40 x objective.

FIG. 4. Effect of the inhibitors of Wortammanin and ML-7 kinases on cell internalization. 10¹² particles of Delta Pb phage (white bars) or of Pb phage (striped bars) are adsorbed on HeLa cells. The internalized phage is recovered and titrated. The figure also shows the tests carried out in presence of inhibitors of the kinases Wortammanin (WTN, 1 mu M) and ML-7 chloride (ML-7, 2 mu M). Data are shown as percentages of control enrichments carried out without inhibitors. Th results are average values of three different tests carried out in two series; SD (Standard Deviation) is also shown.

FIG. 5. Chimeric phages transduce eukaryotic cells in a receptordependent way. Cells are incubated for 1 hour at 4 degrees C. and for 3 hours at 37 degrees C. with 2 x 10¹³ particles of PbGFP phage or Delta Pb-GFP phage. After 72 hours said cells are analyzed with FACS. For competition tests they are preincubated with GRGDSP or GRGESP peptides (4.86 mu M, corresponding to a molar excess of about 2000 times) for 1 hour at 4 degrees C. and then incubated with chimeric phages. Data are analyzed with WinMDI2.8 software. 104 cells for each well are counted. a) White bars correspond to Delta Pb-GFP phages; b) striped bars correspond to Pb-GFP b) phage.

FIG. 6. In-vitro binding of chimeric lambda phages to integrins. Plates, where alpha nu beta 3 integrin receptor has been immobilized, are incubated with M13 Delta Pb phage (1 x 10¹² particles/well), or with lambda Delta Pb phage (1 x 10⁸ and 1 x 10⁹ particles/well), detected with a primary anti-M13 antibody and with a primary anti-lambda-phage rabbit polyclonal antibody, respectively, then with a secondary anti-pVIII-HRP antibody and with an anti-rabbit HRP antibody (AmershamPharmacia Biotech), respectively. Data are shown as average OD values from tests carried out on two series.

L4 ANSWER 4 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN
AN 04064836 IFIPAT;IFIUDB;IFICDB
TI USES OF TRANSPORT PROTEINS
IN Brewis Neil Douglas (GB); Normand Nadia Michelle (FR); O'Hare Peter Francis Joseph (GB); Phelan Anne (GB)
PA Phogen Ltd GB (59743)
PI US 6734167 B2 20040511
US 2002155988 A1 20021024
AI US 2000-747772 20001220
FI US 6734167 20040511
US 2002155988 20021024
DT Utility; Granted Patent - Utility, with Pre-Grant Publication
FS CHEMICAL
GRANTED
CLMN 11

L4 ANSWER 5 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN
AN 04013021 IFIPAT;IFIUDB;IFICDB
TI RECOMBINANT, MODIFIED ADENOVIRAL VECTORS FOR TUMOR SPECIFIC GENE EXPRESSION AND USES THEREOF; USEFUL FOR REGULATING TRANSGENE EXPRESSION IN CELLS SUCH AS TUMOR CELLS AND THEREFORE, FOR THERAPY OF A VARIETY OF CANCERS
IN Carlson Cheryl A; Lieber Andre; Mi Jie; Steinwaerder Dirk S (DE)
PA Washington, University of (2937)
PI US 6686196 B2 20040203

AI US 2001-849106 20010503
 PRAI US 2000-202367P 20000503 (Provisional)
 FI US 6686196 20040203
 US 2002037280 20020328
 DT Utility; Granted Patent - Utility, with Pre-Grant Publication
 FS CHEMICAL
 GRANTED
 MRN 012425 MFN: 0396
 CLMN 26
 GI 27 Drawing Sheet(s), 32 Figure(s).
 FIGS. 1A, 1B: Hypothetical mechanisms for the formation of a Delta Ad.IR genome, replication activated expression system.
 FIGS. 2I, 2II, 2III: The structure of Ad vectors and a scheme of replication activated transgene expression.
 FIGS. 3A, 3B: Activation of transgene expression in vitro upon Ad vector replication.
 FIG. 4: Comparison of the replication and transgene expression kinetics of Ad.IR-BG and Ad.BG
 FIGS. 5A, 5B, 5C: Expression of HPV E6 and E7 efficiently supports AdE1-DNA replication in vitro and in vivo.
 FIG. 6: A proposed mechanism of replication activated Ad vectors for tumor-specific gene expression which is dependent on recombination between two vectors, each vector containing one homology element.
 FIGS. 7A, 7B: Activation of transgene expression upon coinfection of two Ad vectors each carrying one half of the transgene.
 FIG. 8: Tumor specific beta-Gal expression from Ad.IR-BG in hepatic metastases derived from HeLa cells.
 FIG. 9: Productive AdE1-replication in hepatic metastases in vivo.
 FIG. 10: Replication dependent and tumor specific transgene expression in LOVO cells after infection with Ad.IR-BG.
 FIGS. 11A, 11B: Generation of Rep78 expressing Ad vectors by recombination between two vectors.
 FIG. 12: A fluorescent caspase 3 activity assay.
 FIG. 13: TNF-induced apoptosis.
 FIGS. 14A, 14B: TNF-induced apoptosis on ikBM-expressing HeLa cells facilitates the adenoviral vector release.
 FIG. 15: Induced apoptosis facilitates recombinant Ad vector spreading in mouse model of hepatic metastasis.
 FIGS. 16A, 16B: Analysis of AdE1-DNA replication in tumor cell lines by Southern blot.
 FIG. 17: A table of viral DNA replication ratios in correlation with development of CPE and p53, pRb, and p16 status of tumor cells.
 FIG. 18: AdE1-DNA replication in synchronized HeLa cells infected during different cell cycle phases.
 FIGS. 19A, 19B: AdE1-DNA replication within cells arrested in G2/M by nocodazole.
 FIGS. 20A, 20B, 20C, 20D: Replication of AdE1-in cervical carcinoma cells.

L4 ANSWER 6 OF 297 USPATFULL on STN
 AN 2004:227896 USPATFULL
 TI Cellular delivery and activation of polypeptide-nucleic acid complexes
 IN Dalby, Brian, Carlsbad, CA, UNITED STATES
 Bennett, Robert P., Encinitas, CA, UNITED STATES
 PI US 2004176282 A1 20040909
 AI US 2004-755082 A1 20040109 (10)
 PRAI US 2003-438778P 20030109 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5636
 INCL INCLM: 514/008.000
 INCLS: 514/012.000
 NCL NCLM: 514/008.000
 NCLS: 514/012.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-16

L4 ANSWER 7 OF 297 USPATFULL on STN
 AN 2004:226999 USPATFULL
 TI Protein kinase C as a target for the treatment of respiratory syncytial virus
 IN Mohapatra, Shyam S., Tampa, FL, UNITED STATES
 Vergara, Homero Gabriel San Juan, Tampa, FL, UNITED STATES
 PI US 2004175384 A1 20040909
 AI US 2003-734548 A1 20031212 (10)

DT Utility
FS APPLICATION
LN.CNT 1669
INCL INCLM: 424/146.100
INCLS: 514/044.000
NCL NCLM: 424/146.100
NCLS: 514/044.000
IC [7]
ICM: A61K039-395
ICS: A61K048-00

L4 ANSWER 8 OF 297 USPATFULL on STN
AN 2004:221783 USPATFULL
TI Compositions and methods for enhancing apoptosis
IN Deshayes, Kurt, San Francisco, CA, UNITED STATES
Fairbrother, Wayne, Burlingame, CA, UNITED STATES
Flygare, John, Burlingame, CA, UNITED STATES
Franklin, Matthew C., San Francisco, CA, UNITED STATES
Fischer, Saloumeh, Casto Valley, CA, UNITED STATES
Vucic, Domagoj, San Francisco, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 2004171554 A1 20040902
AI US 2003-364645 A1 20030207 (10)
DT Utility
FS APPLICATION
LN.CNT 2998
INCL INCLM: 514/016.000
INCLS: 530/328.000
NCL NCLM: 514/016.000
NCLS: 530/328.000
IC [7]
ICM: A61K038-08
ICS: C07K007-06

L4 ANSWER 9 OF 297 USPATFULL on STN
AN 2004:215981 USPATFULL
TI Covalent modification of RNA for in vitro and in vivo delivery
IN Monahan, Sean D., Madison, WI, UNITED STATES
Budker, Vladimir G., Middleton, WI, UNITED STATES
Nader, Lisa, Madison, WI, UNITED STATES
Subbotin, Vladimir, Madison, WI, UNITED STATES
Wolff, Jon A., Madison, WI, UNITED STATES
PI US 2004167090 A1 20040826
AI US 2004-782075 A1 20040219 (10)
PRAI US 2003-448789P 20030221 (60)
US 2003-455724P 20030318 (60)
DT Utility
FS APPLICATION
LN.CNT 1757
INCL INCLM: 514/044.000
INCLS: 435/455.000
NCL NCLM: 514/044.000
NCLS: 435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N015-85

L4 ANSWER 10 OF 297 USPATFULL on STN
AN 2004:209319 USPATFULL
TI Modular vector systems
IN Jarrell, Kevin A., Lincoln, MA, UNITED STATES
Donahue, William F., Quincy, MA, UNITED STATES
Turczyk, Brian M., Peabody, MA, UNITED STATES
PI US 2004161752 A1 20040819
AI US 2003-383135 A1 20030305 (10)
RLI Continuation-in-part of Ser. No. US 2001-910354, filed on 20 Jul 2001,
PENDING
PRAI WO 2001-US22831 20010720
US 2002-362253P 20020306 (60)
US 2000-219820P 20000721 (60)
DT Utility
FS APPLICATION
LN.CNT 1521
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/023.200

IC NCLS: 435/091.200; 536/023.200
 [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12P019-34

L4 ANSWER 11 OF 297 USPATFULL on STN
 AN 2004:196462 USPATFULL
 TI Protein and peptide delivery to mammalian cells in vitro
 IN Monahan, Sean D., Madison, WI, UNITED STATES
 Budker, Vladimir G., Middleton, WI, UNITED STATES
 Ekena, Kirk, Middleton, WI, UNITED STATES
 Nader, Lisa, Madison, WI, UNITED STATES
 PI US 2004151766 A1 20040805
 AI US 2004-767329 A1 20040129 (10)
 PRAI US 2003-443645P 20030130 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1621
 INCL INCLM: 424/450.000
 NCL NCLM: 424/450.000
 IC [7]
 ICM: A61K009-127
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 297 USPATFULL on STN
 AN 2004:196392 USPATFULL
 TI Oncolytic adenovirus
 IN Johnson, Leisa, Lafayette, CA, UNITED STATES
 Fattaey, Ali, San Francisco, CA, UNITED STATES
 Hermiston, Terry, Corte Madera, CA, UNITED STATES
 Shen, Yuguao, Orinda, CA, UNITED STATES
 Laquerre, Sylvie, Conshohocken, PA, UNITED STATES
 PI US 2004151696 A1 20040805
 AI US 2002-303598 A1 20021125 (10)
 RLI Continuation-in-part of Ser. No. US 2000-714409, filed on 14 Nov 2000,
 PENDING
 PRAI US 1999-165638P 19991115 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1673
 INCL INCLM: 424/093.200
 INCLS: 435/456.000; 435/235.100
 NCL NCLM: 424/093.200
 NCLS: 435/456.000; 435/235.100
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-861
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 297 USPATFULL on STN
 AN 2004:190174 USPATFULL
 TI Reverse protein delivery into cells on coded microparticles
 IN Fang, Ye, Painted Post, NY, UNITED STATES
 Webb, Brian L., Painted Post, NY, UNITED STATES
 PI US 2004146944 A1 20040729
 AI US 2003-353496 A1 20030129 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 705
 INCL INCLM: 435/007.200
 NCL NCLM: 435/007.200
 IC [7]
 ICM: G01N033-53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 297 USPATFULL on STN
 AN 2004:190119 USPATFULL
 TI Inducible regulatory system and use thereof
 IN Dowdy, Steven F., Clayton, MO, UNITED STATES
 Jessee, Joel A., Mount Airy, MD, UNITED STATES
 PA Washington University (U.S. corporation)
 PI US 2004146889 A1 20040729
 AI US 2003-680576 A1 20031006 (10)
 RLI Continuation of Ser. No. US 1998-134793, filed on 14 Aug 1998, ABANDONED
 PRAI US 1997-56713P 19970822 (60)

FS APPLICATION
LN.CNT 848
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/455.000; 435/325.000
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/455.000; 435/325.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 297 USPATFULL on STN
AN 2004:185006 USPATFULL
TI Autogene nucleic acids encoding a secretable RNA polymerase
IN Finn, John, Vancouver, CANADA
MacLachlan, Ian, Vancouver, CANADA
PA The University of British Columbia, Vancouver, CANADA, V6T 1Z3 (non-U.S. corporation)
PI US 2004142892 A1 20040722
AI US 2003-688299 A1 20031016 (10)
RLI Continuation-in-part of Ser. No. US 2002-136738, filed on 30 Apr 2002, PENDING
PRAI US 2001-287974P 20010430 (60)
DT Utility
FS APPLICATION
LN.CNT 2661
INCL INCLM: 514/044.000
INCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 514/044.000
NCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N009-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 297 USPATFULL on STN
AN 2004:178455 USPATFULL
TI Modular transfection systems
IN Schmidt, Hanns-Martin, Koln, GERMANY, FEDERAL REPUBLIC OF
Altrogge, Ludger, Pulheim, GERMANY, FEDERAL REPUBLIC OF
Lenz, Dietmar, Koln, GERMANY, FEDERAL REPUBLIC OF
Riemen, Gudula, Langenfeld, GERMANY, FEDERAL REPUBLIC OF
Brosterhus, Helmut, Kirchhunden, GERMANY, FEDERAL REPUBLIC OF
Lorbach, Elke, Koln, GERMANY, FEDERAL REPUBLIC OF
Helfrich, Juliana, Koln, GERMANY, FEDERAL REPUBLIC OF
Hein, Katharina, Koln, GERMANY, FEDERAL REPUBLIC OF
Gremse, Marion, Koln, GERMANY, FEDERAL REPUBLIC OF
Males, Tarjana, Hilden, GERMANY, FEDERAL REPUBLIC OF
Christine, Rainer, Koln, GERMANY, FEDERAL REPUBLIC OF
Siebenkotten, Gregor, Freehen-Konigsdorf, GERMANY, FEDERAL REPUBLIC OF
Ortmann, Bodo, Koln, GERMANY, FEDERAL REPUBLIC OF
Klacs, Andrea, Koln, GERMANY, FEDERAL REPUBLIC OF
PI US 2004137622 A1 20040715
AI US 2003-466368 A1 20030813 (10)
WO 2002-DE60 20020110
PRAI DE 2001-100996 20010110
DT Utility
FS APPLICATION
LN.CNT 1730
INCL INCLM: 435/455.000
NCL NCLM: 435/455.000
IC [7]
ICM: C12N015-63
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 297 USPATFULL on STN
AN 2004:177796 USPATFULL
TI Devices and processes for distribution of genetic material to mammalian limb
IN Wolff, Jon A., Madison, WI, UNITED STATES
Budker, Vladimir, Madison, WI, UNITED STATES
PI US 2004136960 A1 20040715
AI US 2003-339935 A1 20030110 (10)
DT Utility

LN.CNT 1375
INCL INCLM: 424/093.200
INCLS: 514/044.000; 602/013.000; 435/456.000
NCL NCLM: 424/093.200
NCLS: 514/044.000; 602/013.000; 435/456.000
IC [7]
ICM: A61K048-00
ICS: A61F005-00; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 297 USPATFULL on STN
AN 2004:172805 USPATFULL
TI Antibodies, peptides, analogs and uses thereof
IN Melvin, William Thomas, Aberdeen, UNITED KINGDOM
Thompson, William Douglas, Inverurie, UNITED KINGDOM
Stirk, Christina Maureen, Stonghaven, UNITED KINGDOM
PI US 2004132969 A1 20040708
AI US 2004-450073 A1 20040217 (10)
WO 2001-GB5505 20011212
PRAI GB 2000-30309 20001212
DT Utility
FS APPLICATION
LN.CNT 2278
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 297 USPATFULL on STN
AN 2004:171927 USPATFULL
TI Expression vectors encoding epitopes of target-associated antigens and
methods for their design
IN Simard, John J.L., Vancouver, CANADA
Diamond, David C., West Hills, CA, UNITED STATES
Qiu, Zhiyong, Los Angeles, CA, UNITED STATES
Lei, Xiang-Dong, West Hills, CA, UNITED STATES
PI US 2004132088 A1 20040708
AI US 2004-777053 A1 20040210 (10)
RLI Continuation of Ser. No. US 2002-292413, filed on 7 Nov 2002, PENDING
PRAI US 2001-336968P 20011107 (60)
DT Utility
FS APPLICATION
LN.CNT 10074
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 297 USPATFULL on STN
AN 2004:171872 USPATFULL
TI Human heparanase gene regulatory sequences
IN Wolffe, Elizabeth J., Orinda, CA, UNITED STATES
Wolffe, Alan P., Orinda, CA, UNITED STATES LR
Qi, Hong, Cottonwood, CA, UNITED STATES
PI US 2004132033 A1 20040708
AI US 2003-433258 A1 20031023 (10)
WO 2001-US44798 20011130
DT Utility
FS APPLICATION
LN.CNT 2863
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/200.000; 435/320.100; 435/325.000; 536/023.200;
536/021.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/200.000; 435/320.100; 435/325.000; 536/023.200;
536/021.000
IC [7]
ICM: C12Q001-68
ICS: C08B037-10; C07H021-04; C12N009-24

L4 ANSWER 21 OF 297 USPATFULL on STN
 AN 2004:151549 USPATFULL
 TI Polypeptides for increasing mutant CFTR channel activity
 IN Robbins, Paul D., Mt. Lebanon, PA, UNITED STATES
 Frizzell, Raymond, Pittsburgh, PA, UNITED STATES
 Mi, Zhibao, Pittsburgh, PA, UNITED STATES
 Sun, Fei, Warrendale, PA, UNITED STATES
 PI US 2004115770 A1 20040617
 AI US 2003-650435 A1 20030828 (10)
 PRAI US 2002-407461P 20020830 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1177
 INCL INCLM: 435/069.100
 INCLS: 435/455.000; 435/320.100; 435/325.000; 530/350.000
 NCL NCLM: 435/069.100
 NCLS: 435/455.000; 435/320.100; 435/325.000; 530/350.000
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 297 USPATFULL on STN
 AN 2004:150963 USPATFULL
 TI Methods and compositions for modifying apolipoprotein b mrna editing
 IN Smith, Harold C, South Rochester, NY, UNITED STATES
 Yang, Yan, Bar Harbor, ME, UNITED STATES
 Sowden, Mark P, Penfield, NY, UNITED STATES
 PI US 2004115184 A1 20040617
 AI US 2004-468987 A1 20040109 (10)
 WO 2002-US5824 20020226
 DT Utility
 FS APPLICATION
 LN.CNT 3805
 INCL INCLM: 424/094.500
 INCLS: 435/194.000
 NCL NCLM: 424/094.500
 NCLS: 435/194.000
 IC [7]
 ICM: A61K038-48
 ICS: C12N009-12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 297 USPATFULL on STN
 AN 2004:144197 USPATFULL
 TI TSG101-GAG interaction and use thereof
 IN Zavitz, Kenton, Salt Lake City, UT, UNITED STATES
 Morham, Scott, Salt Lake City, UT, UNITED STATES
 Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
 PI US 2004109861 A1 20040610
 AI US 2003-663407 A1 20030915 (10)
 RLI Continuation-in-part of Ser. No. WO 2002-US8146, filed on 14 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2002-223172, filed on 19 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-224999, filed on 20 Aug 2002, PENDING
 PRAI US 2001-276259P 20010314 (60)
 US 2001-313239P 20010818 (60)
 US 2001-313695P 20010820 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4490
 INCL INCLM: 424/148.100
 NCL NCLM: 424/148.100
 IC [7]
 ICM: A61K039-42
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 297 USPATFULL on STN
 AN 2004:138672 USPATFULL
 TI Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
 IN Federoff, Howard J., Rochester, NY, UNITED STATES

PI US 2004105844 A1 20040603
AI US 2003-296551 A1 20030418 (10)
WO 2001-US16682 20010523
DT Utility
FS APPLICATION
LN.CNT 2357
INCL INCLM: 424/093.200
INCLS: 435/005.000
NCL NCLM: 424/093.200
NCLS: 435/005.000
IC [7]
ICM: C12Q001-70
ICS: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 297 USPATFULL on STN
AN 2004:132976 USPATFULL
TI Adenoviral vectors for treating disease
IN Hermiston, Terry, Corte Madera, CA, UNITED STATES
Hawkins, Lynda K., Germantown, MD, UNITED STATES
Johnson, Leisa, Richmond, CA, UNITED STATES
PA Onyx Pharmaceuticals (U.S. corporation)
PI US 2004101512 A1 20040527
AI US 2002-306275 A1 20021127 (10)
RLI Continuation-in-part of Ser. No. US 1999-347604, filed on 2 Jul 1999,
ABANDONED Continuation-in-part of Ser. No. US 1999-290732, filed on 13
Apr 1999, ABANDONED
PRAI US 1999-117103P 19990125 (60)
US 1999-117103P 19990125 (60)

DT Utility
FS APPLICATION
LN.CNT 2471
INCL INCLM: 424/093.200
NCL NCLM: 424/093.200
IC [7]
ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 297 USPATFULL on STN
AN 2004:114006 USPATFULL
TI Superior molecular vaccine linking the translocation domain of a
bacterial toxin to an antigen
IN Wu, Tzyy-Choou, Stevenson, MD, UNITED STATES
Hung, Chien-Fu, Baltimore, MD, UNITED STATES
PI US 2004086845 A1 20040506
AI US 2002-115440 A1 20020404 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US41422, filed on 20 Oct 2000,
PENDING Continuation-in-part of Ser. No. US 2000-501097, filed on 9 Feb
2000, PENDING Continuation-in-part of Ser. No. US 1999-421608, filed on
20 Oct 1999, ABANDONED

PRAI US 2001-281003P 20010404 (60)
DT Utility
FS APPLICATION
LN.CNT 3328
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/391.100;
536/023.530; 435/007.320
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/391.100;
536/023.530; 435/007.320
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-554; G01N033-569; C07H021-04; C07K014-005;
C07K014-195; C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 297 USPATFULL on STN
AN 2004:94866 USPATFULL
TI Molecules that modulate ubiquitin-dependent proteolysis and methods for
identifying same
IN Nash, Piers, Ontario, CANADA
Pawson, Anthony, Ontario, CANADA
Tang, Xiaojing, Ontario, CANADA
Tyers, Michael, Ontario, CANADA
PI US 2004072319 A1 20040415

WO 2001-CA632 20010504
DT Utility
FS APPLICATION
LN.CNT 3792
INCL INCLM: 435/226.000
INCLS: 435/320.100; 435/325.000
NCL NCLM: 435/226.000
NCLS: 435/320.100; 435/325.000
IC [7]
ICM: C12N009-64
ICS: C12N015-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 297 USPATFULL on STN
AN 2004:94818 USPATFULL
TI Cell-based fluorescence resonance energy transfer (FRET) assays for
clostridial toxins
IN Fernandez-Salas, Ester, Fullerton, CA, UNITED STATES
Steward, Lance E., Irvine, CA, UNITED STATES
Aoki, Kei Roger, Coto de Caza, CA, UNITED STATES
PI US 2004072270 A1 20040415
AI US 2002-261161 A1 20020927 (10)
DT Utility
FS APPLICATION
LN.CNT 4693
INCL INCLM: 435/007.320
INCLS: 435/023.000; 530/350.000
NCL NCLM: 435/007.320
NCLS: 435/023.000; 530/350.000
IC [7]
ICM: G01N033-554
ICS: G01N033-569; C12Q001-37; C07K014-33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 297 USPATFULL on STN
AN 2004:83451 USPATFULL
TI Gene differentially expressed in breast and bladder cancer and encoded
polypeptides
IN Zauderer, Maurice, Pittsford, NY, UNITED STATES
Evans, Elizabeth E., Rochester, NY, UNITED STATES
Borrello, Melinda A., Pittsford, NY, UNITED STATES
PI US 2004063907 A1 20040401
AI US 2003-457829 A1 20030610 (10)
PRAI US 2003-464650P 20030423 (60)
US 2002-432241P 20021211 (60)
US 2002-386738P 20020610 (60)
DT Utility
FS APPLICATION
LN.CNT 15662
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 297 USPATFULL on STN
AN 2004:64282 USPATFULL
TI Use of activity-dependent neurotrophic factor-derived polypeptides for
enhancing learning and memory:pre-and post-natal administration
IN Spong, Catherine Y, Arlington, VA, UNITED STATES
Brenneman, Douglas, Damascus, MD, UNITED STATES
Gozes, Illana, Ramat Hasharon, ISRAEL
PI US 2004048801 A1 20040311
AI US 2002-296849 A1 20021127 (10)
WO 2001-US17758 20010531
DT Utility
FS APPLICATION
LN.CNT 2426
INCL INCLM: 514/015.000
INCLS: 514/016.000
NCL NCLM: 514/015.000
NCLS: 514/016.000

ICM: A61K038-10

ICS: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 297 USPATFULL on STN
AN 2004:57461 USPATFULL
TI Peptide-tagged proteins and compositions for regulating features of the
skin or hair; methods of making, and methods of using thereof
IN Rao, Pingfan, Fuzhou, CHINA
PI US 2004043463 A1 20040304
AI US 2002-232410 A1 20020903 (10)
DT Utility
FS APPLICATION
LN.CNT 849
INCL INCLM: 435/184.000
INCLS: 435/189.000; 435/193.000; 435/198.000; 435/069.700
NCL NCLM: 435/184.000
NCLS: 435/189.000; 435/193.000; 435/198.000; 435/069.700
IC [7]
ICM: C12N009-99
ICS: C12N009-02; C12N009-10; C12N009-20; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 297 USPATFULL on STN
AN 2004:50873 USPATFULL
TI Biologic modulations with nanoparticles
IN Unger, Gretchen M., Chaska, MN, UNITED STATES
PI US 2004038303 A1 20040226
AI US 2003-378044 A1 20030228 (10)
PRAI US 2002-394315P 20020708 (60)
US 2002-370882P 20020408 (60)
US 2002-428296P 20021122 (60)
DT Utility
FS APPLICATION
LN.CNT 2912
INCL INCLM: 435/007.100
INCLS: 530/350.000; 530/387.100; 530/396.000; 536/123.000
NCL NCLM: 435/007.100
NCLS: 530/350.000; 530/387.100; 530/396.000; 536/123.000
IC [7]
ICM: G01N033-53
ICS: C07K014-705; C07K014-415; C07K016-28; C08B037-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 297 USPATFULL on STN
AN 2004:45205 USPATFULL
TI Human pellino polypeptides
IN Bird, Timothy A, Bainbridge Island, UNITED KINGDOM
Cosman, David J., Bainbridge Island, UNITED KINGDOM
PI US 2004034199 A1 20040219
AI US 2003-258703 A1 20030729 (10)
WO 2001-US13676 20010427
DT Utility
FS APPLICATION
LN.CNT 3597
INCL INCLM: 530/358.000
INCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 530/358.000
NCLS: 435/069.100; 435/199.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-22
ICS: C07H021-04; C07K014-705; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 297 USPATFULL on STN
AN 2004:38742 USPATFULL
TI Carrier vectors through an epithelium with tight junctions
IN Joliot, Alain, Paris, FRANCE
Dupont, Edmond, Paris, FRANCE
Prochiantz, Alain, Paris, FRANCE
PI US 2004029281 A1 20040212
AI US 2003-432291 A1 20030520 (10)
WO 2001-FR3631 20011120
PRAI FR 2000-14945 20001120
DT Utility

LN.CNT 638
INCL INCLM: 435/456.000
INCLS: 530/326.000; 530/327.000
NCL NCLM: 435/456.000
NCLS: 530/326.000; 530/327.000
IC [7]
ICM: C12N015-867
ICS: C07K007-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 297 USPATFULL on STN
AN 2004:38157 USPATFULL
TI Molecular vaccine linking intercellular spreading protein to an antigen
IN Wu, Tzyy Choou, Brookeville, MD, UNITED STATES
Hung, Chien-Fu, Baltimore, MD, UNITED STATES
PI US 2004028693 A1 20040212
AI US 2003-343719 A1 20030808 (10)
WO 2001-US23966 20010801
DT Utility
FS APPLICATION
LN.CNT 3384
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 297 USPATFULL on STN
AN 2004:38071 USPATFULL
TI Methods of modulating tubulin deacetylase activity
IN Verdin, Eric M., San Francisco, CA, UNITED STATES
North, Brian J., San Francisco, CA, UNITED STATES
Ulrich, Scott M., Ithaca, NY, UNITED STATES
PI US 2004028607 A1 20040212
AI US 2003-441854 A1 20030519 (10)
PRAI US 2002-382218P 20020520 (60)
DT Utility
FS APPLICATION
LN.CNT 2808
INCL INCLM: 424/001.110
INCLS: 435/019.000
NCL NCLM: 424/001.110
NCLS: 435/019.000
IC [7]
ICM: A61M036-14
ICS: A61K051-00; C12Q001-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 297 USPATFULL on STN
AN 2004:31252 USPATFULL
TI Method and device for protein delivery into cells
IN Fang, Ye, Painted Post, NY, UNITED STATES
Lai, Fang, Painted Post, NY, UNITED STATES
Picard, Laurent A.G., Corning, NY, UNITED STATES
Webb, Brian L., Painted Post, NY, UNITED STATES
PI US 2004023391 A1 20040205
AI US 2002-208894 A1 20020730 (10)
DT Utility
FS APPLICATION
LN.CNT 1324
INCL INCLM: 435/458.000
INCLS: 435/366.000
NCL NCLM: 435/458.000
NCLS: 435/366.000
IC [7]
ICM: C12N005-08
ICS: C12N015-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 297 USPATFULL on STN
AN 2004:30632 USPATFULL
TI Methods and compositions to induce antitumor response
IN LaFace, Drake M., San Diego, CA, UNITED STATES
PI US 2004022769 A1 20040205
AI US 2003-435893 A1 20030512 (10)

Pat. No. US 6649158
PRAI US 1998-104370P 19981015 (60)
DT Utility
FS APPLICATION
LN.CNT 1031
INCL INCLM: 424/093.200
INCLS: 435/456.000; 435/235.100; 435/320.100
NCL NCLM: 424/093.200
NCLS: 435/456.000; 435/235.100; 435/320.100
IC [7]
ICM: A61K048-00
ICS: C12N015-861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 297 USPATFULL on STN
AN 2004:25160 USPATFULL
TI Gene repair involving the induction of double-stranded DNA cleavage at a
chromosomal target site
IN Choulika, Andre, Paris, FRANCE
Mulligan, Richard C., Lincoln, MA, UNITED STATES
PA The Children's Medical Center Corporation, Boston, MA (non-U.S.
corporation)
The Institute Pasteur, Paris, FRANCE (non-U.S. corporation)
PI US 2004019002 A1 20040129
AI US 2003-337229 A1 20030106 (10)
RLI Continuation of Ser. No. US 2001-917295, filed on 27 Jul 2001, ABANDONED
Continuation of Ser. No. WO 2000-US3014, filed on 3 Feb 2000, PENDING
PRAI US 1999-118669P 19990203 (60)
DT Utility
FS APPLICATION
LN.CNT 1130
INCL INCLM: 514/044.000
INCLS: 435/455.000
NCL NCLM: 514/044.000
NCLS: 435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N015-85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 297 USPATFULL on STN
AN 2004:12649 USPATFULL
TI Anti-pathogen treatments
IN Rider, Todd H., Littleton, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA (U.S. corporation)
PI US 2004009167 A1 20040115
AI US 2003-361208 A1 20030207 (10)
PRAI US 2002-355359P 20020207 (60)
US 2002-355022P 20020207 (60)
US 2002-432386P 20021210 (60)
DT Utility
FS APPLICATION
LN.CNT 9654
INCL INCLM: 424/132.100
INCLS: 424/159.100; 424/164.100
NCL NCLM: 424/132.100
NCLS: 424/159.100; 424/164.100
IC [7]
ICM: A61K039-40
ICS: A61K039-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 297 USPATFULL on STN
AN 2004:12634 USPATFULL
TI Materials and methods for prevention and treatment of RNA viral diseases
IN Mohapatra, Shyam S., Tampa, FL, UNITED STATES
Behera, Aruna K., Boston, MA, UNITED STATES
PI US 2004009152 A1 20040115
AI US 2003-426436 A1 20030430 (10)
PRAI US 2002-319216P 20020430 (60)
US 2002-319313P 20020612 (60)
DT Utility
FS APPLICATION
LN.CNT 4097
INCL INCLM: 424/093.200

NCL NCLM: 424/093.200
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 297 USPATFULL on STN
AN 2004:7465 USPATFULL
TI Poroplasts
IN Surber, Mark W., Coronado, CA, UNITED STATES
Giacalone, Matthew, San Diego, CA, UNITED STATES
PI US 2004005700 A1 20040108
AI US 2002-157339 A1 20020528 (10)
DT Utility
FS APPLICATION
LN.CNT 18539
INCL INCLM: 435/317.100
INCLS: 435/455.000; 435/252.300
NCL NCLM: 435/317.100
NCLS: 435/455.000; 435/252.300
IC [7]
ICM: C12N001-20
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 297 USPATFULL on STN
AN 2004:2432 USPATFULL
TI Targeted immunogens
IN Uger, Robert Adam, Richmond Hill, CA, UNITED STATES
Salha, Danielle, Toronto, CANADA
Barber, Brian, White Plains, NY, UNITED STATES
Morse, Clarence C., Asbury, NJ, UNITED STATES
Guo, Yong, Freshmeadows, NJ, UNITED STATES
Cheng, Su, Bridgewater, NJ, UNITED STATES
PA Aventis Pasteur, Ltd., Toronto, CANADA (U.S. corporation)
Aventis Pharmaceuticals, Inc., Bridgewater, NJ (U.S. corporation)
PI US 2004002455 A1 20040101
AI US 2003-353678 A1 20030129 (10)
RLI Continuation-in-part of Ser. No. US 2002-219850, filed on 15 Aug 2002,
PENDING
PRAI US 2002-352892P 20020129 (60)
DT Utility
FS APPLICATION
LN.CNT 1498
INCL INCLM: 514/012.000
INCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 514/012.000
NCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06; C07K014-705; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 297 USPATFULL on STN
AN 2004:223709 USPATFULL
TI Interaction between the VHL tumor suppressor and hypoxia inducible
factor, and assay methods relating thereto
IN Ratcliffe, Peter John, Oxford, UNITED KINGDOM
Maxwell, Patrick Henry, Oxford, UNITED KINGDOM
Pugh, Christopher William, Oxford, UNITED KINGDOM
PA ISIS Innovation Limited, Oxford, UNITED KINGDOM (non-U.S. corporation)
PI US 6787326 B1 20040907
WO 2000069908 20001123
AI US 2001-959873 20011109 (9)
WO 2000-GB1826 20000512
PRAI GB 1999-11047 19990512
DT Utility
FS GRANTED
LN.CNT 2081
INCL INCLM: 435/014.000
INCLS: 435/006.000; 435/007.100; 435/008.000; 530/350.000
NCL NCLM: 435/014.000
NCLS: 435/006.000; 435/007.100; 435/008.000; 530/350.000
IC [7]
ICM: C12Q001-54

EXF 435/8; 435/14; 435/4; 435/6; 435/7.1; 435/7.2; 435/7.31; 530/350

L4 ANSWER 45 OF 297 USPATFULL on STN
AN 2004:223661 USPATFULL
TI Peptide having for fibrinogen fragment E activity, analogs, antibodies and uses thereof
IN Melvin, William Thomas, Aberdeen, UNITED KINGDOM
Thompson, William Douglas, Aberdeen, UNITED KINGDOM
Stirk, Christina Maureen, Aberdeen, UNITED KINGDOM
PA The University Court of The University of Aberdeen, Aberdeen, UNITED KINGDOM (non-U.S. corporation)
PI US 6787141 B1 20040907
WO 2000075175 20001214
AI US 2002-9049 20020401 (10)
WO 2000-GB2197 20000607
PRAI GB 1999-12994 19990607
DT Utility
FS GRANTED
LN.CNT 1463
INCL INCLM: 424/185.100
INCLS: 530/326.000; 514/014.000
NCL NCLM: 424/185.100
NCLS: 530/326.000; 514/014.000
IC [7]
ICM: A61K039-00
ICS: A61K038-00; C07K007-00
EXF 530/326; 424/185.1; 424/192.1; 514/2; 514/14

L4 ANSWER 46 OF 297 USPATFULL on STN
AN 2004:211555 USPATFULL
TI RIP60 nucleic acid and polypeptide sequences and uses therefor
IN Heintz, Nicholas H., Jericho, VT, United States
Houchens, Christopher R., Baltimore, MD, United States
PA University of Vermont and State Agricultural College, Burlington, VT, United States (U.S. corporation)
PI US 6780986 B1 20040824
AI US 2000-477392 20000104 (9)
PRAI US 1999-114745P 19990104 (60)
US 1999-114743P 19990104 (60)
DT Utility
FS GRANTED
LN.CNT 3978
INCL INCLM: 536/023.500
INCLS: 536/023.100; 435/069.100; 435/071.100; 435/091.400; 435/455.000
NCL NCLM: 536/023.500
NCLS: 536/023.100; 435/069.100; 435/071.100; 435/091.400; 435/455.000
IC [7]
ICM: C07H021-04
EXF 536/23.1; 536/23.5; 435/69.1; 435/71.1; 435/91.4; 435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 297 USPATFULL on STN
AN 2004:199506 USPATFULL
TI Delivery of functional protein sequences by translocating polypeptides
IN Dalby, Brian, Carlsbad, CA, United States
Bennett, Robert P., Encinitas, CA, United States
PA Invitrogen Corporation, Carlsbad, CA, United States (U.S. corporation)
PI US 6773920 B1 20040810
WO 2000058488 20001005
AI US 2002-937837 20020107 (9)
WO 2000-US8571 20000331
PRAI US 1999-127467P 19990331 (60)
DT Utility
FS GRANTED
LN.CNT 2141
INCL INCLM: 435/462.000
INCLS: 435/455.000; 435/471.000; 435/468.000; 530/300.000; 530/350.000
NCL NCLM: 435/462.000
NCLS: 435/455.000; 435/471.000; 435/468.000; 530/300.000; 530/350.000
IC [7]
ICM: C12N015-87
ICS: C12N015-67; A61K038-00
EXF 435/462; 435/455; 435/471; 435/468; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:129601 USPATFULL
 TI Nucleic acid transfer phage
 IN Akuta, Teruo, Kumamoto, JAPAN
 Yokoi, Haruhiko, Tokyo, JAPAN
 Okuyama, Hajime, Hyogo, JAPAN
 Takeda, Katsuo, late of Tokyo, JAPAN deceased
 Eiko Takeda, United States legal representative
 Hasegawa, Mamoru, Ibaraki, JAPAN
 Nakanishi, Mahito, Osaka, JAPAN
 PA DNAMEC Research, Inc., JAPAN (non-U.S. corporation)
 PI US 6740524 B1 20040525
 WO 9966061 19991223
 AI US 2001-720003 20010904 (9)
 WO 1999-JP3272 19990618
 PRAI JP 1998-189845 19980618
 DT Utility
 FS GRANTED
 LN.CNT 887
 INCL INCLM: 435/456.000
 INCLS: 530/350.000; 435/320.100; 435/252.300; 435/252.330; 435/235.100;
 435/069.700; 435/975.000; 536/023.400
 NCL NCLM: 435/456.000
 NCLS: 435/069.700; 435/235.100; 435/252.300; 435/252.330; 435/320.100;
 435/975.000; 530/350.000; 536/023.400
 IC [7]
 ICM: C12N015-86
 ICS: C12N015-62; C12N001-21; C12N005-10; C07K019-00
 EXF 530/350; 435/235.1; 435/320.1; 435/252.33; 435/456; 435/69.7; 435/975;
 536/23.4; 424/93.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 49 OF 297 USPATFULL on STN
 AN 2004:53300 USPATFULL
 TI Tethered ligands and methods of use
 IN Schall, Thomas J., Menlo Park, CA, United States
 Premack, Brett, San Francisco, CA, United States
 Miao, Zhenhua, San Jose, CA, United States
 Wei, Zheng, Redwood City, CA, United States
 PA ChemoCentryx, Inc., San Carlos, CA, United States (U.S. corporation)
 PI US 6699677 B1 20040302
 AI US 2000-721908 20001124 (9)
 PRAI US 2000-186626P 20000303 (60)
 US 1999-172979P 19991220 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2860
 INCL INCLM: 435/007.240
 INCLS: 435/069.700; 435/325.000; 436/501.000
 NCL NCLM: 435/007.240
 NCLS: 435/069.700; 435/325.000; 436/501.000
 IC [7]
 ICM: G01N033-567
 ICS: G01N033-566; C12P021-04; C12N005-00
 EXF 436/501; 435/7.24; 435/69.7; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 50 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 DUPLICATE 4
 AN 2003-19598 BIOTECHDS
 TI New peptides and related expression vectors, useful for inhibiting
 tumors, especially where caused by human papilloma virus, bind to the
 phosphorylation site of casein kinase II;
 recombinant fusion protein for use in cancer and virus infection
 therapy
 AU PEREA RODRIGUEZ S E; REYES ACOSTA O; SANTIAGO VISPO N F; PUCHADES
 IZAGUIRRE Y; SILVA RODRIGUEZ R; MORO SORIA A; SANTOS SAVIO A; GONZALEZ
 LOPEZ L J; GONZALEZ BARRIOS B
 PA CENT ING GENETICA and BIOTECNOLOGIA
 PI WO 2003054002 3 Jul 2003
 AI WO 2002-CU10 4 Dec 2002
 PRAI CU 2001-309 20 Dec 2001; CU 2001-309 20 Dec 2001
 DT Patent
 LA Spanish
 OS WPI: 2003-514183 [48]

DUPLICATE 5
 AN 2003-17348 BIOTECHDS
 TI Transient immortalization of cells, useful for preparing transplant material and for organ regeneration, by supplying immortalizing proteins externally;
 plasmid, liposome, electroporation or microinjection-mediated fusion protein gene transfer and expression in feeder cell for tissue engineering for use in transplantation and disease therapy
 AU KUEPER J; MEYER R; MEYER-FICCA M; KUHN A
 PA HEART BIOSYSTEMS GMBH
 PI WO 2003035884 1 May 2003
 AI WO 2002-EP11200 7 Oct 2002
 PRAI DE 2001-1052972 18 Oct 2001; DE 2001-1052972 18 Oct 2001
 DT Patent
 LA German
 OS WPI: 2003-430421 [40]

L4 ANSWER 52 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
 AN 2003:203275 CAPLUS
 DN 138:217843
 TI Identification of inhibitors of herpesvirus gene expression replication and pathogenesis, and their antiviral use thereof
 IN Schaffer, Priscilla A.; Schang, Luis M.; Jordan, Robert
 PA USA
 SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of U.S. Ser. No. 951,058.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003049602	A1	20030313	US 2000-905689	20001206
	WO 2000006170	A1	20000210	WO 1999-US16252	19990716
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1998-94805P	P	19980731		
	US 1999-131264P	P	19990427		
	US 1999-140926P	P	19990624		
	WO 1999-US16252	A1	19990716		
	US 2000-656592	A2	20000907		
	US 2000-951058	A2	20000912		

L4 ANSWER 53 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 7
 AN 10375351 IFIPAT;IFIUDB;IFICDB
 TI INTERCELLULAR DELIVERY OF A HERPES SIMPLEX VIRUS ***VP22*** FUSION PROTEIN FROM CELLS INFECTED WITH LENTIVIRAL VECTORS; RECOMBINANT LENTIVIRAL VECTORS CONTAINING A THERAPEUTIC GENE OF INTEREST FUSED IN-FRAME WITH AN INTERCELLULAR TRAFFICKING GENE FOR THE GLOBAL DELIVERY OF THERAPEUTIC PROTEINS IN NONDIVIDING CELLS.
 IN Brady Roscoe O; Lai Zhennan; Reiser Jakob
 PA Unassigned Or Assigned To Individual (68000)
 PI US 2003119770 A1 20030626
 AI US 2002-212634 20020802
 PRAI US 2001-310012P 20010802 (Provisional)
 FI US 2003119770 20030626
 DT Utility; Patent Application - First Publication
 FS CHEMICAL APPLICATION
 OS CA 139:47137
 CLMN 20
 GI 8 Figure(s).

FIG. 1 shows HIV-1-based gene transfer systems. (A) Helper (packaging) construct. The triangle symbolizes a deletion affecting the packaging signal between the 5' splice donor site and the beginning of the gag sequence. The poly(A) site was derived from the bovine growth hormone gene. (B) Transducing vector constructs. The HIV-EGFP/HSA (i) and HIV-***VP22*** EGFP/HSA (ii) constructs are shown. Boxes interrupted by jagged lines contain partial deletions. CMV, Human CMV-IE promoter. (C) Env expression construct encoding vesicular stomatitis virus G glycoprotein (VSV-G). VSV-G expression is driven by the HIV-1 LTR. The poly(A) site was derived from the simian virus 40 late region. EGFP, enhanced green fluorescent protein; HSA, heatstable antigen.
 FIG. 2 shows HIV-1-based gene transfer vectors. Boxes interrupted by jagged lines contain partial deletions. Abbreviations: P, heterologous

FIG. 3 shows an EGFP expression cassette consisting of EGFP sequences and the CMV IE promoter which was inserted within the viral env-coding region. HSA sequences were inserted at the 5' end of nef.

FIG. 4 shows an enhanced green fluorescent protein (EGFP) expression cassette consisting of EGFP sequences and the CMV IE promoter which was inserted within the viral gag-pol coding region. A second expression cassette consisting of neo sequences driven by the ***SV40*** early promoter was placed within the env-coding region. HSA sequences were inserted at the 5' end of nef.

FIG. 5 shows vector construct containing EGFP and HSA reporter genes linked by the ECMV IRES.

FIG. 6 shows vector constructs containing the CMV IE or CEF promoter and an ECMV or Gtx IRES element.

FIG. 7 is a diagrammatic illustration of the recombinant lentiviral vector. (A) Vector construct contains reporter gene encoding EGFP driven by a CMV promoter. (B) A NSE promoter is inserted into the lentiviral vector to replace the CMV promoter.

FIG. 8 shows the in vivo distribution of EGFP-positive cells in the central nervous system. The numbers of EGFP-positive cells in striatum (A) and hippocampus (B) were counted by laser scanning under the confocal microscopy and were analyzed threedimensionally with a computer program. The statistical evaluation for the data was performed using a Student's unpaired t-test, the values are means+-S.D. (n=5; *P less-than 0.05)

L4 ANSWER 54 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 8
 AN 10364469 IFIPAT;IFIUDB;IFICDB
 TI AUTOGENE NUCLEIC ACIDS ENCODING A SECRETABLE RNA POLYMERASE; GENE
 EXPRESSION CASSETTES; TRANSCRIPTION
 IN Finn John (CA); MacLachlan Ian (CA)
 PA Protiva Biotherapeutics Inc CA (61667)
 PI US 2003108886 A1 20030612
 AI US 2002-136738 20020430
 PRAI US 2001-287974P 20010430 (Provisional)
 FI US 2003108886 20030612
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION

CLMN 42

GI 7 Figure(s).

FIG. 1 depicts the secretable RNA polymerase expression cassette of the present invention.

FIG. 2 illustrates in vitro transfection of Neuro 2A cells with Tat-RNAP (Tat: SEQ ID NO:1). Neuro 2A cells were transfected with T7-luciferase and CMV-Tat-RNAP constructs in DOPE:DODAC (50:50) large unilamellar vesicles (LUVs). Cells were harvested 24, 48, and 72 hours after transfection and luciferase activity was measured.

FIG. 3 illustrates in vitro transfection of BHK cells with VP22RNAP (***VP22*** : SEQ ID NO:21). BHK cells were transfected with T7luciferase and CMV-***VP22***-RNAP constructs in DOPE:DODAC (50:50) large unilamellar vesicles (LUVs). Cells were harvested 24, 48, and 72 hours after transfection and luciferase activity was measured.

FIG. 4 illustrates in vitro transcription and translation of ***VP22***-RNAP. 500 ng of a SP6-***VP22***-T7-RNAP (***VP22*** : SEQ ID NO:21) construct was added to 250 ng of a T7-luciferase construct and 1 mu l of SP6 RNA polymerase. Luciferase activity was measured over time.

FIG. 5 illustrates in vitro transcription and translation of TatRNAP. 500 ng of a SP6-Tat-T7-RNAP (Tat: SEQ ID NO: 1) construct was added to 250 ng of a T7-luciferase construct and 1 mu l of SP6 RNA polymerase. Luciferase activity was measured over time.

FIG. 6 illustrates in vitro transfection and translation of TatRNAP and luciferase. BHK cells were transfected with 5, 50, or 250 mmol of purified Tat-RNAP (Tat: SEQ ID NO: 1) for 4 hours, washed with PBS, and transfected with 0.75 mu g of a T7luciferase construct.

FIG. 7 illustrates in vitro transfection of ***VP22***-RNAP. BHK cells were transfected with 1 mu g of a CMV-T7 RNAP construct or a CMV-***VP22***-T7RNAP construct (***VP22*** : SEQ ID NO:21). Four hours after transfection, the BHK cells were trypsinized and added to BHK cells transfected with T7-luciferase. Cells were harvested 24, 48, or 72 hours after mixing of the cell populations and luciferase activity was measured.

L4 ANSWER 55 OF 297 USPATFULL on STN DUPLICATE 9
 AN 2003:86246 USPATFULL
 TI Protein quantitation with cell imaging densitometry
 IN Smith, Steven Jay, Bronx, NY, UNITED STATES

US 6746848 B2 20040608
AI US 2001-840404 A1 20010424 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US15743, filed on 13 Jul 1999,
UNKNOWN
PRAI US 1998-105163P 19981021 (60)
DT Utility
FS APPLICATION
LN.CNT 3895
INCL INCLM: 435/007.200
INCLS: 435/040.500; 435/007.230
NCL NCLM: 435/007.230
NCLS: 435/007.210; 435/960.000; 435/967.000; 436/063.000; 436/064.000;
436/518.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 56 OF 297 USPATFULL on STN DUPLICATE 10
AN 2003:78080 USPATFULL
TI Anti-pathogen system and methods of use thereof
IN Dowdy, Steven F., Clayton, MO, UNITED STATES
PA Washington University (U.S. corporation)
PI US 2003054000 A1 20030320
US 6645501 B2 20031111
AI US 2001-775052 A1 20010201 (9)
PRAI US 1998-82402P 19980420 (60)
US 1997-69012P 19971210 (60)
DT Utility
FS APPLICATION
LN.CNT 3366
INCL INCLM: 424/094.630
INCLS: 435/226.000; 530/327.000; 530/350.000; 536/023.400; 536/024.330
NCL NCLM: 424/192.100
NCLS: 424/195.110; 424/196.110
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C07K014-00; A61K038-04; C07K016-00; C07K005-00;
C07H021-04; C07K007-00; C07K017-00; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 57 OF 297 USPATFULL on STN DUPLICATE 11
AN 2003:64307 USPATFULL
TI Compositions and methods for treating Papillomavirus-infected cells
IN Howley, Peter M., Wellesley, MA, UNITED STATES
Benson, John, Brookline, MA, UNITED STATES
Kasukawa, Hiroaki, Princeton, NJ, UNITED STATES
PI US 2003044427 A1 20030306
US 6673354 B2 20040106
AI US 2002-161499 A1 20020603 (10)
RLI Continuation of Ser. No. US 1999-347504, filed on 2 Jul 1999, GRANTED,
Pat. No. US 6399075
PRAI US 1998-91661P 19980702 (60)
DT Utility
FS APPLICATION
LN.CNT 3479
INCL INCLM: 424/204.100
INCLS: 514/012.000; 530/321.000; 530/325.000; 530/326.000; 530/350.000;
530/388.400; 536/023.740
NCL NCLM: 424/204.100
NCLS: 514/012.000; 530/321.000; 530/325.000; 530/326.000; 530/350.000;
530/388.400; 536/023.740
IC [7]
ICM: A61K038-00
ICS: A61K039-12; C07K007-00; C07K017-00; A61K038-04; C07K014-00;
C07H021-04; C07K005-00; C07K016-00; A61K038-12; C07K001-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 297 USPATFULL on STN DUPLICATE 12
AN 2003:23338 USPATFULL
TI HERPES SIMPLEX VIRUS ***VP22*** VACCINES AND METHODS OF USE
IN BURKE, RAE LYNN, SAN FRANCISCO, CA, UNITED STATES
TIGGES, MICHAEL A., OAKLAND, CA, UNITED STATES
PI US 2003017174 A1 20030123
US 6635258 B2 20031021

PRAI US 1997-47359P 19970602 (60)
DT Utility
FS APPLICATION
LN.CNT 2255
INCL INCLM: 424/231.100
INCLS: 424/204.100; 530/826.000; 530/300.000; 530/350.000
NCL NCLM: 424/231.100
NCLS: 424/185.100; 424/204.100; 424/229.100; 530/350.000
IC [7]
ICM: A61K031-70
ICS: A01N043-04; A61K039-12; A61K039-245; C07K002-00; C07K004-00;
C07K005-00; C07K007-00; C07K014-00; C07K016-00; C07K017-00; A61K038-00;
C07K001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 297 USPATFULL on STN
AN 2003:335040 USPATFULL
TI Novel methods for the delivery of polynucleotides to cells
IN Monahan, Sean D., Madison, WI, UNITED STATES
Nader, Lisa, Madison, WI, UNITED STATES
Wolff, Jon A., Madison, WI, UNITED STATES
Budker, Vladimir G., Middleton, WI, UNITED STATES
Hagstrom, James E., Middleton, WI, UNITED STATES

PI US 2003235916 A1 20031225
AI US 2003-462138 A1 20030616 (10)
PRAI US 2002-388685P 20020614 (60)

DT Utility
FS APPLICATION
LN.CNT 3331
INCL INCLM: 435/455.000
INCLS: 514/044.000
NCL NCLM: 435/455.000
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
ICS: C12N015-85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 297 USPATFULL on STN
AN 2003:334699 USPATFULL
TI Identification of oligoadenylate synthetase-like genes
IN Matzuk, Martin M., Pearland, TX, UNITED STATES
Bai, Yuchen, Newtown, PA, UNITED STATES
Yan, Wei, Houston, TX, UNITED STATES

PA WYETH (U.S. corporation)
Baylor College of Medicine (U.S. corporation)

PI US 2003235575 A1 20031225
AI US 2003-439741 A1 20030516 (10)
PRAI US 2002-381408P 20020517 (60)

DT Utility
FS APPLICATION
LN.CNT 5806
INCL INCLM: 424/094.610
INCLS: 435/006.000; 435/069.100; 435/199.000; 435/320.100; 435/325.000;
536/023.200
NCL NCLM: 424/094.610
NCLS: 435/006.000; 435/069.100; 435/199.000; 435/320.100; 435/325.000;
536/023.200
IC [7]
ICM: A61K038-47
ICS: C12Q001-68; C07H021-04; C12N009-22; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 297 USPATFULL on STN
AN 2003:330566 USPATFULL
TI Modulation of gene expression using insulator binding proteins
IN Wolffe, Alan P., UNITED STATES
Wolffe, Elizabeth J., UNITED STATES LR
PI US 2003232781 A1 20031218
AI US 2003-446901 A1 20030527 (10)
RLI Continuation of Ser. No. WO 2001-US44654, filed on 28 Nov 2001, PENDING
PRAI US 2000-253678P 20001128 (60)
DT Utility
FS APPLICATION
LN.CNT 2015

NCL INCLS: 424/094.610; 435/455.000
NCLM: 514/044.000
NCLS: 424/094.610; 435/455.000
IC [7]
ICM: A61K038-47
ICS: C12N015-85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 62 OF 297 USPATFULL on STN
AN 2003:330124 USPATFULL
TI Minicell-based screening for compounds and proteins that modulate the
activity of signalling proteins
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003232335 A1 20031218
AI US 2002-157317 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18564
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567

L4 ANSWER 63 OF 297 USPATFULL on STN
AN 2003:329803 USPATFULL
TI Phosphorylated proteins and uses related thereto
IN Burke, Daniel J., Charlottesville, VA, UNITED STATES
Ross, Mark M., Charlottesville, VA, UNITED STATES
Stukenberg, P. Todd, Charlottesville, VA, UNITED STATES
White, Forest M., Charlottesville, VA, UNITED STATES
PA MDS Proteomics Inc., Toronto, CANADA, M9W 7H4 (U.S. corporation)
University of Virginia, Charlottesville, VA (U.S. corporation)
PI US 2003232014 A1 20031218
AI US 2003-378173 A1 20030303 (10)
PRAI US 2002-360787P 20020301 (60)
DT Utility
FS APPLICATION
LN.CNT 2591
INCL INCLM: 424/001.690
INCLS: 530/400.000; 530/388.100; 705/002.000
NCL NCLM: 424/001.690
NCLS: 530/400.000; 530/388.100; 705/002.000
IC [7]
ICM: A61K051-00
ICS: C07K016-18; C07K014-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 297 USPATFULL on STN
AN 2003:325220 USPATFULL
TI Membrane penetrating peptides and uses thereof
IN Guo, Yong, Fresh Meadows, NY, UNITED STATES
Morse, Clarence C., Asbury, NJ, UNITED STATES
Yao, Zhengbin, Sugar Land, TX, UNITED STATES
Keesler, George A., Hillsborough, NJ, UNITED STATES
PI US 2003229202 A1 20031211
AI US 2001-933780 A1 20010821 (9)
PRAI GB 2001-3110 20010702
US 2000-227647P 20000825 (60)
DT Utility
FS APPLICATION
LN.CNT 1771
INCL INCLM: 530/350.000
INCLS: 514/012.000; 435/455.000; 514/044.000
NCL NCLM: 530/350.000
NCLS: 514/012.000; 435/455.000; 514/044.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17; C07K014-475; C12N015-87

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:325057 USPATFULL
 TI Gene repair involving in vivo excision of targeting DNA
 IN Choulaka, Andre, Paris, FRANCE
 Mulligan, Richard C., Lincoln, MA, UNITED STATES
 PA The Children's Medical Center Corporation, Boston, MA (non-U.S.
 corporation)
 Institute Pasteur, Paris, FRANCE (non-U.S. corporation)
 PI US 2003229039 A1 20031211
 AI US 2003-336069 A1 20030102 (10)
 RLI Continuation of Ser. No. US 2001-922495, filed on 3 Aug 2001, ABANDONED
 Continuation of Ser. No. WO 2000-US2949, filed on 3 Feb 2000, PENDING
 PRAI US 1999-118472P 19990203 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1231
 INCL INCLM: 514/044.000
 INCLS: 424/093.200; 435/456.000
 NCL NCLM: 514/044.000
 NCLS: 424/093.200; 435/456.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-86
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 297 USPATFULL on STN
 AN 2003:324659 USPATFULL
 TI Expression vectors encoding epitopes of target-associated antigens and
 methods for their design
 IN Simard, John J.L., Vancouver, CANADA
 Diamond, David C., West Hills, CA, UNITED STATES
 Qiu, Zhiyong, Los Angeles, CA, UNITED STATES
 Lei, Xiang-Dong, West Hills, CA, UNITED STATES
 PI US 2003228634 A1 20031211
 AI US 2002-292413 A1 20021107 (10)
 PRAI US 2001-336968P 20011107 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4635
 INCL INCLM: 435/007.200
 INCLS: 435/320.100; 530/350.000
 NCL NCLM: 435/007.200
 NCLS: 435/320.100; 530/350.000
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-567; C12N015-00; C07K014-47
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 297 USPATFULL on STN
 AN 2003:318700 USPATFULL
 TI Antibodies to native conformations of membrane proteins
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Surber, Mark W., Coronado, CA, UNITED STATES
 PI US 2003224444 A1 20031204
 AI US 2002-157491 A1 20020528 (10)
 PRAI US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18559
 INCL INCLM: 435/007.100
 INCLS: 435/069.100; 435/326.000; 530/387.100
 NCL NCLM: 435/007.100
 NCLS: 435/069.100; 435/326.000; 530/387.100
 IC [7]
 ICM: G01N033-53
 ICS: C12N005-06; C07K016-00; C12P021-02

L4 ANSWER 68 OF 297 USPATFULL on STN
 AN 2003:318625 USPATFULL
 TI Reverse screening and target identification with minicells
 IN Surber, Mark W., Coronado, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Gerhart, William, La Mesa, CA, UNITED STATES
 PI US 2003224369 A1 20031204
 AI US 2002-157171 A1 20020528 (10)

DT Utility
FS APPLICATION
LN.CNT 18610
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

L4 ANSWER 69 OF 297 USPATFULL on STN
AN 2003:318223 USPATFULL
TI Expression of HIV polypeptides and production of virus-like particles
IN Barnett, Susan, San Francisco, CA, UNITED STATES
Megede, Jan Zur, San Francisco, CA, UNITED STATES
Lian, Ying, Vallejo, CA, UNITED STATES
Hartog, Karin, Piedmont, CA, UNITED STATES
Liu, Hong, Castro Valley, CA, UNITED STATES
Greer, Catherine, Oakland, CA, UNITED STATES
Selby, Mark, Berkeley, CA, UNITED STATES
PI US 2003223964 A1 20031204
AI US 2003-387336 A1 20030311 (10)
RLI Continuation of Ser. No. US 1999-475515, filed on 30 Dec 1999, GRANTED,
Pat. No. US 6602705
PRAI US 1998-114495P 19981231 (60)
US 1999-168471P 19991201 (60)
DT Utility
FS APPLICATION
LN.CNT 8448
INCL INCLM: 424/093.200
INCLS: 435/456.000; 435/235.100; 435/325.000
NCL NCLM: 424/093.200
NCLS: 435/456.000; 435/235.100; 435/325.000
IC [7]
ICM: A61K048-00
ICS: C12N007-01; C12N015-867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 70 OF 297 USPATFULL on STN
AN 2003:312867 USPATFULL
TI Conjugate of biodegradable aliphatic polyester with Tat49-57 peptide or
peptide chain containing Tat49-57 peptide and nanoparticle manufactured
using the same
IN Park, Ju Young, Yongin-si, KOREA, REPUBLIC OF
Nam, Yoon Sung, Yongin-si, KOREA, REPUBLIC OF
Han, Sang Hoon, Suwon-si, KOREA, REPUBLIC OF
Chang, Ih Seop, Yongin-si, KOREA, REPUBLIC OF
PA PACIFIC CORPORATION, Seoul, KOREA, REPUBLIC OF, 140-777 (non-U.S.
corporation)
PI US 2003220474 A1 20031127
AI US 2002-185593 A1 20020628 (10)
PRAI KR 2002-27328 20020517
DT Utility
FS APPLICATION
LN.CNT 787
INCL INCLM: 530/350.000
INCLS: 436/518.000; 436/531.000
NCL NCLM: 530/350.000
NCLS: 436/518.000; 436/531.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00; G01N033-543; G01N033-545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 71 OF 297 USPATFULL on STN
AN 2003:312659 USPATFULL
TI Reversible modification of membrane interaction
IN Rozema, David B., Madison, WI, UNITED STATES
Wakefield, Darren, Madison, WI, UNITED STATES
Wolff, Jon A., Madison, WI, UNITED STATES
Ekena, Kirk, Madison, WI, UNITED STATES
Hagstrom, James E., Middleton, WI, UNITED STATES
PI US 2003220264 A1 20031127
AI US 2003-444662 A1 20030523 (10)
PRAI US 2002-383298P 20020524 (60)
DT Utility
FS APPLICATION

INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/406.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 530/406.000
IC [7]
ICM: A61K038-16
ICS: C07K014-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 72 OF 297 USPATFULL on STN
AN 2003:312291 USPATFULL
TI Minicell-based bioremediation
IN Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219888 A1 20031127
AI US 2002-157418 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18632
INCL INCLM: 435/262.500
NCL NCLM: 435/262.500
IC [7]
ICM: C12S001-00

L4 ANSWER 73 OF 297 USPATFULL on STN
AN 2003:312262 USPATFULL
TI Transport proteins and their uses
IN O'Hare, Peter Francis Joseph, Surrey, UNITED KINGDOM
Elliott, Gillian Daphne, Surrey, UNITED KINGDOM
PA Marie Curie Cancer Care (non-U.S. corporation)
PI US 2003219859 A1 20031127
AI US 2002-259198 A1 20020927 (10)
RLI Continuation of Ser. No. US 2001-773430, filed on 31 Jan 2001, GRANTED,
Pat. No. US 6521455 Division of Ser. No. US 1998-11073, filed on 26 Jan
1998, GRANTED, Pat. No. US 6184038 A 371 of International Ser. No. WO
1996-GB1831, filed on 25 Jul 1996, UNKNOWN
PRAI GB 1995-15568 19950728
GB 1996-1570 19960126
DT Utility
FS APPLICATION
LN.CNT 975
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06; C07K014-705; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 297 USPATFULL on STN
AN 2003:312229 USPATFULL
TI Identification of peptides that facilitate uptake and cytoplasmic and/or
nuclear transport of proteins, DNA and viruses
IN Robbins, Paul D., Mt. Lebanon, PA, UNITED STATES
Mi, Zhibao, Pittsburgh, PA, UNITED STATES
Frizzell, Raymond, Pittsburgh, PA, UNITED STATES
Glorioso, Joseph C., Cheswick, PA, UNITED STATES
Gambotto, Andrea, Pittsburgh, PA, UNITED STATES
Mai, Jeffrey C., Pittsburgh, PA, UNITED STATES
PI US 2003219826 A1 20031127
AI US 2003-366493 A1 20030212 (10)
RLI Continuation-in-part of Ser. No. US 2002-75869, filed on 13 Feb 2002,
PENDING Continuation-in-part of Ser. No. US 2000-653182, filed on 31 Aug
2000, PENDING
PRAI US 1999-151980P 19990901 (60)
US 2000-188944P 20000313 (60)
DT Utility
FS APPLICATION
LN.CNT 3437
INCL INCLM: 435/007.100
INCLS: 435/194.000; 435/226.000; 530/328.000

NCLS: 435/194.000; 435/226.000; 530/328.000
IC [7]

ICM: G01N033-53

ICS: C12N009-12; C12N009-64; C07K007-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 297 USPATFULL on STN

AN 2003:311814 USPATFULL

TI Methods of making pharmaceutical compositions with minicells

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES

Klepper, Robert, San Diego, CA, UNITED STATES

PI US 2003219408 A1 20031127

AI US 2002-157320 A1 20020528 (10)

RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING

PRAI US 2002-359843P 20020225 (60)

US 2001-293566P 20010524 (60)

DT Utility

FS APPLICATION

LN.CNT 18632

INCL INCLM: 424/093.200

NCL NCLM: 424/093.200

IC [7]

ICM: A61K048-00

L4 ANSWER 76 OF 297 USPATFULL on STN

AN 2003:300375 USPATFULL

TI Minicell-based delivery agents

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES

Klepper, Robert, San Diego, CA, UNITED STATES

Surber, Mark W., Coronado, CA, UNITED STATES

PI US 2003211599 A1 20031113

AI US 2002-157106 A1 20020528 (10)

RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING

PRAI US 2002-359843P 20020225 (60)

US 2001-293566P 20010524 (60)

DT Utility

FS APPLICATION

LN.CNT 18671

INCL INCLM: 435/325.000

INCLS: 435/252.300

NCL NCLM: 435/325.000

NCLS: 435/252.300

IC [7]

ICM: C12N005-02

ICS: C12N001-21

L4 ANSWER 77 OF 297 USPATFULL on STN

AN 2003:300366 USPATFULL

TI Fusion protein for use as vector

IN Hwu, Paul L., Taipei, TAIWAN, PROVINCE OF CHINA

PI US 2003211590 A1 20031113

AI US 2002-144549 A1 20020513 (10)

DT Utility

FS APPLICATION

LN.CNT 906

INCL INCLM: 435/199.000

NCL NCLM: 435/199.000

IC [7]

ICM: C12N009-22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 78 OF 297 USPATFULL on STN

AN 2003:300272 USPATFULL

TI Reverse n-hybrid screening method

IN Hopkins, Richard, North Perth, AUSTRALIA

Serebriiskii, Ilya, Philadelphia, PA, UNITED STATES

Watt, Paul Michael, Mount Claremont, AUSTRALIA

Golemis, Erica, Oreland, PA, UNITED STATES

PI US 2003211495 A1 20031113

AI US 2003-221276 A1 20030114 (10)

WO 2001-US7669 20010308

PRAI AU 2000-6131 20000308

AU 2000-6437 20000323

AU 2000-6830 20000411

AU 2000-1256 20001106

FS APPLICATION
LN.CNT 2836
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/325.000; 435/455.000
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/325.000; 435/455.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 297 USPATFULL on STN
AN 2003:299865 USPATFULL
TI Minicell-based selective absorption
IN Berkley, Neil, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003211086 A1 20031113
AI US 2002-157073 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18553
INCL INCLM: 424/093.210
INCLS: 435/325.000; 424/001.730; 424/001.490
NCL NCLM: 424/093.210
NCLS: 435/325.000; 424/001.730; 424/001.490
IC [7]
ICM: A61K051-00
ICS: A61K048-00; C12N005-00

L4 ANSWER 80 OF 297 USPATFULL on STN
AN 2003:294815 USPATFULL
TI Pharmaceutical compositions with minicells
IN Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003207833 A1 20031106
AI US 2002-156811 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18585
INCL INCLM: 514/044.000
INCLS: 424/093.210
NCL NCLM: 514/044.000
NCLS: 424/093.210
IC [7]
ICM: A61K048-00

L4 ANSWER 81 OF 297 USPATFULL on STN
AN 2003:294436 USPATFULL
TI Methods, compositions, and kits for enhancing oligonucleotide-mediated
nucleic acid sequence alteration using compositions comprising a histone
deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
IN Kmiec, Eric B., Landenberg, PA, UNITED STATES
Parekh-Olmedo, Hetal, Mantua, NJ, UNITED STATES
Brachman, Erin E., Newark, DE, UNITED STATES
PI US 2003207451 A1 20031106
AI US 2003-384918 A1 20030307 (10)
PRAI US 2002-363341P 20020307 (60)
US 2002-363053P 20020307 (60)
US 2002-363054P 20020307 (60)
US 2002-416983P 20021007 (60)
DT Utility
FS APPLICATION
LN.CNT 4367
INCL INCLM: 435/455.000
INCLS: 435/254.200; 435/366.000; 435/419.000; 435/483.000
NCL NCLM: 435/455.000
NCLS: 435/254.200; 435/366.000; 435/419.000; 435/483.000
IC [7]
ICM: C12N005-08
ICS: C12N005-04; C12N001-16; C12N001-18; C12N015-85; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 297 USPATFULL on STN
 AN 2003:289308 USPATFULL
 TI Segments of the human gene for telomerase reverse transcriptase
 IN Morin, Gregg B., Toronto, CANADA
 Andrews, William H., Reno, NV, UNITED STATES
 PI US 2003204069 A1 20031030
 AI US 2002-325810 A1 20021220 (10)
 RLI Continuation of Ser. No. US 1999-402181, filed on 29 Sep 1999, PENDING A
 371 of International Ser. No. WO 1997-US17885, filed on 1 Oct 1997,
 PENDING Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug
 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-912951, filed
 on 14 Aug 1997, GRANTED, Pat. No. US 6475789 Continuation-in-part of
 Ser. No. US 1997-915503, filed on 14 Aug 1997, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 10647
 INCL INCLM: 536/023.200
 INCLS: 435/006.000; 435/069.100; 435/199.000; 435/320.100; 435/325.000;
 435/456.000
 NCL NCLM: 536/023.200
 NCLS: 435/006.000; 435/069.100; 435/199.000; 435/320.100; 435/325.000;
 435/456.000
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12N009-22; C12P021-02; C12N005-06; C12N015-86
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 297 USPATFULL on STN
 AN 2003:289106 USPATFULL
 TI Lipid-comprising drug delivery complexes and methods for their
 production
 IN Harvie, Pierrot, Seattle, WA, UNITED STATES
 Paul, Ralph, Seattle, WA, UNITED STATES
 Cudmore, Sally, Dublin, IRELAND
 O'Mahony, Daniel J., Dublin, IRELAND
 PI US 2003203865 A1 20031030
 AI US 2002-136187 A1 20020430 (10)
 PRAI US 2001-287786P 20010430 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5998
 INCL INCLM: 514/044.000
 INCLS: 435/458.000
 NCL NCLM: 514/044.000
 NCLS: 435/458.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-88
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 297 USPATFULL on STN
 AN 2003:288723 USPATFULL
 TI Conjugated minicells
 IN Surber, Mark W., Coronado, CA, UNITED STATES
 Klepper, Robert, San Diego, CA, UNITED STATES
 PI US 2003203481 A1 20031030
 AI US 2002-157213 A1 20020528 (10)
 PRAI US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18551
 INCL INCLM: 435/325.000
 NCL NCLM: 435/325.000
 IC [7]
 ICM: C12N005-02

L4 ANSWER 85 OF 297 USPATFULL on STN
 AN 2003:288653 USPATFULL
 TI Methods of minicell-based delivery
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Klepper, Robert, San Diego, CA, UNITED STATES
 Surber, Mark W., Coronado, CA, UNITED STATES
 PI US 2003203411 A1 20031030
 AI US 2002-156792 A1 20020528 (10)

US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18582
 INCL INCLM: 435/007.200
 INCLS: 424/001.490
 NCL NCLM: 435/007.200
 NCLS: 424/001.490
 IC [7]
 ICM: A61K051-00
 ICS: G01N033-53; G01N033-567

L4 ANSWER 86 OF 297 USPATFULL on STN
 AN 2003:288179 USPATFULL
 TI Minicell-based diagnostics
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Klepper, Robert, San Diego, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 PI US 2003202937 A1 20031030
 AI US 2002-157178 A1 20020528 (10)
 PRAI US 2001-295566P 20010605 (60)
 US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18527
 INCL INCLM: 424/001.490
 INCLS: 424/009.340; 424/009.500
 NCL NCLM: 424/001.490
 NCLS: 424/009.340; 424/009.500
 IC [7]
 ICM: A61K051-00
 ICS: A61K049-00

L4 ANSWER 87 OF 297 USPATFULL on STN
 AN 2003:282746 USPATFULL
 TI Membrane to membrane delivery
 IN Surber, Mark W., Coronado, CA, UNITED STATES
 Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 PI US 2003199089 A1 20031023
 AI US 2002-157318 A1 20020528 (10)
 PRAI US 2001-295566P 20010605 (60)
 US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18530
 INCL INCLM: 435/449.000
 INCLS: 435/455.000
 NCL NCLM: 435/449.000
 NCLS: 435/455.000
 IC [7]
 ICM: C12N015-85
 ICS: C12N015-02

L4 ANSWER 88 OF 297 USPATFULL on STN
 AN 2003:282745 USPATFULL
 TI Minicell-based gene therapy
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Surber, Mark W., Coronado, CA, UNITED STATES
 PI US 2003199088 A1 20031023
 AI US 2002-156902 A1 20020528 (10)
 PRAI US 2001-295566P 20010605 (60)
 US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15300
 INCL INCLM: 435/449.000
 INCLS: 435/325.000; 435/320.100
 NCL NCLM: 435/449.000
 NCLS: 435/325.000; 435/320.100
 IC [7]
 ICM: C12N015-02
 ICS: C12N005-00

L4 ANSWER 89 OF 297 USPATFULL on STN

TI Solid supports with minicells
 IN Sabbadini, Roger, Lakeside, CA, UNITED STATES
 Klepper, Robert, San Diego, CA, UNITED STATES
 PI US 2003199005 A1 20031023
 AI US 2002-157166 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2002-359843P 20020225 (60)
 US 2001-293566P 20010524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18494
 INCL INCLM: 435/007.210
 INCLS: 435/325.000
 NCL NCLM: 435/007.210
 NCLS: 435/325.000
 IC [7]
 ICM: G01N033-567
 ICS: C12N005-00

 L4 ANSWER 90 OF 297 USPATFULL on STN
 AN 2003:282659 USPATFULL
 TI Clk-2 nucleic acids, polypeptides and uses thereof
 IN Hekimi, Siegfried, Montreal, CANADA
 Benard, Claire, Montreal, CANADA
 Jiang, Ning, Montreal, CANADA
 Kebir, Hania, Montreal, CANADA
 McCright, Brenton, Gaithersburg, MD, UNITED STATES
 Lakowski, Bernard, Paris, FRANCE
 PI US 2003199002 A1 20031023
 AI US 2003-349507 A1 20030122 (10)
 RLI Continuation-in-part of Ser. No. US 2003-312187, filed on 9 Apr 2003,
 PENDING A 371 of International Ser. No. WO 2001-CA913, filed on 20 Jun
 2001, UNKNOWN
 PRAI US 2000-213174P 20000622 (60)
 US 2000-254932P 20001213 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6246
 INCL INCLM: 435/007.200
 INCLS: 435/069.700; 435/193.000; 435/320.100; 435/325.000; 536/023.200
 NCL NCLM: 435/007.200
 NCLS: 435/069.700; 435/193.000; 435/320.100; 435/325.000; 536/023.200
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-567; C07H021-04; C12P021-04; C12N009-10; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L4 ANSWER 91 OF 297 USPATFULL on STN
 AN 2003:282653 USPATFULL
 TI Minicell libraries
 IN Surber, Mark W., Coronado, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Gerhart, William, La Mesa, CA, UNITED STATES
 Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 PI US 2003198996 A1 20031023
 AI US 2002-157147 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2001-293566P 20010524 (60)
 US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18482
 INCL INCLM: 435/007.100
 INCLS: 435/325.000
 NCL NCLM: 435/007.100
 NCLS: 435/325.000
 IC [7]
 ICM: G01N033-53
 ICS: C12N005-00

 L4 ANSWER 92 OF 297 USPATFULL on STN
 AN 2003:282652 USPATFULL
 TI Forward screening with minicells
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES

Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003198995 A1 20031023
AI US 2002-156831 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 18533
INCL INCLM: 435/007.100
INCLS: 435/007.210; 435/005.000
NCL NCLM: 435/007.100
NCLS: 435/007.210; 435/005.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G01N033-567

L4 ANSWER 93 OF 297 USPATFULL on STN
AN 2003:276773 USPATFULL
TI Minicell compositions and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003194798 A1 20031016
AI US 2002-154951 A1 20020524 (10)
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LN.CNT 18583
INCL INCLM: 435/252.100
INCLS: 435/252.300
NCL NCLM: 435/252.100
NCLS: 435/252.300
IC [7]
ICM: C12N001-20
ICS: C12N001-21

L4 ANSWER 94 OF 297 USPATFULL on STN
AN 2003:276702 USPATFULL
TI Phenotypic screen of chimeric proteins
IN Kim, Jin-Soo, Yuseong-gu, KOREA, REPUBLIC OF
Park, Kyung-Soon, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Dong-Ki, Yuseong-gu, KOREA, REPUBLIC OF
Seol, Wongi, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Horim, Chungcheongnam-do, KOREA, REPUBLIC OF
Lee, Seong-Il, Yuseong-gu, KOREA, REPUBLIC OF
Yang, Hyo-Young, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Yangsoon, Yuseong-gu, KOREA, REPUBLIC OF
Jang, Young-Soon, Yuseong-gu, KOREA, REPUBLIC OF
PI US 2003194727 A1 20031016
AI US 2002-314669 A1 20021209 (10)
PRAI US 2001-338441P 20011207 (60)
US 2002-376053P 20020426 (60)
US 2002-400904P 20020802 (60)
US 2002-401089P 20020805 (60)
DT Utility
FS APPLICATION
LN.CNT 5577
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/252.300; 435/007.200;
435/254.200; 435/219.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/252.300; 435/007.200;
435/254.200; 435/219.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12N001-18; C12P021-02; C12N001-21;
C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 297 USPATFULL on STN
AN 2003:276689 USPATFULL
TI Minicell-based transformation
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES

PI US 2003194714 A1 20031016
 AI US 2002-157299 A1 20020528 (10)
 PRAI US 2001-295566P 20010605 (60)
 US 2002-359843P 20020225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18595
 INCL INCLM: 435/006.000
 INCLS: 435/325.000; 435/455.000
 NCL NCLM: 435/006.000
 NCLS: 435/325.000; 435/455.000
 IC [7]
 ICM: C12Q001-68
 ICS: C12N005-00; C12N015-85

L4 ANSWER 96 OF 297 USPATFULL on STN
 AN 2003:271146 USPATFULL
 TI Minicell-producing parent cells
 IN Surber, Mark W., Coronado, CA, UNITED STATES
 Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Segall, Anca M., San Diego, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 PI US 2003190749 A1 20031009
 AI US 2002-157215 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2002-359843P 20020225 (60)
 US 2001-293566P 20010524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18577
 INCL INCLM: 435/375.000
 NCL NCLM: 435/375.000
 IC [7]
 ICM: C12N005-10

L4 ANSWER 97 OF 297 USPATFULL on STN
 AN 2003:271080 USPATFULL
 TI Minicell-based rational drug design
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Surber, Mark W., Coronado, CA, UNITED STATES
 PI US 2003190683 A1 20031009
 AI US 2002-157302 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2002-359843P 20020225 (60)
 US 2001-293566P 20010524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18539
 INCL INCLM: 435/007.210
 INCLS: 435/325.000; 702/019.000
 NCL NCLM: 435/007.210
 NCLS: 435/325.000; 702/019.000
 IC [7]
 ICM: G01N033-567
 ICS: G06F019-00; G01N033-48; G01N033-50; C12N005-00

L4 ANSWER 98 OF 297 USPATFULL on STN
 AN 2003:271061 USPATFULL
 TI Pharmacogenomics and identification of drug targets by reconstruction of
 signal transduction pathways based on sequences of accessible regions
 IN Wolffe, Alan, Orinda, CA, UNITED STATES
 Urnov, Fyodor, Richmond, CA, UNITED STATES
 Guschin, Dmitry, Richmond, CA, UNITED STATES
 Collingwood, Trevor, San Pablo, CA, UNITED STATES
 Li, Xiao-Yong, Richmond, CA, UNITED STATES
 Johnstone, Brian, Benicia, CA, UNITED STATES
 PI US 2003190664 A1 20031009
 AI US 2003-434947 A1 20030508 (10)
 RLI Continuation of Ser. No. US 2001-844265, filed on 27 Apr 2001, PENDING
 PRAI US 2000-200590P 20000428 (60)
 US 2000-214674P 20000627 (60)
 US 2000-228608P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5179

INCLS: 435/091.200; 435/007.200
 NCL NCLM: 435/006.000
 NCLS: 435/091.200; 435/007.200
 IC [7]
 ICM: C12Q001-68
 ICS: C12P019-34; G01N033-53; G01N033-567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 99 OF 297 USPATFULL on STN
 AN 2003:270998 USPATFULL
 TI Target display on minicells
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Surber, Mark W., Coronada, CA, UNITED STATES
 PI US 2003190601 A1 20031009
 AI US 2002-157096 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2002-359843P 20020225 (60)
 US 2001-293566P 20010524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18581
 INCL INCLM: 435/005.000
 INCLS: 435/006.000; 435/007.100; 435/007.210
 NCL NCLM: 435/005.000
 NCLS: 435/006.000; 435/007.100; 435/007.210
 IC [7]
 ICM: C12Q001-70
 ICS: C12Q001-68; G01N033-53; G01N033-567

L4 ANSWER 100 OF 297 USPATFULL on STN
 AN 2003:257726 USPATFULL
 TI Rapid identification of transcriptional regulatory domains
 IN Bartsevich, Victor, Albany, CA, UNITED STATES
 PI US 2003180777 A1 20030925
 AI US 2003-387320 A1 20030311 (10)
 PRAI US 2002-365004P 20020312 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2147
 INCL INCLM: 435/006.000
 INCLS: 435/007.200; 435/226.000
 NCL NCLM: 435/006.000
 NCLS: 435/007.200; 435/226.000
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-53; G01N033-567; C12N009-64
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 297 USPATFULL on STN
 AN 2003:257662 USPATFULL
 TI Cells for drug discovery
 IN Case, Casey, San Mateo, CA, UNITED STATES
 PI US 2003180713 A1 20030925
 AI US 2003-412109 A1 20030410 (10)
 RLI Division of Ser. No. US 2001-779233, filed on 8 Feb 2001, PENDING
 PRAI US 2000-181117P 20000208 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3573
 INCL INCLM: 435/004.000
 INCLS: 435/006.000; 435/007.200
 NCL NCLM: 435/004.000
 NCLS: 435/006.000; 435/007.200
 IC [7]
 ICM: C12Q001-00
 ICS: C12Q001-68; G01N033-53; G01N033-567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 297 USPATFULL on STN
 AN 2003:251172 USPATFULL
 TI Methods for using bag expression as a cell differentiation agent and marker
 IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES
 Kermer, Pawel, San Diego, CA, UNITED STATES

PI US 2003175958 A1 20030918
AI US 2002-99553 A1 20020315 (10)
DT Utility
FS APPLICATION
LN.CNT 1817
INCL INCLM: 435/368.000
INCLS: 435/325.000; 435/455.000
NCL NCLM: 435/368.000
NCLS: 435/325.000; 435/455.000
IC [7]
ICM: C12N005-08
ICS: C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 297 USPATFULL on STN
AN 2003:251004 USPATFULL
TI Cells for drug discovery
IN Case, Casey, San Mateo, CA, UNITED STATES
PI US 2003175790 A1 20030918
AI US 2003-412105 A1 20030410 (10)
RLI Division of Ser. No. US 2001-779233, filed on 8 Feb 2001, PENDING
PRAI US 2000-181117P 20000208 (60)
DT Utility
FS APPLICATION
LN.CNT 3571
INCL INCLM: 435/006.000
INCLS: 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 297 USPATFULL on STN
AN 2003:250986 USPATFULL
TI Compositions for DNA mediated gene silencing
IN Wang, Jiwu, San Diego, CA, UNITED STATES
PI US 2003175772 A1 20030918
AI US 2002-330772 A1 20021226 (10)
RLI Continuation-in-part of Ser. No. US 2002-217564, filed on 12 Aug 2002,
PENDING Continuation-in-part of Ser. No. US 2002-202479, filed on 23 Jul
2002, PENDING
PRAI US 2001-343697P 20011227 (60)
DT Utility
FS APPLICATION
LN.CNT 3804
INCL INCLM: 435/006.000
INCLS: 435/287.200; 536/024.300
NCL NCLM: 435/006.000
NCLS: 435/287.200; 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 297 USPATFULL on STN
AN 2003:244904 USPATFULL
TI Composition and method for treating viral infection
IN Morham, Scott, Salt Lake City, UT, UNITED STATES
Zavitz, Kenton, Salt Lake City, UT, UNITED STATES
Hobden, Adrian, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108
(U.S. corporation)
PI US 2003171318 A1 20030911
AI US 2002-224999 A1 20020820 (10)
PRAI US 2001-313695P 20010820 (60)
DT Utility
FS APPLICATION
LN.CNT 5787
INCL INCLM: 514/044.000
INCLS: 514/012.000; 424/186.100; 435/069.100; 435/006.000
NCL NCLM: 514/044.000
NCLS: 514/012.000; 424/186.100; 435/069.100; 435/006.000
IC [7]

ICS: A61K038-18; A61K039-12; C12Q001-68; A61K038-00; A61K031-70;
A01N043-04; C12P021-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 297 USPATFULL on STN
AN 2003:244462 USPATFULL
TI Alphavirus-based vectors for persistent infection
IN Dubensky, Thomas W., JR., Piedmont, CA, UNITED STATES
Polo, John M., Hayward, CA, UNITED STATES
Perri, Silvia, Castro Valley, CA, UNITED STATES
Belli, Barbara, San Diego, CA, UNITED STATES
PA CHIRON CORPORATION (U.S. corporation)
PI US 2003170871 A1 20030911
AI US 2001-841994 A1 20010425 (9)
PRAI US 2000-199579P 20000425 (60)
DT Utility
FS APPLICATION
LN.CNT 1945
INCL INCLM: 435/235.100
INCLS: 424/093.210; 435/325.000; 435/456.000; 435/069.100; 536/023.720
NCL NCLM: 435/235.100
NCLS: 424/093.210; 435/325.000; 435/456.000; 435/069.100; 536/023.720
IC [7]
ICM: A61K048-00
ICS: C12P021-02; C12N015-86; C12N005-06; C12N007-00; C07H021-04;
A01N063-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 297 USPATFULL on STN
AN 2003:243807 USPATFULL
TI SYN3 compositions and methods
IN Ihnat, Peter M., Brooklyn, NY, UNITED STATES
Witchey-Lakshmanan, Leonore C., Piscataway, NJ, UNITED STATES
Sandweiss, Varda, Forest Hills, NY, UNITED STATES
Ugwu, Sydney O., Chicago, IL, UNITED STATES
PA Schering-Plough Corporation, Kenilworth, NJ, 07033-0530 (U.S. corporation)
PI US 2003170216 A1 20030911
AI US 2002-329043 A1 20021220 (10)
PRAI US 2001-342329P 20011220 (60)
DT Utility
FS APPLICATION
LN.CNT 1157
INCL INCLM: 424/093.210
INCLS: 514/044.000
NCL NCLM: 424/093.210
NCLS: 514/044.000
IC [7]
ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 297 USPATFULL on STN
AN 2003:238346 USPATFULL
TI Therapeutic compositions and methods for treating viral infection
IN Morham, Scott, Salt Lake City, UT, UNITED STATES
Zavitz, Kenton, Salt Lake City, UT, UNITED STATES
Hobden, Adrian, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
PI US 2003166504 A1 20030904
AI US 2002-226629 A1 20020822 (10)
PRAI US 2001-314182P 20010822 (60)
DT Utility
FS APPLICATION
LN.CNT 2553
INCL INCLM: 514/002.000
INCLS: 424/450.000
NCL NCLM: 514/002.000
NCLS: 424/450.000
IC [7]
ICM: A61K009-127
ICS: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 297 USPATFULL on STN

TI Minicell-based transfection
 IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 PI US 2003166279 A1 20030904
 AI US 2002-157391 A1 20020528 (10)
 RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
 PRAI US 2002-359843P 20020225 (60)
 US 2001-293566P 20010524 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 18548
 INCL INCLM: 435/449.000
 INCLS: 435/320.100; 435/325.000
 NCL NCLM: 435/449.000
 NCLS: 435/320.100; 435/325.000
 IC [7]
 ICM: C12N015-02
 ICS: C12N005-00

 L4 ANSWER 110 OF 297 USPATFULL on STN
 AN 2003:238003 USPATFULL
 TI Compounds and molecular complexes comprising multiple binding regions
 directed to transcytotic ligands
 IN Hawley, Stephen B., San Diego, CA, UNITED STATES
 Chapin, Steven, San Diego, CA, UNITED STATES
 Sheridan, Philip L., San Diego, CA, UNITED STATES
 Houston, L. L., Del Mar, CA, UNITED STATES
 Glynn, Jacqueline M., San Diego, CA, UNITED STATES
 PI US 2003166160 A1 20030904
 AI US 2001-949039 A1 20010906 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 7008
 INCL INCLM: 435/069.700
 INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
 NCL NCLM: 435/069.700
 NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12P021-04; C12P021-02; C12N005-06; C07K014-435
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L4 ANSWER 111 OF 297 USPATFULL on STN
 AN 2003:237984 USPATFULL
 TI Regulation of endogenous gene expression in cells using zinc finger
 proteins
 IN Case, Casey C., San Mateo, CA, UNITED STATES
 Cox, George N., III, Louisville, CO, UNITED STATES
 Eisenberg, Stephen P., Boulder, CO, UNITED STATES
 Liu, Qiang, Foster City, CA, UNITED STATES
 Rebar, Edward J., El Cerrito, CA, UNITED STATES
 PA Sangamo Biosciences, Inc., Richmond, CA, UNITED STATES, 94804 (U.S.
 corporation)
 PI US 2003166141 A1 20030904
 AI US 2002-245415 A1 20020916 (10)
 RLI Continuation-in-part of Ser. No. US 1999-229007, filed on 12 Jan 1999,
 GRANTED, Pat. No. US 6453242 Continuation-in-part of Ser. No. US
 1999-229037, filed on 12 Jan 1999, GRANTED, Pat. No. US 6534261
 Continuation-in-part of Ser. No. US 2000-731558, filed on 6 Dec 2000,
 GRANTED, Pat. No. US 6503717 Continuation-in-part of Ser. No. US
 1999-456100, filed on 6 Dec 1999, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 4131
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 435/325.000; 435/366.000; 435/456.000; 702/019.000
 NCL NCLM: 435/069.100
 NCLS: 435/320.100; 435/325.000; 435/366.000; 435/456.000; 702/019.000
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; G06F019-00; G01N033-48; G01N033-50; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L4 ANSWER 112 OF 297 USPATFULL on STN
 AN 2003:237942 USPATFULL

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
 Surber, Mark W., Coronado, CA, UNITED STATES
 Berkley, Neil, San Diego, CA, UNITED STATES
 Segall, Anca M., San Diego, CA, UNITED STATES
 Klepper, Robert, San Diego, CA, UNITED STATES

PI US 2003166099 A1 20030904
 AI US 2002-157305 A1 20020528 (10)
 PRAI US 2001-295566P 20010605 (60)
 US 2002-359843P 20020225 (60)

DT Utility
 FS APPLICATION
 LN.CNT 18580
 INCL INCLM: 435/069.100
 INCLS: 435/325.000
 NCL NCLM: 435/069.100
 NCLS: 435/325.000
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-00

L4 ANSWER 113 OF 297 USPATFULL on STN
 AN 2003:237788 USPATFULL
 TI Human Pellino polypeptides
 IN Bird, Timothy A., Bainbridge Island, WA, UNITED STATES
 Cosman, David J., Bainbridge Island, WA, UNITED STATES
 Li, Xiaoxia, Solon, OH, UNITED STATES

PI US 2003165945 A1 20030904
 AI US 2002-317250 A1 20021211 (10)
 RLI Continuation-in-part of Ser. No. US 2001-843905, filed on 27 Apr 2001,
 PENDING

PRAI US 2000-200198P 20000428 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3738
 INCL INCLM: 435/006.000
 INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.500
 NCL NCLM: 435/006.000
 NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-53; C07H021-04; C07K014-705; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 297 USPATFULL on STN
 AN 2003:237325 USPATFULL
 TI Methods and compositions for tissue regeneration
 IN Rolland, Eric, Divonne les bains, FRANCE
 Hunziker, Thomas, Oberhofen, SWITZERLAND
 Mis, Beatrice, Lausanne, SWITZERLAND
 Rinsch, Christopher, Lausanne, SWITZERLAND

PI US 2003165482 A1 20030904
 AI US 2002-324257 A1 20021219 (10)
 RLI Continuation-in-part of Ser. No. US 2001-943114, filed on 30 Aug 2001,
 PENDING

PRAI US 2002-408565P 20020906 (60)
 US 2000-230286P 20000901 (60)
 US 2001-299003P 20010618 (60)

DT Utility
 FS APPLICATION
 LN.CNT 2521
 INCL INCLM: 424/093.210
 INCLS: 424/093.700
 NCL NCLM: 424/093.210
 NCLS: 424/093.700
 IC [7]
 ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 297 USPATFULL on STN
 AN 2003:231621 USPATFULL
 TI Reversible immortalization
 IN Kupper, Jan-Heiner, Kusterdingen, GERMANY, FEDERAL REPUBLIC OF
 Kandolf, Reinhard, Hechingen, GERMANY, FEDERAL REPUBLIC OF

PI US 2003161819 A1 20030828
 AI US 2003-257687 A1 20030311 (10)
 WO 2001-EP2967 20010315
 PRAI DE 2000-100 20000417
 DT Utility
 FS APPLICATION
 LN.CNT 929
 INCL INCLM: 424/093.210
 INCLS: 435/456.000; 435/366.000; 536/023.200
 NCL NCLM: 424/093.210
 NCLS: 435/456.000; 435/366.000; 536/023.200
 IC [7]
 ICM: C07H021-04
 ICS: A61K048-00; C12N005-08; C12N015-86
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 297 USPATFULL on STN
 AN 2003:231611 USPATFULL
 TI Compositions and methods for the transport of biologically active agents
 across cellular barriers
 IN Houston, L. L., Del Mar, CA, UNITED STATES
 Sheridan, Philip J., San Diego, CA, UNITED STATES
 Hawley, Stephen B., San Diego, CA, UNITED STATES
 Glynn, Jacqueline M., San Diego, CA, UNITED STATES
 Chapin, Steven, San Diego, CA, UNITED STATES
 PI US 2003161809 A1 20030828
 AI US 2001-969748 A1 20011002 (9)
 PRAI US 2000-237929P 20001002 (60)
 US 2000-248478P 20001113 (60)
 US 2000-248819P 20001114 (60)
 US 2001-267601P 20010209 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 11304
 INCL INCLM: 424/085.200
 INCLS: 424/178.100; 514/044.000; 435/006.000; 530/351.000; 530/391.100;
 530/395.000
 NCL NCLM: 424/085.200
 NCLS: 424/178.100; 514/044.000; 435/006.000; 530/351.000; 530/391.100;
 530/395.000
 IC [7]
 ICM: A61K039-395
 ICS: C12Q001-68; A61K038-20; A61K048-00; C07K014-52; C07K016-46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 297 USPATFULL on STN
 AN 2003:226299 USPATFULL
 TI Selective induction of apoptosis to treat ocular disease
 IN Campochiaro, Peter A., Baltimore, MD, UNITED STATES
 PA Johns Hopkins University School of Medicine, Baltimore, MD, UNITED
 STATES (U.S. corporation)
 PI US 2003158112 A1 20030821
 AI US 2003-367038 A1 20030214 (10)
 PRAI US 2002-357340P 20020215 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2121
 INCL INCLM: 514/012.000
 INCLS: 514/044.000
 NCL NCLM: 514/012.000
 NCLS: 514/044.000
 IC [7]
 ICM: A61K038-17
 ICS: A61K048-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 297 USPATFULL on STN
 AN 2003:219785 USPATFULL
 TI TGF-beta-specific covalently closed antisense molecule
 IN Park, Jong-Gu, Daegu, KOREA, REPUBLIC OF
 Moon, Ik-Jae, Daegu, KOREA, REPUBLIC OF
 Choi, Young-Kook, Daegu, KOREA, REPUBLIC OF
 Park, Kwankyu, Daegu, KOREA, REPUBLIC OF
 PI US 2003153075 A1 20030814
 AI US 2002-334411 A1 20021230 (10)

DT Utility
FS APPLICATION
LN.CNT 1172
INCL INCLM: 435/375.000
INCLS: 514/044.000; 536/023.200
NCL NCLM: 435/375.000
NCLS: 514/044.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 297 USPATFULL on STN
AN 2003:219655 USPATFULL
TI Cell cycle progression proteins
IN Deak, Peter, Cambridge, UNITED KINGDOM
Glover, David Moore, Sandy, UNITED KINGDOM
Midgley, Carol, Milton Keynes, UNITED KINGDOM
PA Cyclacel Limited, Dundee, UNITED KINGDOM, GB (non-U.S. corporation)
PI US 2003152945 A1 20030814
AI US 2002-161051 A1 20020530 (10)
RLI Continuation-in-part of Ser. No. WO 2001-GB1297, filed on 23 Mar 2001,
UNKNOWN
PRAI GB 2000-7268 20000324
DT Utility
FS APPLICATION
LN.CNT 2533
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 297 USPATFULL on STN
AN 2003:214330 USPATFULL
TI MAGE-A1 peptides for treating or preventing cancer
IN Emtage, Peter, Boston, MA, UNITED STATES
Karunakaran, Liza, Toronto, CANADA
Pedyczak, Arthur, Toronto, CANADA
Barber, Brian H., Hawthorne, NY, UNITED STATES
PI US 2003148973 A1 20030807
AI US 2002-150797 A1 20020517 (10)
PRAI US 2001-292590P 20010523 (60)
DT Utility
FS APPLICATION
LN.CNT 1761
INCL INCLM: 514/044.000
INCLS: 424/093.200; 424/185.100; 536/023.100
NCL NCLM: 514/044.000
NCLS: 424/093.200; 424/185.100; 536/023.100
IC [7]
ICM: C07H021-04
ICS: A61K048-00; A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 297 USPATFULL on STN
AN 2003:214311 USPATFULL
TI Agents and methods for modulating activator protein-1-mediated cellular
processes
IN Bresnick, Emery H., Middleton, WI, UNITED STATES
Norton, Jason E., Madison, WI, UNITED STATES
Chu, Jianlin, Madison, WI, UNITED STATES
PA Wisconsin Alumni Research Foundation (U.S. corporation)
PI US 2003148954 A1 20030807
AI US 2002-287196 A1 20021104 (10)
PRAI US 2001-335379P 20011102 (60)
DT Utility
FS APPLICATION
LN.CNT 2304
INCL INCLM: 514/012.000
INCLS: 435/006.000; 435/007.200
NCL NCLM: 514/012.000

IC [7]
ICM: A61K038-17
ICS: C12Q001-68; G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 297 USPATFULL on STN
AN 2003:213873 USPATFULL
TI Induction of immunity using inhibitors of granzymes
IN Ashton-Rickardt, Philip G., Chicago, IL, UNITED STATES
Opferman, Joseph T., Brookline, MA, UNITED STATES
PI US 2003148511 A1 20030807
AI US 2001-993363 A1 20011114 (9)
DT Utility
FS APPLICATION
LN.CNT 3725
INCL INCLM: 435/339.000
INCLS: 435/343.000; 435/343.200; 435/344.000; 514/044.000
NCL NCLM: 435/339.000
NCLS: 435/343.000; 435/343.200; 435/344.000; 514/044.000
IC [7]

ICM: A61K031-70
ICS: A01N043-04; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 297 USPATFULL on STN
AN 2003:213626 USPATFULL
TI Methods and compositions using genetic package display
IN Larocca, David, Encinitas, CA, UNITED STATES
Kassner, Paul, San Mateo, CA, UNITED STATES
Baird, Andrew, London, UNITED KINGDOM
Burg, Michael Alan, San Diego, CA, UNITED STATES
PA Selective Genetics, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
PI US 2003148263 A1 20030807
AI US 2002-151204 A1 20020517 (10)
RLI Continuation-in-part of Ser. No. US 2001-866073, filed on 24 May 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US25361, filed on 29 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-258689, filed on 26 Feb 1999, GRANTED, Pat. No. US 6451527 Continuation-in-part of Ser. No. US 1998-193445, filed on 17 Nov 1998, PENDING Continuation-in-part of Ser. No. US 1998-195379, filed on 17 Nov 1998, GRANTED, Pat. No. US 6472146
PRAI US 1997-57067P 19970829 (60)
DT Utility
FS APPLICATION
LN.CNT 4740
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/320.100
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/320.100
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 297 USPATFULL on STN
AN 2003:207869 USPATFULL
TI Peptide-enhanced transfections
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES
Lan, Jianqing, Germantown, MD, UNITED STATES
Shih, PoJen, Columbia, MD, UNITED STATES
Jessee, Joel A., Mt. Airy, MD, UNITED STATES
Schifferli, Kevin P., Germantown, MD, UNITED STATES
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES
Evans, Krista L., Germantown, MD, UNITED STATES
PI US 2003144230 A1 20030731
AI US 2002-200879 A1 20020723 (10)
RLI Continuation of Ser. No. US 2001-911569, filed on 23 Jul 2001, PENDING Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, GRANTED, Pat. No. US 6376248 Continuation-in-part of Ser. No. US 1997-818200, filed on 14 Mar 1997, GRANTED, Pat. No. US 6051429 Continuation-in-part of Ser. No. US 1996-658130, filed on 4 Jun 1996, GRANTED, Pat. No. US 5736392 Continuation-in-part of Ser. No. US 1995-477354, filed on 7 Jun 1995, ABANDONED

FS APPLICATION
LN.CNT 4805
INCL INCLM: 514/044.000
INCLS: 435/458.000
NCL NCLM: 514/044.000
NCLS: 435/458.000
IC [7]
ICM: A61K048-00
ICS: C12N015-88

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 297 USPATFULL on STN
AN 2003:207323 USPATFULL
TI Human ataxin-1-like polypeptide IMX97018
IN Anderson, Dirk M., Seattle, WA, UNITED STATES
PI US 2003143681 A1 20030731
AI US 2002-207706 A1 20020726 (10)
PRAI US 2001-309056P 20010730 (60)
DT Utility
FS APPLICATION

LN.CNT 3589
INCL INCLM: 435/069.100
INCLS: 435/199.000; 435/320.100; 435/325.000; 435/006.000; 435/254.200;
536/023.200
NCL NCLM: 435/069.100
NCLS: 435/199.000; 435/320.100; 435/325.000; 435/006.000; 435/254.200;
536/023.200

IC [7]
ICM: C12Q001-68
ICS: C12N009-22; C07H021-04; C12N001-18; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 297 USPATFULL on STN
AN 2003:200968 USPATFULL
TI Method for the generation of 3' RNA fragments and N-terminally truncated polypeptides
IN Weizsacker, Fritz Von, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Thoma, Christian, Pforzheim, GERMANY, FEDERAL REPUBLIC OF
Offensperger, Wolf-Bernhard, Ehrenkirchen, GERMANY, FEDERAL REPUBLIC OF
PI US 2003138953 A1 20030724
AI US 2002-56161 A1 20020124 (10)
DT Utility
FS APPLICATION

LN.CNT 777
INCL INCLM: 435/375.000
INCLS: 435/471.000
NCL NCLM: 435/375.000
NCLS: 435/471.000

IC [7]
ICM: C12N015-74
ICS: C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 297 USPATFULL on STN
AN 2003:200460 USPATFULL
TI Composition and method for treating HIV infection
IN Zavitz, Kenton, Salt Lake City, UT, UNITED STATES
Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES
Morham, Scott, Salt Lake City, UT, UNITED STATES
Hobden, Adrian, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108
(U.S. corporation)
PI US 2003138444 A1 20030724
AI US 2002-223172 A1 20020819 (10)
PRAI US 2001-313239P 20010818 (60)
DT Utility
FS APPLICATION

LN.CNT 1627
INCL INCLM: 424/188.100
NCL NCLM: 424/188.100
IC [7]

ICM: A61K039-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 297 USPATFULL on STN

TI Human and murine cytokine polypeptides
IN Baum, Peter R., Seattle, WA, UNITED STATES
Mosley, Bruce A., Seattle, WA, UNITED STATES
Ketchem, Randal R., Everett, WA, UNITED STATES
PI US 2003134306 A1 20030717
AI US 2002-263568 A1 20021002 (10)
PRAI US 2001-327122P 20011003 (60)
DT Utility
FS APPLICATION
LN.CNT 4532
INCL INCLM: 435/006.000
INCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500;
424/085.100
NCL NCLM: 435/006.000
NCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500;
424/085.100
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C07K014-52; C12N005-06; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 297 USPATFULL on STN
AN 2003:188391 USPATFULL
TI Methods of inducing cell death
IN Gaston, Kevin Leon, Bristol, UNITED KINGDOM
Stern, Peter Leslie, Stockport, UNITED KINGDOM
Clarke, Anthony Russell, Bristol, UNITED KINGDOM
PA The University of Bristol, Bristol, UNITED KINGDOM (non-U.S.
corporation)
PI US 2003130184 A1 20030710
AI US 2002-47990 A1 20020114 (10)
RLI Continuation of Ser. No. WO 1999-GB2693, filed on 13 Jul 1999, UNKNOWN
PRAI GB 1999-16363 19990713
DT Utility
FS APPLICATION
LN.CNT 1260
INCL INCLM: 514/012.000
INCLS: 435/325.000
NCL NCLM: 514/012.000
NCLS: 435/325.000
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 297 USPATFULL on STN
AN 2003:187813 USPATFULL
TI Databases of regulatory sequences; methods of making and using same
IN Wolffe, Alan P., UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
Guschin, Dmitry, Richmond, CA, UNITED STATES
Collingwood, Trevor, San Pablo, CA, UNITED STATES
Li, Xiao-Yong, Richmond, CA, UNITED STATES
Johnstone, Brian, Benicia, CA, UNITED STATES
Wolffe, Elizabeth J., UNITED STATES LR
PI US 2003129603 A1 20030710
AI US 2001-83682 A1 20011024 (10)
RLI Continuation-in-part of Ser. No. US 2001-844501, filed on 27 Apr 2001,
PENDING
PRAI US 2000-200590P 20000428 (60)
US 2000-214674P 20000627 (60)
US 2000-228556P 20000828 (60)
DT Utility
FS APPLICATION
LN.CNT 6351
INCL INCLM: 435/006.000
INCLS: 435/270.000; 536/025.400
NCL NCLM: 435/006.000
NCLS: 435/270.000; 536/025.400
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 131 OF 297 USPATFULL on STN

TI Methods of detecting a cell
IN Tse, Eric, Cambridge, UNITED KINGDOM
Rabbitts, Terence, Cambridge, UNITED KINGDOM
PI US 2003124629 A1 20030703
AI US 2002-265002 A1 20021004 (10)
RLI Continuation-in-part of Ser. No. WO 2001-GB1540, filed on 4 Apr 2001,
UNKNOWN
PRAI GB 2000-8256 20000404
GB 2002-8254 20020404
DT Utility
FS APPLICATION
LN.CNT 2533
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 297 USPATFULL on STN
AN 2003:173923 USPATFULL
TI Modulators of bone homeostasis identified in a high-throughput screen
IN Rompaey, Luc Van, Keerbergen, BELGIUM
Van Es, Helmuth Hendrikus Gerardus, Haarlem, NETHERLANDS
Tomme, Peter Herwig Maria, Gent, BELGIUM
Klaassen, Hubertus Johannes Matheus, Herent, BELGIUM
PI US 2003119771 A1 20030626
AI US 2002-225630 A1 20020822 (10)
PRAI US 2001-314056P 20010822 (60)
US 2002-356935P 20020214 (60)
DT Utility
FS APPLICATION
LN.CNT 4299
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/366.000; 435/226.000;
530/350.000; 536/023.200
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/366.000; 435/226.000;
530/350.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-08; C12N009-64;
C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 297 USPATFULL on STN
AN 2003:172756 USPATFULL
TI Transfer compounds, production and use thereof
IN Gerdes, Johannes, Feldhorst, GERMANY, FEDERAL REPUBLIC OF
Scholzen, Thomas, Neritz, GERMANY, FEDERAL REPUBLIC OF
Wohlenberg, Claudia, Hamburg, GERMANY, FEDERAL REPUBLIC OF
PA FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH, Leipzig,
GERMANY, FEDERAL REPUBLIC OF, 04109 (non-U.S. corporation)
PI US 2003118600 A1 20030626
AI US 2002-152212 A1 20020520 (10)
RLI Continuation of Ser. No. WO 2000-EP11482, filed on 17 Nov 2000, UNKNOWN
PRAI DE 1999-19955576 19991118
DT Utility
FS APPLICATION
LN.CNT 524
INCL INCLM: 424/185.100
INCLS: 435/069.300; 435/320.100; 435/325.000; 530/350.000; 514/044.000;
536/023.200
NCL NCLM: 424/185.100
NCLS: 435/069.300; 435/320.100; 435/325.000; 530/350.000; 514/044.000;
536/023.200
IC [7]
ICM: A61K048-00
ICS: C12P021-02; C12N005-06; C07H021-04; A61K039-00; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 134 OF 297 USPATFULL on STN
AN 2003:166063 USPATFULL
TI Immunogenic targets for melanoma
IN Emtage, Peter, Sunnyvale, CA, UNITED STATES
Karunakaran, Liza, Thornhill, CANADA

Barber, Brian, White Plains, NY, UNITED STATES

PA Aventis Pasteur, Ltd. (U.S. corporation)

PI US 2003113919 A1 20030619

AI US 2002-219850 A1 20020815 (10)

PRAI US 2001-313438P 20010817 (60)

US 2001-313572P 20010817 (60)

US 2001-313573P 20010817 (60)

US 2001-313574P 20010817 (60)

DT Utility

FS APPLICATION

LN.CNT 2347

INCL INCLM: 435/456.000

INCLS: 435/320.100; 435/235.100

NCL NCLM: 435/456.000

NCLS: 435/320.100; 435/235.100

IC [7]

ICM: C12N015-86

ICS: C12N007-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 297 USPATFULL on STN

AN 2003:165439 USPATFULL

TI Compositions and methods for delivery of an agent using attenuated
Salmonella containing phage

IN Bermudes, David G., Wallingford, CT, UNITED STATES

King, Ivan C., North Haven, CT, UNITED STATES

Clairmont, Caroline A., Cheshire, CT, UNITED STATES

PA Vion Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003113293 A1 20030619

AI US 2002-76117 A1 20020213 (10)

RLI Continuation of Ser. No. US 2000-645418, filed on 24 Aug 2000, ABANDONED

PRAI US 1999-150928P 19990826 (60)

DT Utility

FS APPLICATION

LN.CNT 2322

INCL INCLM: 424/093.200

INCLS: 435/252.300

NCL NCLM: 424/093.200

NCLS: 435/252.300

IC [7]

ICM: A61K048-00

ICS: C12N001-21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 297 USPATFULL on STN

AN 2003:159267 USPATFULL

TI Modified zinc finger binding proteins

IN Rebar, Edward, El Cerrito, CA, UNITED STATES

Jamieson, Andrew, San Francisco, CA, UNITED STATES

PA Sangamo BioSciences, Richmond, CA (U.S. corporation)

PI US 2003108880 A1 20030612

AI US 2002-55711 A1 20020122 (10)

PRAI US 2001-263445P 20010122 (60)

US 2001-290716P 20010511 (60)

DT Utility

FS APPLICATION

LN.CNT 2403

INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/226.000; 435/325.000; 435/320.100; 536/023.200

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/226.000; 435/325.000; 435/320.100; 536/023.200

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 297 USPATFULL on STN

AN 2003:154409 USPATFULL

TI Random integration of a polynucleotide by in vivo linearization

IN Chouluka, Andre, Paris, FRANCE

Joly, Jean-Stephane, Versailles, FRANCE

Thermes, Violette, Paris, FRANCE

Ristoratore, Filomena, Ercolano, ITALY

PI US 2003106077 A1 20030605

AI US 2002-242664 A1 20020913 (10)

US 2001-330639P 20011026 (60)
DT Utility
FS APPLICATION
LN.CNT 2990
INCL INCLM: 800/008.000
INCLS: 800/014.000; 800/015.000; 800/016.000; 800/018.000; 800/288.000;
800/019.000; 800/020.000; 435/455.000; 800/021.000; 119/300.000;
435/325.000; 435/419.000; 424/093.210
NCL NCLM: 800/008.000
NCLS: 800/014.000; 800/015.000; 800/016.000; 800/018.000; 800/288.000;
800/019.000; 800/020.000; 435/455.000; 800/021.000; 119/300.000;
435/325.000; 435/419.000; 424/093.210
IC [7]
ICM: A01K067-027
ICS: A01H001-00; C12N015-82; C12N015-85; C12N005-06; C12N005-04;
A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 297 USPATFULL on STN
AN 2003:153609 USPATFULL
TI Compositions and therapeutic methods for viral infection
IN Morham, Scott, Salt Lake City, UT, UNITED STATES
Zavitz, Kenton, Salt Lake City, UT, UNITED STATES
Hobden, Adrian, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2003105277 A1 20030605
AI US 2002-226007 A1 20020821 (10)
PRAI US 2001-313883P 20010821 (60)
DT Utility
FS APPLICATION
LN.CNT 3724
INCL INCLM: 530/300.000
INCLS: 514/012.000; 424/186.100; 530/350.000
NCL NCLM: 530/300.000
NCLS: 514/012.000; 424/186.100; 530/350.000
IC [7]
ICM: A61K039-12
ICS: C07K014-005; C07K014-15; A61K038-00; C07K001-00; C07K014-00;
C07K017-00; C07K002-00; C07K004-00; C07K005-00; C07K007-00; C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 297 USPATFULL on STN
AN 2003:152956 USPATFULL
TI Identification of peptides that facilitate uptake and cytoplasmic and/or
nuclear transport of proteins, DNA and viruses
IN Robbins, Paul D., Mt. Lebanon, PA, UNITED STATES
Mi, Zhibao, Pittsburgh, PA, UNITED STATES
Frizzell, Raymond, Pittsburgh, PA, UNITED STATES
Glorioso, Joseph C., Cheswick, PA, UNITED STATES
Gambotto, Andrea, Pittsburgh, PA, UNITED STATES
PI US 2003104622 A1 20030605
AI US 2002-75869 A1 20020213 (10)
RLI Continuation-in-part of Ser. No. US 2000-653182, filed on 31 Aug 2000,
PENDING
PRAI US 1999-151980P 19990901 (60)
US 2000-188944P 20000313 (60)
DT Utility
FS APPLICATION
LN.CNT 3099
INCL INCLM: 435/455.000
INCLS: 530/326.000; 530/327.000; 514/014.000; 514/015.000
NCL NCLM: 435/455.000
NCLS: 530/326.000; 530/327.000; 514/014.000; 514/015.000
IC [7]
ICM: A61K038-08
ICS: A61K038-10; C07K007-06; C07K007-08; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 140 OF 297 USPATFULL on STN
AN 2003:152913 USPATFULL
TI Cytokine polypeptides
IN Baum, Peter R., Seattle, WA, UNITED STATES
Mosley, Bruce A., Seattle, WA, UNITED STATES
Ketchem, Randal R., Seattle, WA, UNITED STATES
Taylor, Scott L., Seattle, WA, UNITED STATES

AI US 2002-142717 A1 20020508 (10)
 PRAI US 2001-290239P 20010510 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4149
 INCL INCLM: 435/069.500
 INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
 NCL NCLM: 435/069.500
 NCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; C07K014-52; C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 297 USPATFULL on STN
 AN 2003:152860 USPATFULL
 TI Position dependent recognition of GNN nucleotide triplets by zinc fingers
 IN Liu, Qiang, Foster City, CA, UNITED STATES
 PI US 2003104526 A1 20030605
 AI US 2001-989994 A1 20011120 (9)
 RLI Continuation-in-part of Ser. No. US 2000-535008, filed on 23 Mar 2000, GRANTED, Pat. No. US 6465629 Continuation-in-part of Ser. No. US 2000-716637, filed on 20 Nov 2000, PENDING
 PRAI US 1999-126238P 19990324 (60)
 US 1999-126239P 19990324 (60)
 US 1999-146595P 19990730 (60)
 US 1999-146615P 19990730 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3005
 INCL INCLM: 435/069.100
 INCLS: 435/006.000; 435/226.000; 435/320.100; 435/325.000; 536/023.200
 NCL NCLM: 435/069.100
 NCLS: 435/006.000; 435/226.000; 435/320.100; 435/325.000; 536/023.200
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 297 USPATFULL on STN
 AN 2003:152326 USPATFULL
 TI Clasp membrane proteins
 IN Lu, Peter S., Mountain View, CA, UNITED STATES
 Garman, Jonathan David, San Jose, CA, UNITED STATES
 Candia, Albert F., III, Menlo Park, CA, UNITED STATES
 PA ARBOR VITA CORPORATION, SUNNYVALE, CA, 94086 (U.S. corporation)
 PI US 2003103992 A1 20030605
 AI US 2001-978244 A1 20011015 (9)
 RLI Continuation-in-part of Ser. No. US 2000-737246, filed on 13 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2001-736969, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-736968, filed on 13 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-736960, filed on 13 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, PENDING
 PRAI US 2001-310028P 20010803 (60)
 US 2000-240545P 20001013 (60)
 US 2000-240508P 20001013 (60)
 US 2000-240503P 20001013 (60)
 US 2000-240539P 20001013 (60)
 US 2000-240543P 20001013 (60)
 US 2000-196267P 20000411 (60)
 US 2000-196527P 20000411 (60)
 US 2000-196528P 20000411 (60)
 US 2000-196460P 20000411 (60)
 US 1999-160860P 19991021 (60)
 US 1999-162498P 19991029 (60)
 US 1999-170453P 19991213 (60)
 US 2000-176195P 20000114 (60)
 US 2000-182296P 20000214 (60)
 US 2000-240545P 20001013 (60)

US 2000-240503P 20001013 (60)
 US 2000-240539P 20001013 (60)
 US 2000-240543P 20001013 (60)
 US 2000-240545P 20001013 (60)
 US 2000-240508P 20001013 (60)
 US 2000-240503P 20001013 (60)
 US 2000-240539P 20001013 (60)
 US 2000-240543P 20001013 (60)
 US 2000-240545P 20001013 (60)
 US 2000-240508P 20001013 (60)
 US 2000-240503P 20001013 (60)
 US 2000-240539P 20001013 (60)
 US 2000-240543P 20001013 (60)

DT Utility
 FS APPLICATION
 LN.CNT 5557
 INCL INCLM: 424/185.100
 INCLS: 435/226.000; 536/023.200; 435/069.100; 435/320.100; 435/325.000
 NCL NCLM: 424/185.100
 NCLS: 435/226.000; 536/023.200; 435/069.100; 435/320.100; 435/325.000
 IC [7]
 ICM: C07H021-04
 ICS: A61K039-00; C12N009-64; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 297 USPATFULL on STN
 AN 2003:146347 USPATFULL
 TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
 IN Cech, Thomas R., Boulder, CO, UNITED STATES
 Lingner, Joachim, Pl. Croix-Blanche, SWITZERLAND
 Nakamura, Toru, Boulder, CO, UNITED STATES
 Chapman, Karen B., Sausalito, CA, UNITED STATES
 Morin, Gregg B., Davis, CA, UNITED STATES
 Harley, Calvin B., Palo Alto, CA, UNITED STATES
 Andrews, William H., Richmond, CA, UNITED STATES

PI US 2003100093 A1 20030529
 AI US 2002-44539 A1 20020111 (10)
 RLI Continuation of Ser. No. US 1997-912951, filed on 14 Aug 1997, PENDING
 Continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997,
 GRANTED, Pat. No. US 6261836 Continuation-in-part of Ser. No. US
 1997-851843, filed on 6 May 1997, GRANTED, Pat. No. US 6093809
 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997,
 ABANDONED Continuation-in-part of Ser. No. US 1997-844419, filed on 18
 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-724643,
 filed on 1 Oct 1996, ABANDONED

DT Utility
 FS APPLICATION
 LN.CNT 11968
 INCL INCLM: 435/199.000
 INCLS: 435/320.100; 435/325.000; 435/368.000; 435/069.100; 536/023.200
 NCL NCLM: 435/199.000
 NCLS: 435/320.100; 435/325.000; 435/368.000; 435/069.100; 536/023.200
 IC [7]
 ICM: C12N009-22
 ICS: C07H021-04; C12P021-02; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 297 USPATFULL on STN
 AN 2003:146199 USPATFULL
 TI Combination therapy involving drugs which target cellular proteins and
 drugs which target pathogen-encoded proteins
 IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
 Schang, Luis M., Edmonton, CANADA

PI US 2003099944 A1 20030529
 AI US 2000-905687 A1 20001206 (9)
 RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep
 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul
 1999, PENDING

PRAI US 1998-94805P 19980731 (60)
 US 1999-131264P 19990427 (60)
 US 1999-140926P 19990624 (60)

DT Utility
 FS APPLICATION
 LN.CNT 4046

INCLS: 514/263.380; 514/263.400; 435/005.000; 424/204.100
NCL NCLM: 435/006.000
NCLS: 514/263.380; 514/263.400; 435/005.000; 424/204.100
IC [7]
ICM: A61K031-522
ICS: A61K031-52; C12Q001-70; C12Q001-68; A61K039-12; A01N043-90
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 297 USPATFULL on STN
AN 2003:140890 USPATFULL
TI Telomerase expression repressor proteins and methods of using the same
IN Andrews, William H., Reno, NV, UNITED STATES
Foster, Christopher A., Carmichael, CA, UNITED STATES
PI US 2003096732 A1 20030522
AI US 2002-177744 A1 20020621 (10)
PRAI US 2001-300115P 20010621 (60)
US 2002-366069P 20020319 (60)
DT Utility
FS APPLICATION
LN.CNT 2591
INCL INCLM: 514/001.000
INCLS: 435/007.100
NCL NCLM: 514/001.000
NCLS: 435/007.100
IC [7]
ICM: A61K031-00
ICS: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 297 USPATFULL on STN
AN 2003:140503 USPATFULL
TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
IN Cech, Thomas R., Boulder, CO, UNITED STATES
Lingner, Joachim, PI. Croix-Blanche 25, SWITZERLAND
Nakamura, Toru, Boulder, CO, UNITED STATES
Chapman, Karen B., Sausalito, CA, UNITED STATES
Morin, Gregg B., Davis, CA, UNITED STATES
Harley, Calvin B., Palo Alto, CA, UNITED STATES
Andrews, William H., Richmond, CA, UNITED STATES
PI US 2003096344 A1 20030522
AI US 2002-44692 A1 20020111 (10)
RLI Continuation of Ser. No. US 1997-912951, filed on 14 Aug 1997, PENDING
Continuation of Ser. No. US 1997-854050, filed on 9 May 1997, GRANTED,
Pat. No. US 6261836 Continuation-in-part of Ser. No. US 1997-851843,
filed on 6 May 1997, GRANTED, Pat. No. US 6093809 Continuation-in-part
of Ser. No. US 1997-846017, filed on 25 Apr 1997, ABANDONED
Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997,
ABANDONED Continuation-in-part of Ser. No. US 1996-724643, filed on 1
Oct 1996, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 7257
INCL INCLM: 435/069.100
INCLS: 435/199.000; 435/320.100; 435/325.000; 424/146.100
NCL NCLM: 435/069.100
NCLS: 435/199.000; 435/320.100; 435/325.000; 424/146.100
IC [7]
ICM: C12P021-02
ICS: C12N005-06; A61K039-395; C12N009-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 297 USPATFULL on STN
AN 2003:127602 USPATFULL
TI Regulation of endogenous gene expression in cells using zinc finger
proteins
IN Cox, George Norbert, III, Louisville, CO, UNITED STATES
Case, Casey Christopher, San Mateo, CA, UNITED STATES
Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric Edward, Boulder, CO, UNITED STATES
Spratt, Sharon Kaye, Vacaville, CA, UNITED STATES
PA Sangamo BioSciences, Inc. (U.S. corporation)
PI US 2003087817 A1 20030508
AI US 2001-897844 A1 20010702 (9)
RLI Continuation of Ser. No. US 1999-229037, filed on 12 Jan 1999, PENDING
DT Utility

LN.CNT 3696
INCL INCLM: 514/012.000
INCLS: 435/455.000
NCL NCLM: 514/012.000
NCLS: 435/455.000
IC [7]
ICM: A61K038-48
ICS: C12N015-87

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 297 USPATFULL on STN
AN 2003:127198 USPATFULL
TI Death associated kinase containing ankyr in repeats (DAKAR) and methods
of use
IN Bird, Timothy A., Bainbridge Island, WA, UNITED STATES
Holland, Pamela M., Seattle, WA, UNITED STATES
Peschon, Jacques J., Seattle, WA, UNITED STATES
Virca, George D., Bellevue, WA, UNITED STATES
PI US 2003087411 A1 20030508
AI US 2002-164080 A1 20020604 (10)
PRAI US 2001-295959P 20010604 (60)
US 2001-334362P 20011129 (60)
DT Utility
FS APPLICATION
LN.CNT 5574
INCL INCLM: 435/194.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/194.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-12
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 297 USPATFULL on STN
AN 2003:126693 USPATFULL
TI Therapeutic regimen for treating cancer
IN Rasmussen, Henrik S., Arnold, MD, UNITED STATES
Chu, Karen W., New York, NY, UNITED STATES
PA GenVec, Inc., Gaithersburg, MD, 20878 (U.S. corporation)
PI US 2003086904 A1 20030508
AI US 2002-151633 A1 20020517 (10)
RLI Continuation-in-part of Ser. No. US 2001-1017, filed on 2 Nov 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 2002
INCL INCLM: 424/093.200
INCLS: 435/456.000; 435/235.100
NCL NCLM: 424/093.200
NCLS: 435/456.000; 435/235.100
IC [7]
ICM: A61K048-00
ICS: C12N007-00; C12N015-861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 297 USPATFULL on STN
AN 2003:126692 USPATFULL
TI Therapeutic regimen for treating cancer
IN Rasmussen, Henrik S., Arnold, MD, UNITED STATES
Chu, Karen W., New York, NY, UNITED STATES
PA GenVec, Inc., Gaithersburg, MD, UNITED STATES (U.S. corporation)
PI US 2003086903 A1 20030508
AI US 2001-1017 A1 20011102 (10)
DT Utility
FS APPLICATION
LN.CNT 1832
INCL INCLM: 424/093.100
NCL NCLM: 424/093.100
IC [7]
ICM: A01N063-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 297 USPATFULL on STN
AN 2003:120821 USPATFULL

IN Palese, Peter, Leonia, NJ, UNITED STATES
Garcia-Sastre, Adolfo, New York, NY, UNITED STATES
PI US 2003083305 A1 20030501
AI US 2002-269513 A1 20021010 (10)
PRAI US 2001-328573P 20011010 (60)
DT Utility
FS APPLICATION
LN.CNT 2366
INCL INCLM: 514/044.000
INCLS: 424/093.200
NCL NCLM: 514/044.000
NCLS: 424/093.200
IC [7]
ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 152 OF 297 USPATFULL on STN
AN 2003:120069 USPATFULL
TI Modulation of gene expression using localization domains
IN Wolffe, Alan P., UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
Lai, Albert, Richmond, CA, UNITED STATES
Raschke, Eva, Berkeley, CA, UNITED STATES
Wolffe, Elizabeth J., San Francisco, CA, UNITED STATES LR
PI US 2003082552 A1 20030501
AI US 2001-967869 A1 20010928 (9)
PRAI US 2000-236884P 20000929 (60)
DT Utility
FS APPLICATION
LN.CNT 3097
INCL INCLM: 435/006.000
INCLS: 435/455.000; 435/317.100
NCL NCLM: 435/006.000
NCLS: 435/455.000; 435/317.100
IC [7]
ICM: C12Q001-68
ICS: C12N015-85; C12N001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 297 USPATFULL on STN
AN 2003:113094 USPATFULL
TI Surface transfection and expression procedure
IN Uhler, Michael D., Ann Arbor, MI, UNITED STATES
PI US 2003077827 A1 20030424
AI US 2002-123435 A1 20020416 (10)
RLI Continuation-in-part of Ser. No. US 2001-960454, filed on 21 Sep 2001,
PENDING Continuation-in-part of Ser. No. US 2001-2802, filed on 2 Nov
2001, PENDING
PRAI US 2000-245892P 20001103 (60)
US 2001-305552P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 4701
INCL INCLM: 435/455.000
INCLS: 435/069.100; 435/325.000; 435/006.000
NCL NCLM: 435/455.000
NCLS: 435/069.100; 435/325.000; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C12N015-85; C12P021-02; C12N001-21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 297 USPATFULL on STN
AN 2003:112531 USPATFULL
TI Modulation of angiogenesis by A-beta peptides
IN Paris, Daniel, Wesley Chapel, FL, UNITED STATES
Mullan, Michael, Tampa, FL, UNITED STATES
PI US 2003077261 A1 20030424
AI US 2002-217584 A1 20020812 (10)
PRAI US 2001-311656P 20010810 (60)
DT Utility
FS APPLICATION
LN.CNT 2523
INCL INCLM: 424/093.210
INCLS: 514/012.000; 514/044.000

IC NCLS: 514/012.000; 514/044.000
[7]
ICM: A61K048-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 155 OF 297 USPATFULL on STN
AN 2003:100071 USPATFULL
TI Alternative splice forms of proteins as basis for multiple therapeutic modalities
IN Wong, Albert J., Philadelphia, PA, UNITED STATES
PI US 2003069181 A1 20030410
AI US 2002-156932 A1 20020528 (10)
PRAI US 2001-293791P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 3613
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/324.000; 530/325.000; 530/328.000; 530/329.000; 530/330.000; 530/326.000; 530/327.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/324.000; 530/325.000; 530/328.000; 530/329.000; 530/330.000; 530/326.000; 530/327.000
IC [7]
ICM: A61K038-16
ICS: A61K038-10; A61K038-08; C07K014-435; C07K007-08; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 156 OF 297 USPATFULL on STN
AN 2003:100063 USPATFULL
TI Peptide-enhanced transfections
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES
Lan, Jianqing, Germantown, MD, UNITED STATES
Shih, PoJen, Columbia, MD, UNITED STATES
Jessee, Joel A., Mt. Airy, MD, UNITED STATES
Schifferli, Kevin P., Germantown, MD, UNITED STATES
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES
Evans, Krista L., Germantown, MD, UNITED STATES
PA Life Technologies, Inc. (U.S. corporation)
PI US 2003069173 A1 20030410
AI US 2001-911569 A1 20010723 (9)
RLI Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 4787
INCL INCLM: 514/008.000
INCLS: 514/044.000; 435/458.000
NCL NCLM: 514/008.000
NCLS: 514/044.000; 435/458.000
IC [7]
ICM: A61K048-00
ICS: C12N015-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 157 OF 297 USPATFULL on STN
AN 2003:99570 USPATFULL
TI Position dependent recognition of GNN nucleotide triplets by zinc fingers
IN Liu, Qiang, Foster City, CA, UNITED STATES
PI US 2003068675 A1 20030410
AI US 2001-990186 A1 20011120 (9)
RLI Continuation-in-part of Ser. No. US 2000-535008, filed on 23 Mar 2000, PENDING
Continuation-in-part of Ser. No. US 2000-716637, filed on 20 Nov 2000, PENDING
PRAI US 1999-126238P 19990324 (60)
US 1999-126239P 19990324 (60)
US 1999-146595P 19990730 (60)
US 1999-146615P 19990730 (60)
DT Utility
FS APPLICATION
LN.CNT 2883
INCL INCLM: 435/069.100

NCL NCLM: 435/069.100
 NCLS: 435/226.000; 702/019.000; 435/006.000
 IC [7]
 ICM: C12P021-02
 ICS: C12Q001-68; G06F019-00; G01N033-48; G01N033-50; C12N009-64
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 158 OF 297 USPATFULL on STN
 AN 2003:86849 USPATFULL
 TI Cellular proteins as targets for the treatment of pathogens resistant to
 drugs that target pathogen-encoded proteins
 IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
 Schang, Luis M., Edmonton, CANADA
 PI US 2003060457 A1 20030327
 AI US 2000-905695 A1 20001206 (9)
 RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep
 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul
 1999, PENDING
 PRAI US 1998-94805P 19980731 (60)
 US 1999-131264P 19990427 (60)
 US 1999-140926P 19990624 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3979
 INCL INCLM: 514/211.080
 INCLS: 514/263.400; 514/456.000; 514/473.000; 514/414.000; 514/285.000;
 514/518.000
 NCL NCLM: 514/211.080
 NCLS: 514/263.400; 514/456.000; 514/473.000; 514/414.000; 514/285.000;
 514/518.000
 IC [7]
 ICM: A61K031-553
 ICS: A61K031-52; A61K031-4745; A61K031-365; A61K031-404; A61K031-255
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 159 OF 297 USPATFULL on STN
 AN 2003:78489 USPATFULL
 TI Novel complex-forming proteins
 IN Jerome, Valerie, Coelbe, GERMANY, FEDERAL REPUBLIC OF
 Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
 Mueller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
 PI US 2003054409 A1 20030320
 AI US 2002-201949 A1 20020725 (10)
 RLI Continuation of Ser. No. US 2000-481593, filed on 12 Jan 2000, PENDING
 PRAI DE 2000-19900743 20000112
 DT Utility
 FS APPLICATION
 LN.CNT 2397
 INCL INCLM: 435/007.100
 INCLS: 435/069.700; 435/069.500; 435/320.100; 435/325.000; 530/350.000;
 530/351.000; 435/183.000
 NCL NCLM: 435/007.100
 NCLS: 435/069.700; 435/069.500; 435/320.100; 435/325.000; 530/350.000;
 530/351.000; 435/183.000
 IC [7]
 ICM: G01N033-53
 ICS: C12P021-02; C12N009-00; C07K014-715; C07K014-52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 297 USPATFULL on STN
 AN 2003:78071 USPATFULL
 TI Retinoic acid receptor beta-2, its agonists, and gene therapy vectors
 for the treatment of neurological disorders
 IN Kingsman, Alan John, Robert Robinson Avenue, UNITED KINGDOM
 Maden, Malcolm, London, UNITED KINGDOM
 Thomas Corcoran, Jonathan Patrick, London, UNITED KINGDOM
 PI US 2003053991 A1 20030320
 AI US 2002-239804 A1 20020923 (10)
 WO 2001-GB1478 20010330
 PRAI GB 2000-24300 20001004
 DT Utility
 FS APPLICATION
 LN.CNT 5801
 INCL INCLM: 424/093.200

NCL NCLM: 424/093.200
 NCLS: 435/235.100; 435/456.000; 435/320.100; 435/368.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N007-00; C12N015-867; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 297 USPATFULL on STN
 AN 2003:71556 USPATFULL
 TI High throughput or capillary-based screening for a bioactivity or biomolecule
 IN Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
 Keller, Martin, San Diego, CA, UNITED STATES
 Lafferty, William Michael, Encinitas, CA, UNITED STATES
 PI US 2003049841 A1 20030313
 AI US 2001-975036 A1 20011010 (9)
 RLI Continuation-in-part of Ser. No. US 2001-894956, filed on 27 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-790321, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-687219, filed on 12 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-685432, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-444112, filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1998-98206, filed on 16 Jun 1998, GRANTED, Pat. No. US 6174673 Continuation-in-part of Ser. No. US 1997-876276, filed on 16 Jun 1997, PENDING
 PRAI US 2001-309101P 20010731 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6452
 INCL INCLM: 435/449.000
 NCL NCLM: 435/449.000
 IC [7]
 ICM: C12N015-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 162 OF 297 USPATFULL on STN
 AN 2003:71364 USPATFULL
 TI Targeted modification of chromatin structure
 IN Wolffe, Alan P., UNITED STATES
 Wolffe, Elizabeth J., UNITED STATES LR
 Collingwood, Trevor, San Pablo, CA, UNITED STATES
 Snowden, Andrew, Richmond, CA, UNITED STATES
 PI US 2003049649 A1 20030313
 AI US 2002-84826 A1 20020224 (10)
 RLI Continuation-in-part of Ser. No. US 2001-844508, filed on 27 Apr 2001, PENDING
 PRAI US 2000-200590P 20000428 (60)
 US 2000-228523P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4122
 INCL INCLM: 435/006.000
 INCLS: 435/455.000; 435/468.000; 435/199.000
 NCL NCLM: 435/006.000
 NCLS: 435/455.000; 435/468.000; 435/199.000
 IC [7]
 ICM: C12Q001-68
 ICS: C12N009-22; C12N015-82; C12N015-87
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 297 USPATFULL on STN
 AN 2003:65374 USPATFULL
 TI Materials and methods for treating ocular-related disorders
 IN Kovesdi, Imre, Rockville, MD, UNITED STATES
 Brough, Douglas E., Gaithersburg, MD, UNITED STATES
 Wei, Lisa, Gaithersburg, MD, UNITED STATES
 McVey, Duncan L., Derwood, MD, UNITED STATES
 PA GenVec, Inc., Gaithersburg, MD, 20878 (non-U.S. corporation)
 PI US 2003045498 A1 20030306
 AI US 2002-211701 A1 20020802 (10)
 RLI Continuation of Ser. No. WO 2001-US4203, filed on 9 Feb 2001, PENDING Continuation of Ser. No. US 2000-599997, filed on 23 Jun 2000, PENDING
 PRAI US 2000-228337P 20000828 (60)
 US 2000-181743P 20000211 (60)
 US 2000-181743P 20000211 (60)

FS APPLICATION
LN.CNT 1823
INCL INCLM: 514/044.000
INCLS: 435/320.100; 435/455.000
NCL NCLM: 514/044.000
NCLS: 435/320.100; 435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 297 USPATFULL on STN
AN 2003:64284 USPATFULL
TI Regulation of angiogenesis with zinc finger proteins
IN Rebar, Edward, El Cerrito, CA, UNITED STATES
Jamieson, Andrew, San Francisco, CA, UNITED STATES
Liu, Qiang, Foster City, CA, UNITED STATES
Liu, Pei-Qi, Richmond, CA, UNITED STATES
Wolffe, Alan, Orinda, CA, UNITED STATES
Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric, Boulder, CO, UNITED STATES
PI US 2003044404 A1 20030306
AI US 2001-846033 A1 20010430 (9)
RLI Continuation-in-part of Ser. No. US 2000-736083, filed on 12 Dec 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-733604, filed on 7
Dec 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4997
INCL INCLM: 424/094.630
INCLS: 435/226.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 424/094.630
NCLS: 435/226.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 297 USPATFULL on STN
AN 2003:57474 USPATFULL
TI INDUCIBLE REGULATORY SYSTEM AND USE THEREOF
IN DOWDY, STEVEN F., CLAYTON, MO, UNITED STATES
JESSEE, JOEL A., MOUNT AIRY, MD, UNITED STATES
PI US 2003040038 A1 20030227
AI US 1998-134793 A1 19980814 (9)
PRAI US 1997-56713P 19970822 (60)
DT Utility
FS APPLICATION
LN.CNT 886
INCL INCLM: 435/069.100
INCLS: 435/455.000; 435/320.100; 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/455.000; 435/320.100; 435/325.000
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 297 USPATFULL on STN
AN 2003:51206 USPATFULL
TI Novel PN9826 nucleic acids and use thereof
IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES
Mauck, Kimberly A., Sandy, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108
(U.S. corporation)
PI US 2003036163 A1 20030220
AI US 2002-195142 A1 20020710 (10)
PRAI US 2001-304323P 20010710 (60)
DT Utility
FS APPLICATION
LN.CNT 5944
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200

ICM: C12P021-02
ICS: C12N005-06; C07K014-435; C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 297 USPATFULL on STN
AN 2003:45285 USPATFULL
TI Targeting nucleic acids to a cellular nucleus
IN Sebestyen, Magdolna G., Madison, WA, UNITED STATES
PI US 2003032597 A1 20030213
AI US 2002-200800 A1 20020722 (10)
PRAI US 2001-309319P 20010731 (60)
DT Utility
FS APPLICATION
LN.CNT 1334
INCL INCLM: 514/012.000
INCLS: 514/044.000
NCL NCLM: 514/012.000
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 297 USPATFULL on STN
AN 2003:37690 USPATFULL
TI Genome engineering by cell-permeable DNA site-specific recombinases
IN Ruley, H. Earl, Nashville, TN, UNITED STATES
Jo, Daewoong, Nashville, TN, UNITED STATES
PI US 2003027335 A1 20030206
AI US 2001-948193 A1 20010907 (9)
PRAI US 2000-230690P 20000907 (60)
DT Utility
FS APPLICATION
LN.CNT 1670
INCL INCLM: 435/455.000
INCLS: 435/199.000; 435/004.000
NCL NCLM: 435/455.000
NCLS: 435/199.000; 435/004.000
IC [7]
ICM: C12N015-87
ICS: C12Q001-00; C12N009-22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 297 USPATFULL on STN
AN 2003:30383 USPATFULL
TI APOA2-interacting proteins and use thereof
IN Bartel, Paul, Salt Lake City, UT, UNITED STATES
Sugiyama, Janice, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2003022330 A1 20030130
AI US 2002-125639 A1 20020418 (10)
PRAI US 2001-285324P 20010419 (60)
US 2002-349843P 20020117 (60)
DT Utility
FS APPLICATION
LN.CNT 4780
INCL INCLM: 435/183.000
INCLS: 435/226.000; 435/007.100
NCL NCLM: 435/183.000
NCLS: 435/226.000; 435/007.100
IC [7]
ICM: G01N033-53
ICS: C12N009-00; C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 297 USPATFULL on STN
AN 2003:29834 USPATFULL
TI Regulation of angiogenesis with zinc finger proteins
IN Rebar, Edward, El Cerrito, CA, UNITED STATES
Jamieson, Andrew, San Francisco, CA, UNITED STATES
Liu, Qiang, Foster City, CA, UNITED STATES
Liu, Pei-Qi, Richmond, CA, UNITED STATES
Wolffe, Alan, Orinda, CA, UNITED STATES
Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric, Boulder, CO, UNITED STATES

corporation)
PI US 2003021776 A1 20030130
AI US 2001-6069 A1 20011206 (10)
RLI Continuation-in-part of Ser. No. US 2001-846033, filed on 30 Apr 2001,
PENDING Continuation-in-part of Ser. No. US 2000-736083, filed on 12 Dec
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-733604, filed
on 7 Dec 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 5975
INCL INCLM: 424/094.630
INCLS: 514/006.000; 435/226.000
NCL NCLM: 424/094.630
NCLS: 514/006.000; 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 171 OF 297 USPATFULL on STN
AN 2003:23712 USPATFULL
TI Modular vector systems
IN Jarrell, Kevin A., Lincoln, MA, UNITED STATES
Donahue, William, Quincy, MA, UNITED STATES
PI US 2003017552 A1 20030123
AI US 2001-910354 A1 20010720 (9)
PRAI US 2000-219820P 20000721 (60)
DT Utility
FS APPLICATION
LN.CNT 1123
INCL INCLM: 435/091.200
INCLS: 435/455.000; 435/320.100
NCL NCLM: 435/091.200
NCLS: 435/455.000; 435/320.100
IC [7]
ICM: C12P019-34
ICS: C12N015-85; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 297 USPATFULL on STN
AN 2003:17417 USPATFULL
TI Transcription factor E2F DNA-binding domain inhibitor peptides and their
use
IN Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
Kontermann, Roland E., Marburg, GERMANY, FEDERAL REPUBLIC OF
Montigiani, Silvia, Siena, ITALY
PI US 2003013169 A1 20030116
AI US 2001-912414 A1 20010726 (9)
RLI Continuation of Ser. No. WO 2000-GB227, filed on 26 Jan 2000, UNKNOWN
PRAI GB 1999-1710 19990126
DT Utility
FS APPLICATION
LN.CNT 1014
INCL INCLM: 435/184.000
INCLS: 530/330.000
NCL NCLM: 435/184.000
NCLS: 530/330.000
IC [7]
ICM: C12N009-99
ICS: C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 173 OF 297 USPATFULL on STN
AN 2003:10704 USPATFULL
TI Regulated expression of recombinant proteins using RNA viruses
IN Jessee, Joel A., Mount Airy, MD, UNITED STATES
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES
PA Invitrogen Corporation (U.S. corporation)
PI US 2003008399 A1 20030109
AI US 2002-213071 A1 20020807 (10)
RLI Division of Ser. No. US 1999-361740, filed on 28 Jul 1999, GRANTED, Pat.
No. US 6451579
PRAI US 1998-94476P 19980729 (60)
DT Utility
FS APPLICATION

INCL INCLM: 435/456.000
INCLS: 514/044.000; 435/235.100
NCL NCLM: 435/456.000
NCLS: 514/044.000; 435/235.100
IC [7]
ICM: A61K048-00
ICS: C12N015-86; C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 297 USPATFULL on STN
AN 2003:10678 USPATFULL
TI APOA1-interacting proteins and use thereof
IN Bartel, Paul, Salt Lake City, UT, UNITED STATES
Szankasi, Philippe, Salt Lake City, UT, UNITED STATES
Sugiyama, Janice, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2003008373 A1 20030109
AI US 2002-124767 A1 20020417 (10)
PRAI US 2001-284220P 20010417 (60)
US 2002-354899P 20020206 (60)
DT Utility
FS APPLICATION
LN.CNT 4667
INCL INCLM: 435/226.000
INCLS: 435/183.000; 435/007.100
NCL NCLM: 435/226.000
NCLS: 435/183.000; 435/007.100
IC [7]
ICM: G01N033-53
ICS: C12N009-00; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 297 USPATFULL on STN
AN 2003:10629 USPATFULL
TI Caspase-7-interacting protein and use thereof
IN Bartel, Paul, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2003008324 A1 20030109
AI US 2002-124550 A1 20020417 (10)
PRAI US 2001-284404P 20010417 (60)
DT Utility
FS APPLICATION
LN.CNT 4771
INCL INCLM: 435/007.100
INCLS: 435/226.000; 435/069.100; 435/069.700; 435/320.100; 435/325.000
NCL NCLM: 435/007.100
NCLS: 435/226.000; 435/069.100; 435/069.700; 435/320.100; 435/325.000
IC [7]
ICM: G01N033-53
ICS: C12P021-04; C12N009-64; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 297 USPATFULL on STN
AN 2003:302698 USPATFULL
TI Methods and compositions to induce antitumor response
IN LaFace, Drake M., San Diego, CA, United States
PA Canji, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6649158 B1 20031118
AI US 1999-416813 19991013 (9)
PRAI US 1998-104370P 19981015 (60)
DT Utility
FS GRANTED
LN.CNT 1069
INCL INCLM: 424/093.170
INCLS: 435/069.100; 435/083.000; 435/320.100; 435/325.000
NCL NCLM: 424/093.200
NCLS: 435/069.100; 435/083.000; 435/320.100; 435/325.000
IC [7]
ICM: A01N063-00
ICS: C12N021-06; C12N019-52; C12N015-00; C12N005-00
EXF 435/320.1; 435/69.1; 435/83; 435/325; 514/44; 424/93.17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 297 USPATFULL on STN
AN 2003:279114 USPATFULL

IN Murphy, Richard B., San Diego, CA, United States
PA Canji, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6635476 B1 20031021
AI US 2000-687930 20001013 (9)
PRAI US 1999-159782P 19991015 (60)
DT Utility
FS GRANTED
LN.CNT 1555
INCL INCLM: 435/320.100
INCLS: 424/199.100; 424/093.100; 424/093.200; 435/235.100
NCL NCLM: 435/320.100
NCLS: 424/093.100; 424/093.200; 424/199.100; 435/235.100
IC [7]
ICM: C12N015-00
ICS: C12N015-09; C12N015-63; C12N015-70; C12N015-74
EXF 435/320.1; 435/455; 435/235.1; 424/9.1; 424/93.2; 424/199.1; 424/93.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 297 USPATFULL on STN
AN 2003:260757 USPATFULL
TI Temperature-sensitive regulation of viral vector production
IN Samulski, Richard Jude, Chapel Hill, NC, United States
Gavin, Denise, Silver Spring, MD, United States
Muzyczka, Nicholas, Gainesville, FL, United States
Abernathy, Corinne, Gainesville, FL, United States
Pereira, Daniel, Alexandria, VA, United States
PA University of North Carolina at Chapel Hill, Chapel Hill, NC, United States (U.S. corporation)
PI US 6627617 B1 20030930
AI US 2000-676726 20000929 (9)
PRAI US 1999-157245P 19991001 (60)
US 1999-157248P 19991001 (60)
DT Utility
FS GRANTED
LN.CNT 2671
INCL INCLM: 514/044.000
INCLS: 424/233.100; 435/320.100; 435/235.100; 435/325.000
NCL NCLM: 514/044.000
NCLS: 424/233.100; 435/235.100; 435/320.100; 435/325.000
IC [7]
ICM: C12N015-63
ICS: C12N015-00; A61K039-23
EXF 424/233.1; 435/320.1; 435/235.1; 435/325; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 297 USPATFULL on STN
AN 2003:240307 USPATFULL
TI Cells immortalized with telomerase reverse transcriptase for use in drug screening
IN Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmond, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
University Technology Corporation, Boulder, CO, United States (U.S. corporation)
PI US 6617110 B1 20030909
AI US 2000-721456 20001124 (9)
RLI Continuation of Ser. No. US 1997-974549, filed on 19 Nov 1997, now patented, Pat. No. US 6166178 Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997, now patented, Pat. No. US 6475789 Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997, now patented, Pat. No. US 6261836 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 11102
INCL INCLM: 435/006.000

NCL NCLM: 435/006.000
NCLS: 435/029.000; 435/069.200; 435/194.000; 435/325.000; 536/023.200
IC [7]
ICM: C12G001-68
ICS: C12N009-12; C12N015-09; C12N005-00; C12Q001-02
EXF 435/194; 435/6; 435/325; 435/69.2; 435/29; 536/23.1; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 297 USPATFULL on STN
AN 2003:228405 USPATFULL
TI Promoter for telomerase reverse transcriptase
IN Morin, Gregg B., Davis, CA, United States
Andrews, William H., Richmond, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6610839 B1 20030826
WO 9814593 19980409
AI US 1999-402181 19990929 (9)
WO 1997-US17885 19971001
RLI Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997
Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997,
now abandoned Continuation-in-part of Ser. No. US 1997-915503, filed on
14 Aug 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 10430
INCL INCLM: 536/024.100
INCLS: 435/194.000; 435/320.100
NCL NCLM: 536/024.100
NCLS: 435/194.000; 435/320.100
IC [7]
ICM: C07H021-04
ICS: C12N009-12; C12N015-00
EXF 435/194; 435/320.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 297 USPATFULL on STN
AN 2003:222018 USPATFULL
TI Regulation of endogenous gene expression in cells using zinc finger
proteins
IN Cox, III, George N., Louisville, CO, United States
Case, Casey C., San Mateo, CA, United States
Eisenberg, Stephen P., Boulder, CO, United States
Jarvis, Eric E., Boulder, CO, United States
Spratt, Sharon K., Vacaville, CA, United States
PA Sangamo BioSciences, Inc., Richmond, CA, United States (U.S.
corporation)
PI US 6607882 B1 20030819
AI US 2000-478681 20000106 (9)
RLI Continuation-in-part of Ser. No. US 1999-229037, filed on 12 Jan 1999
DT Utility
FS GRANTED
LN.CNT 4053
INCL INCLM: 435/006.000
INCLS: 435/320.100; 435/455.000; 435/468.000; 536/023.100; 536/023.400;
536/024.100
NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/455.000; 435/468.000; 536/023.100; 536/023.400;
536/024.100
IC [7]
ICM: C12Q001-68
ICS: C12N005-10; C12N015-11; C12N015-63
EXF 435/6; 435/320.1; 435/455; 435/468; 530/350; 536/23.1; 536/24.1;
536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 182 OF 297 USPATFULL on STN
AN 2003:209962 USPATFULL
TI Expression of HIV polypeptides and production of virus-like particles
IN Barnett, Susan W., San Francisco, CA, United States
Megede, Jan zur, San Francisco, CA, United States
Greer, Catherine, Oakland, CA, United States
Selby, Mark, San Francisco, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 6602705 B1 20030805
AI US 1999-475515 19991230 (9)

US 1999-168471P 19991201 (60)
 DT Utility
 FS GRANTED
 LN.CNT 8403
 INCL INCLM: 435/320.100
 INCLS: 536/023.100; 536/023.720; 424/184.100; 424/185.100; 424/187.100;
 424/188.100; 424/207.100
 NCL NCLM: 435/320.100
 NCLS: 424/184.100; 424/185.100; 424/187.100; 424/188.100; 424/207.100;
 536/023.100; 536/023.720
 IC [7]
 ICM: C12N015-00
 ICS: C07H021-02; C07H021-04; A61K039-21
 EXF 435/320.1; 536/23.1; 536/23.72; 424/184.1; 424/185.1; 424/187.1;
 424/188.1; 424/207.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 297 USPATFULL on STN
 AN 2003:203218 USPATFULL
 TI Functional genomics using zinc finger proteins
 IN Case, Casey C., San Mateo, CA, United States
 Zhang, Lei, San Francisco, CA, United States
 PA Sangamo BioScience, Inc., Richmond, CA, United States (U.S. corporation)
 PI US 6599692 B1 20030729
 AI US 1999-395448 19990914 (9)
 DT Utility
 FS GRANTED
 LN.CNT 3576
 INCL INCLM: 435/004.000
 INCLS: 435/006.000; 536/023.100
 NCL NCLM: 435/004.000
 NCLS: 435/006.000; 536/023.100
 IC [7]
 ICM: C12Q001-02
 ICS: C12Q001-68; C12N015-12
 EXF 435/4; 435/6; 435/320.1; 435/69.1; 536/23.1; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 297 USPATFULL on STN
 AN 2003:74259 USPATFULL
 TI Regulation of endogenous gene expression in cells using zinc finger
 proteins
 IN Cox, III, George Norbert, Louisville, CO, United States
 Case, Casey Christopher, San Mateo, CA, United States
 Eisenberg, Stephen P., Boulder, CO, United States
 Jarvis, Eric Edward, Boulder, CO, United States
 Spratt, Sharon Kaye, Vacaville, CA, United States
 PA Sangamo BioSciences, Inc., Richmond, CA, United States (U.S.
 corporation)
 PI US 6534261 B1 20030318
 AI US 1999-229037 19990112 (9)
 DT Utility
 FS GRANTED
 LN.CNT 4099
 INCL INCLM: 435/006.000
 INCLS: 435/029.000; 536/023.500; 536/024.100
 NCL NCLM: 435/006.000
 NCLS: 435/029.000; 536/023.500; 536/024.100
 IC [7]
 ICM: C12Q001-68
 ICS: C12N015-12
 EXF 514/44; 514/725; 435/29; 435/6; 530/387.1; 536/23.1; 536/23.5; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 297 BIOENG COPYRIGHT on STN 2004 CSADUPLICATE 13
 AN 2004447100 BIOENG
 DN 5580167
 TI Intercellular trafficking and enhanced in vivo antitumour activity of a
 non-virally delivered P27- ***VP22*** fusion protein
 AU Zavaglia, D; Favrot, M-C; Eymin, B; Tenaud, C; Coll, J-L
 CS Groupe de Recherche sur le Cancer du Poumon, Equipe INSERM 9924, Institut
 Albert Bonniot, 38706 La Tronche cedex, France
 SO Gene Therapy [Gene Ther.]. Vol. 10, no. 4, pp. 314-325. Feb 2003.
 ISSN: 0969-7128
 DT Journal

SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L4 ANSWER 186 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
DUPLICATE 14
AN 2003-09920 BIOTECHDS
TI Gene therapy vector containing translocation sequence, useful e.g. for
expressing factor VIII, ensures intracellular transport of expression
product;
virus vector expression in host cell for use in somatic gene therapy

AU REISS J
PA REISS J
PI WO 2002102417 27 Dec 2002
AI WO 2002-EP6234 7 Jun 2002
PRAI DE 2001-1028832 15 Jun 2001; DE 2001-1028832 15 Jun 2001
DT Patent
LA German
OS WPI: 2003-167457 [16]

L4 ANSWER 187 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
DUPLICATE 15
AN 2002-14589 BIOTECHDS
TI Novel bacteriophage vector chimerized with polypeptides or proteins of
eukaryotic viruses, useful for gene transduction of eukaryotic cells, and
in gene therapy;
phage, phagemid or plasmid-mediated gene transfer and expression in
host cell for gene therapy

AU SAGGIO I; SALONE B; DI GIOVINE M; YURI M
PA CONSORZIO INTERUNIVERSITARIO NAZ FISICA
PI WO 2002024934 28 Mar 2002
AI WO 2000-IB1742 22 Sep 2000
PRAI IT 2000-2073 22 Sep 2000
DT Patent
LA English
OS WPI: 2002-404957 [43]

L4 ANSWER 188 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 16
AN 10212281 IFIPAT;IFIUDB;IFICDB
TI USES OF TRANSPORT PROTEINS; CONTROL OF THE CELL CYCLE TO REDUCE THE
PROLIFERATING ACTIVITY OF PROLIFERATING CELLS.
IN Brewis Neil Douglas (GB); Normand Nadia Michelle (GB); O'Hare Peter
Francis Joseph (GB); Phelan Anne (GB)
PA Unassigned Or Assigned To Individual (68000)
PPA Phogen Ltd GB (Probable)
PI US 2002155988 A1 20021024
AI US 2000-747772 20001220
PRAI GB 1999-305195 19991224
FI US 2002155988 20021024
US 6734167 20040511
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 16

L4 ANSWER 189 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 17
AN 10162732 IFIPAT;IFIUDB;IFICDB
TI MATERIALS AND METHODS FOR INTRACELLULAR TRANSPORT AND THEIR USES; FOR
INTRACELLULAR DELIVERY OF PROTEIN SEQUENCES, TO EXERT THE CORRESPONDING
EFFECTOR FUNCTION IN THE TARGET CELL
IN Elliott Gillian Daphne (GB); O'Hare Peter Francis Joseph (GB)
PA Unassigned Or Assigned To Individual (68000)
PI US 2002106378 A1 20020808
AI US 2001-800433 20010305
RLI US 1999-395344 19990913 CONTINUATION 6251398
PRAI GB 1997-13635 19970123
GB 1997-163984 19970801
FI US 2002106378 20020808
US 6251398
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 12
GI 6 Figure(s).
FIG. 1 illustrates that:
Mock-transfected cos-1 cells were labelled by indirect immunofluorescence

epitope (FIG. 1d) to establish the levels of background label Cells transfected with pc49epB (FIG. 1b) and labelled for P22 demonstrate a typical ***VP22*** cytoplasmic pattern with clear spread to the nuclei of adjacent cells. Cells transfected with the ***VP22*** -p53 fusion protein construct p4955ep+10 were labelled for ***VP22*** and p53 (FIGS. 1e and 1f) or ***VP22*** and epitope (FIGS. 1g and h): the fusion protein can be detected in the nuclei of cells adjacent to the primary expressing cell.

FIG. 2 is a plasmid map to illustrate p4953ep+10, encoding a fusion protein comprising sequences ***VP22***, p53 and an epitope tag. FIG. 3 illustrates that

Protein extracts from cos-1 cells transfected with a range of plasmid constructs were analysed by western blot The panel shown leftmost has been probed with an antibody against ***VP22*** and demonstrates that pUL49epB and pc49epB plasmids encoding ***VP22*** alone generate a protein of 38kDa, the ***VP22*** -p53 fusion protein expressed from p4953ep+10 produces a protein of approx. 50 kDa with very little degradation.

The panel shown rightmost has been probed with an antibody against p53 and demonstrates that cells transfected with plasmids encoding either p53 alone (pcB6+p53) or the p4953ep+10 fusion protein construct produce p53 protein at 53 kDa. The p4953ep+10 construct also synthesises the ***VP22*** -p53 fusion protein at 90 kDa, the p53 in this sample may be a degradation product or more likely endogenously induced p53.

L4 ANSWER 190 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 18
 AN 10133165 IFIPAT;IFIUDB;IFICDB
 TI TRANSIENTLY IMMORTALIZED CELLS FOR USE IN GENE THERAPY; INCREASING THE
 REPLICATIVE CAPACITY OF NORMALLY QUIESCENT CELLS, SUCH AS NORMAL SOMATIC
 CELLS, BY TRANSIENT IMMORTALIZATION OR TRANSIENT TELOMERIZATION, TO
 PRODUCE CELLS SUITABLE FOR GENE THERAPY
 IN Baetge Edward E (CH); Dupraz Philippe (CH); Thorens Bernard (CH); Wong
 Shou
 PA Unassigned Or Assigned To Individual (68000)
 PPA Modex Therapeutiques CH (Probable)
 PI US 2002076787 A1 20020620
 AI US 2001-823177 20010329
 RLI US 2000-546483 20000410 CONTINUATION-IN-PART PENDING
 PRAI US 1999-128893P 19990412 (Provisional)
 FI US 2002076787 20020620
 US 6451601 20020917
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 OS CA 137:43443
 CLMN 12
 GI 9 Figure(s).

FIG. 1 is a plasmid map of pVP22-hTERT-1091.

FIG. 2 is a depiction of a set of illustrations showing the detection of ***VP22*** -hTERT and ***VP22*** -cMyc chimera proteins by immunocytochemistry (ICC).

FIG. 3 is a Western blot analysis of ***VP22*** -based chimera proteins expressed in COS, wherein Panel A depicts the ***VP22*** -hTERT-(cMycHIS-TAG) fusion protein and Panel B depicts the ***VP22*** -cMyc-(HISTAG) fusion protein.

FIG. 4A is a graphic depiction of the population doubling curve for 1091-MDX01 cell lines, and

FIG. 4B is a graphic depiction of the population doubling curve for mMLV-hTERT immortalized MDX12 ("x" curve) cells compared to the parent primary MDX1 cells (diamond curve) as determined by repetitive serial passaging of the ***VP22*** -hTERT cell line.

FIG. 5 is an illustration of a set of gels showing the telomerase catalytic activities of ***VP22*** -hTERT chimera proteins as demonstrated by TRAP, in COS cells transiently transfected with

VP22, ***VP22*** -hTERT, and ***VP22*** -hTERT-(cMyc-HIS-TAG) fusion constructs (FIG. 5A) or in stable polyclonal p1091/MDX1 cells, with MDX1 as a negative control, and MDX12 as a positive control (FIG. 5B).

FIG. 6 is a set of illustrations showing the detection of the presence of telomerase in p1091/MDX1 by immunocytochemistry ("ICC").

FIG. 7 is a set of illustrations showing endogenous hTERT and ***VP22*** -hTERT mRNA expression as measured by RT-PCR in MDX12 and 1091-MDX01 immortalized cell lines.

FIG. 8 is a set of illustrations showing endogenous hTERT and ***VP22*** -hTERT mRNA expression as measured by RT-PCR in MDX12 and 1091-MDX01

L4 ANSWER 191 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 19
 AN 10093714 IFIPAT;IFIUDB;IFICDB
 TI RECOMBINANT, MODIFIED ADENOVIRAL VECTORS FOR TUMOR SPECIFIC GENE
 EXPRESSION AND USES THEREOF; USEFUL FOR REGULATING TRANSGENE EXPRESSION
 IN CELLS SUCH AS TUMOR CELLS AND THEREFORE, FOR THERAPY OF A VARIETY OF
 CANCERS
 IN Carlson Cheryl A; Lieber Andre; Mi Jie; Steinwaerder Dirk S (DE)
 PA Unassigned Or Assigned To Individual (68000)
 PPA Washington, University of (Probable)
 PI US 2002037280 A1 20020328
 AI US 2001-849106 20010503
 PRAI US 2000-202367P 20000503 (Provisional)
 FI US 2002037280 20020328
 US 6686196 20040203
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 91
 GI 20 Figure(s).
 FIGS. 1A, 1B: Hypothetical mechanisms for the formation of a Delta Ad.IR
 genome, replication activated expression system.
 FIGS. 2I, 2II, 2III: The structure of Ad vectors and a scheme of
 replication activated transgene expression.
 FIGS. 3A, 3B: Activation of transgene expression in vitro upon Ad vector
 replication.
 FIG. 4: Comparison of the replication and transgene expression kinetics of
 Ad.IR-BG and Ad.BG
 FIGS. 5A, 5B, 5C: Expression of HPV E6 and E7 efficiently supports
 AdE1-DNA replication in vitro and in vivo.
 FIG. 6: A proposed mechanism of replication activated Ad vectors for
 tumor-specific gene expression which is dependent on recombination
 between two vectors, each vector containing one homology element.
 FIGS. 7A, 7B: Activation of transgene expression upon coinfection of two
 Ad vectors each carrying one half of the transgene.
 FIG. 8: Tumor specific beta-Gal expression from Ad.IR-BG in hepatic
 metastases derived from HeLa cells.
 FIG. 9: Productive AdE1-replication in hepatic metastases in vivo.
 FIG. 10: Replication dependent and tumor specific transgene expression in
 LOVO cells after infection with Ad.IR-BG.
 FIGS. 11A, 11B: Generation of Rep78 expressing Ad vectors by recombination
 between two vectors.
 FIG. 12: A fluorescent caspase 3 activity assay.
 FIG. 13: TNF-induced apoptosis.
 FIGS. 14A, 14B. TNF-induced apoptosis on ikBM-expressing HeLa cells
 facilitates the adenoviral vector release.
 FIG. 15: Induced apoptosis facilitates recombinant Ad vector spreading in
 mouse model of hepatic metastasis.
 FIGS. 16A, 16B: Analysis of AdE1-DNA replication in tumor cell lines by
 Southern blot.
 FIG. 17: A table of viral DNA replication ratios in correlation with
 development of CPE and p53, pRb, and p16 status of tumor cells.
 FIG. 18: AdE1-DNA replication in synchronized HeLa cells infected during
 different cell cycle phases.
 FIGS. 19A, 19B: AdE1-DNA replication within cells arrested in G2/M by
 nocodazole.
 FIGS. 20A, 20B, 20C, 20D: Replication of AdE1-in cervical carcinoma cells.

L4 ANSWER 192 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 20
 AN 03650805 IFIPAT;IFIUDB;IFICDB
 TI TRANSIENTLY IMMORTALIZED CELLS; FUSION POLYPEPTIDE; FOR USE IN GENE
 THERAPY
 IN Baetge Edward E (CH); Dupraz Philippe (CH); Thorens Bernard (CH); Wong
 Shou (CH)
 PA Modex Therapeutiques CH (50719)
 PI US 6358739 B1 20020319
 AI US 2000-546483 20000410
 PRAI US 1999-128893P 19990412 (Provisional)
 FI US 6358739 20020319
 DT Utility; CERTIFICATE OF CORRECTION
 CDAT 2 Jul 2002
 FS CHEMICAL
 GRANTED
 MRN 010941 MFN: 0351
 CLMN 12

L4 ANSWER 193 OF 297 USPATFULL on STN DUPLICATE 21
 AN 2002:301140 USPATFULL
 TI Human pellino polypeptides
 IN Bird, Timothy A., Bainbridge Island, WA, UNITED STATES
 Cosman, David J., Bainbridge Island, WA, UNITED STATES
 PI US 2002168683 A1 20021114
 US 6703487 B2 20040309
 AI US 2001-843905 A1 20010427 (9)
 PRAI US 2000-200198P 20000428 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3519
 INCL INCLM: 435/007.100
 INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
 NCL NCLM: 530/350.000
 NCLS: 435/069.100; 435/252.300; 435/254.110; 435/254.200; 435/325.000;
 530/324.000; 530/351.000; 536/023.500
 IC [7]
 ICM: G01N033-53
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 297 USPATFULL on STN DUPLICATE 22
 AN 2002:235370 USPATFULL
 TI Pharmacogenomics and identification of drug targets by reconstruction of
 signal transduction pathways based on sequences of accessible regions
 IN Wolfe, Alan, Orinda, CA, UNITED STATES
 Urnov, Fyodor, Richmond, CA, UNITED STATES
 Guschin, Dmitry, Richmond, CA, UNITED STATES
 Collingwood, Trevor, San Pablo, CA, UNITED STATES
 Li, Xiao-Yong, Richmond, CA, UNITED STATES
 Johnstone, Brian, Benicia, CA, UNITED STATES
 PI US 2002127559 A1 20020912
 US 6610489 B2 20030826
 AI US 2001-844265 A1 20010427 (9)
 PRAI US 2000-200590P 20000428 (60)
 US 2000-214674P 20000627 (60)
 US 2000-228608P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5023
 INCL INCLM: 435/006.000
 INCLS: 435/091.200
 NCL NCLM: 435/006.000
 NCLS: 435/007.100
 IC [7]
 ICM: C12Q001-68
 ICS: C12P019-34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 297 USPATFULL on STN DUPLICATE 23
 AN 2002:206176 USPATFULL
 TI Polynucleotide encoding chimeric protein and related vector, cell and
 method of expression thereof
 IN Kovesdi, Imre, Rockville, MD, UNITED STATES
 Bruder, Joseph T., Ijamsville, MD, UNITED STATES
 PI US 2002110869 A1 20020815
 US 6472176 B2 20021029
 AI US 2000-736743 A1 20001214 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 944
 INCL INCLM: 435/069.700
 INCLS: 435/325.000; 435/320.100; 536/023.100
 NCL NCLM: 435/069.100
 NCLS: 435/069.700; 435/069.800; 435/320.100; 435/325.000; 435/455.000;
 536/023.100; 536/023.200; 536/023.400; 536/023.500; 536/023.700;
 536/024.100
 IC [7]
 ICM: C12P021-04
 ICS: C07H021-04; C12N005-06; C12N015-74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 297 USPATFULL on STN DUPLICATE 24

TI Gene identification
IN Case, Casey C., San Mateo, CA, UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
PI US 2002094529 A1 20020718
US 6780590 B2 20040824
AI US 2001-941450 A1 20010828 (9)
RLI Continuation-in-part of Ser. No. US 1999-395448, filed on 14 Sep 1999,
PENDING
DT Utility
FS APPLICATION
LN.CNT 3838
INCL INCLM: 435/006.000
INCLS: 435/004.000; 435/455.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 197 OF 297 USPATFULL on STN DUPLICATE 25
AN 2002:157015 USPATFULL
TI Functional genomics using zinc finger proteins
IN Case, Casey C., San Mateo, CA, UNITED STATES
Zhang, Lei, San Francisco, CA, UNITED STATES
PA Sangamo BioSciences, Inc. (U.S. corporation)
PI US 2002081614 A1 20020627
US 6777185 B2 20040817
AI US 2001-925796 A1 20010809 (9)
RLI Continuation of Ser. No. US 1999-395448, filed on 14 Sep 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 3297
INCL INCLM: 435/006.000
INCLS: 435/007.210; 702/019.000
NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/069.100; 536/023.100; 536/023.400
IC [7]
ICM: C12Q001-68
ICS: G01N033-567; G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 297 USPATFULL on STN DUPLICATE 26
AN 2002:148570 USPATFULL
TI Methods for designing exogenous regulatory molecules
IN Wolffe, Alan, Orinda, CA, UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
Guschin, Dmitry, Richmond, CA, UNITED STATES
Collingwood, Trevor, San Pablo, CA, UNITED STATES
Li, Xiao-Yong, Richmond, CA, UNITED STATES
Johnstone, Brian, Benicia, CA, UNITED STATES
PI US 2002076711 A1 20020620
US 6511808 B2 20030128
AI US 2001-844493 A1 20010427 (9)
PRAI US 2000-200590P 20000428 (60)
DT Utility
FS APPLICATION
LN.CNT 5246
INCL INCLM: 435/006.000
INCLS: 435/091.200; 702/020.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 297 USPATFULL on STN DUPLICATE 27
AN 2002:141137 USPATFULL
TI Herpes simplex virus for treating unwanted hyperproliferative cell
growth
IN Laquerre, Sylvie, Walnut Creek, CA, UNITED STATES
Hermiston, Terry, Corte Madera, CA, UNITED STATES
PI US 2002072119 A1 20020613
US 6660259 B2 20031209
AI US 2000-733807 A1 20001208 (9)
PRAI US 1999-169829P 19991208 (60)

FS APPLICATION
LN.CNT 632
INCL INCLM: 435/456.000
INCLS: 424/093.600; 435/235.100
NCL NCLM: 424/093.200
NCLS: 435/069.100; 435/091.410; 435/320.100; 435/325.000
IC [7]
ICM: A61K048-00
ICS: C12N015-869; C12N007-00

L4 ANSWER 200 OF 297 USPATFULL on STN DUPLICATE 28
AN 2002:133848 USPATFULL
TI INHIBITORS OF CELL-CYCLE PROGRESSION AND USES RELATED THERETO
IN GYURIS, JENO, WINCHESTER, MA, UNITED STATES
LAMPHERE, LOU, BOSTON, MA, UNITED STATES
BEACH, DAVID H., HUNTINGTON BAY, NY, UNITED STATES
PI US 2002068706 A1 20020606
US 6495526 B2 20021217
AI US 1997-902572 A1 19970729 (8)
RLI Continuation-in-part of Ser. No. US 1996-589981, filed on 23 Jan 1996,
GRANTED, Pat. No. US 5672508
DT Utility
FS APPLICATION
LN.CNT 3464
INCL INCLM: 514/044.000
INCLS: 435/455.000; 536/023.400; 536/023.720; 536/024.100
NCL NCLM: 514/044.000
NCLS: 536/023.400; 536/023.720; 536/024.100
IC [7]
ICM: A61K031-70
ICS: C12N015-63; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 201 OF 297 USPATFULL on STN DUPLICATE 29
AN 2002:133421 USPATFULL
TI Methods using genetic package display for detecting and identifying
protein-protein interactions that facilitate internalization and
transgene expression and cells or tissues competent for the same and
methods for evolving gene delivery vectors
IN Larocca, David, Encinitas, CA, UNITED STATES
Kassner, Paul, San Mateo, CA, UNITED STATES
Baird, Andrew, San Diego, CA, UNITED STATES
PI US 2002068272 A1 20020606
US 6723512 B2 20040420
AI US 2001-866073 A1 20010524 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US9925361, filed on 25 May
2000, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 2965
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100
NCL NCLM: 435/006.000
NCLS: 435/005.000; 435/069.100; 435/320.100; 435/DIG.002; 435/DIG.004;
435/DIG.014; 435/DIG.015; 435/DIG.035; 536/023.100
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 297 USPATFULL on STN DUPLICATE 30
AN 2002:92046 USPATFULL
TI Methods and compositions for tissue regeneration
IN Baetge, E. Edward, St Sulpice, SWITZERLAND
Hunziker, Thomas, Oberhofen, SWITZERLAND
Ronfard, Vincent, Lausanne, SWITZERLAND
PI US 2002048563 A1 20020425
US 6673603 B2 20040106
AI US 2001-943114 A1 20010830 (9)
PRAI US 2000-230286P 20000901 (60)
US 2001-299003P 20010618 (60)
DT Utility
FS APPLICATION
LN.CNT 1222
INCL INCLM: 424/093.700

NCL NCLM: 435/325.000
NCLS: 435/366.000; 435/371.000
IC [7]
ICM: A61K045-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 297 USPATFULL on STN DUPLICATE 31
AN 2002:85118 USPATFULL
TI Cells for drug discovery
IN Case, Casey, San Mateo, CA, UNITED STATES
PI US 2002045158 A1 20020418
US 6689558 B2 20040210
AI US 2001-779233 A1 20010208 (9)
PRAI US 2000-181117P 20000208 (60)
DT Utility
FS APPLICATION
LN.CNT 3557
INCL INCLM: 435/004.000
INCLS: 435/325.000
NCL NCLM: 435/004.000
NCLS: 435/006.000; 435/007.210; 435/007.400; 435/029.000
IC [7]
ICM: C12Q001-00
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 204 OF 297 USPATFULL on STN DUPLICATE 32
AN 2002:72628 USPATFULL
TI Transport proteins and their uses
IN O'Hare, Peter Francis Joseph, Surrey, UNITED KINGDOM
Elliott, Gillian Daphne, Surrey, UNITED KINGDOM
PI US 2002039765 A1 20020404
US 6521455 B2 20030218
AI US 2001-773430 A1 20010131 (9)
RLI Division of Ser. No. US 1998-11073, filed on 26 Jan 1998, PATENTED
PRAI GB 1995-15568 19950728
GB 1996-1570 19960126
DT Utility
FS APPLICATION
LN.CNT 920
INCL INCLM: 435/069.700
INCLS: 435/320.100; 530/350.000; 536/023.500; 435/069.100; 435/325.000;
435/471.000; 435/472.000
NCL NCLM: 435/455.000
NCLS: 435/243.000; 435/320.100; 435/325.000; 435/410.000; 435/458.000;
435/468.000; 435/471.000; 536/023.400
IC [7]
ICM: C07K017-00
ICS: C07K014-00; C07K001-00; C12N005-02; C12N005-00; C12N015-74;
C12N015-70; C12N015-63; C12N015-09; C12N015-00; C12P021-04; C12P021-06;
C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 297 IFIPAT COPYRIGHT 2004 IFI on STN
AN 03752870 IFIPAT;IFIUDB;IFICDB
TI TRANSIENTLY IMMORTALIZED CELLS FOR USE IN GENE THERAPY; INCREASING THE
REPLICATIVE CAPACITY OF NORMALLY QUIESCENT CELLS, SUCH AS NORMAL SOMATIC
CELLS, BY TRANSIENT IMMORTALIZATION OR TRANSIENT TELOMERIZATION, TO
PRODUCE CELLS SUITABLE FOR GENE THERAPY
IN Baetge Edward E (CH); Dupraz Philippe (CH); Thorens Bernard (CH); Wong
Shou
PA Modex Therapeutiques CH (50719)
PI US 6451601 B2 20020917
AI US 2001-823177 20010329
RLI US 2000-546483 20000410 CONTINUATION-IN-PART PENDING
PRAI US 1999-128893P 19990412 (Provisional)
FI US 6451601 20020917
US 2002076787 20020620
DT Utility
FS CHEMICAL
GRANTED
MRN 012069 MFN: 0258
CLMN 12
GI 8 Drawing Sheet(s), 15 Figure(s).

L4 ANSWER 206 OF 297 USPATFULL on STN
 AN 2002:343965 USPATFULL
 TI FLT4-interacting proteins and use thereof
 IN Sugiyama, Janice, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
 PI US 2002197691 A1 20021226
 AI US 2002-135802 A1 20020429 (10)
 PRAI US 2001-287513P 20010430 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4778
 INCL INCLM: 435/183.000
 INCLS: 435/320.100; 435/325.000; 435/007.230
 NCL NCLM: 435/183.000
 NCLS: 435/320.100; 435/325.000; 435/007.230
 IC [7]
 ICM: G01N033-574
 ICS: C12N009-00; C12N005-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 297 USPATFULL on STN
 AN 2002:329464 USPATFULL
 TI Methods and compositions for reducing immune response
 IN LaFace, Drake M., San Diego, CA, UNITED STATES
 Rahman, Amena, San Diego, CA, UNITED STATES
 Shabram, Paul W., Olivenhain, CA, UNITED STATES
 Tsai, Van T., San Diego, CA, UNITED STATES
 PI US 2002187143 A1 20021212
 AI US 2002-222722 A1 20020816 (10)
 RLI Division of Ser. No. US 2000-653474, filed on 31 Aug 2000, GRANTED, Pat. No. US 6464976
 PRAI US 1999-152650P 19990907 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1482
 INCL INCLM: 424/140.100
 INCLS: 435/320.100; 536/023.720
 NCL NCLM: 424/140.100
 NCLS: 435/320.100; 536/023.720
 IC [7]
 ICM: A61K039-395
 ICS: A61K039-00; C07H021-04; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 297 USPATFULL on STN
 AN 2002:315203 USPATFULL
 TI BCL-XL-interacting protein and use thereof
 IN Bartel, Paul, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
 PI US 2002177692 A1 20021128
 AI US 2002-122573 A1 20020415 (10)
 PRAI US 2001-284095P 20010416 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4757
 INCL INCLM: 530/350.000
 INCLS: 435/069.700; 435/325.000; 435/184.000; 435/320.100; 435/287.200
 NCL NCLM: 530/350.000
 NCLS: 435/069.700; 435/325.000; 435/184.000; 435/320.100; 435/287.200
 IC [7]
 ICM: G01N033-574
 ICS: C12P021-04; C12N009-99; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 297 USPATFULL on STN
 AN 2002:314730 USPATFULL
 TI Tsg101-interacting proteins and use thereof
 IN Sugiyama, Janice, Salt Lake City, UT, UNITED STATES
 Cimborra, Daniel, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
 PI US 2002177207 A1 20021128

PRAI US 2001-276259P 20010314 (60)
US 2001-304101P 20010710 (60)
DT Utility
FS APPLICATION
LN.CNT 7034
INCL INCLM: 435/196.000
INCLS: 435/226.000; 435/199.000
NCL NCLM: 435/196.000
NCLS: 435/226.000; 435/199.000
IC [7]
ICM: C12N009-16
ICS: C12N009-22; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 297 USPATFULL on STN
AN 2002:314700 USPATFULL
TI Interaction between ***cyclin*** D1 and steroid receptor
co-activators and uses thereof in assays
IN Bernards, Rene, Alconde, NETHERLANDS
Zwijzen, Renate, Utrecht, NETHERLANDS
PA Prolifix Limited, Abingdon, UNITED KINGDOM (non-U.S. corporation)
PI US 2002177177 A1 20021128
AI US 2001-953031 A1 20010914 (9)
RLI Continuation of Ser. No. US 1999-302305, filed on 30 Apr 1999, PATENTED
Continuation of Ser. No. WO 1999-GB440, filed on 12 Feb 1999, UNKNOWN
PRAI GB 1998-3035 19980212
GB 1998-18243 19980820
DT Utility
FS APPLICATION
LN.CNT 1505
INCL INCLM: 435/007.230
INCLS: 530/326.000; 530/327.000; 530/328.000; 514/014.000; 514/015.000;
514/016.000
NCL NCLM: 435/007.230
NCLS: 530/326.000; 530/327.000; 530/328.000; 514/014.000; 514/015.000;
514/016.000
IC [7]
ICM: G01N033-574
ICS: A61K038-10; A61K038-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 297 USPATFULL on STN
AN 2002:314675 USPATFULL
TI COX 1-interacting proteins and use thereof
IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2002177152 A1 20021128
AI US 2002-100503 A1 20020318 (10)
PRAI US 2001-277013P 20010319 (60)
DT Utility
FS APPLICATION
LN.CNT 4721
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000
IC [7]
ICM: C12Q001-68
ICS: C12N009-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 297 USPATFULL on STN
AN 2002:307902 USPATFULL
TI Survivin-interacting proteins and use thereof
IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES
Cimbora, Daniel, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)
PI US 2002173026 A1 20021121
AI US 2002-99924 A1 20020314 (10)
PRAI US 2001-276179P 20010315 (60)
US 2001-307233P 20010723 (60)
DT Utility
FS APPLICATION
LN.CNT 5137
INCL INCLM: 435/199.000

NCL NCLM: 435/199.000
NCLS: 435/226.000; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C12N009-22
ICS: C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 213 OF 297 USPATFULL on STN
AN 2002:301734 USPATFULL
TI Clasp-7 transmembrane protein
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Garman, Jonathan David, San Jose, CA, UNITED STATES
Candia, Albert F., III, Menlo Park, CA, UNITED STATES
PI US 2002169283 A1 20021114
AI US 2000-736968 A1 20001213 (9)
PRAI US 2000-240508P 20001013 (60)
US 2000-240503P 20001013 (60)
US 2000-240539P 20001013 (60)
US 2000-240543P 20001013 (60)
US 2000-196267P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196460P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)

DT Utility
FS APPLICATION

LN.CNT 4837

INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/325.000; 435/320.100
IC [7]

ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 214 OF 297 USPATFULL on STN
AN 2002:295302 USPATFULL
TI Protein-protein interactions
IN Cimbora, Daniel M., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT (U.S. corporation)
PI US 2002165352 A1 20021107
AI US 2001-24599 A1 20011221 (10)
PRAI US 2000-256986P 20001221 (60)

DT Utility
FS APPLICATION

LN.CNT 1980

INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]

ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 215 OF 297 USPATFULL on STN
AN 2002:294623 USPATFULL
TI Protein-protein interactions
IN Cimbora, Daniel M., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRAID GENETICS, INC., Salt Lake City, UT (2)
PI US 2002164666 A1 20021107
AI US 2001-23446 A1 20011220 (10)
PRAI US 2000-256985P 20001221 (60)

DT Utility
FS APPLICATION

LN.CNT 2029

INCL INCLM: 435/007.230
INCLS: 435/183.000; 530/388.100; 530/350.000

NCLS: 435/183.000; 530/388.100; 530/350.000

IC [7]

ICM: G01N033-574

ICS: C12N009-00; C07K016-30; C07K014-72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 216 OF 297 USPATFULL on STN

AN 2002:294532 USPATFULL

TI Gene identification

IN Case, Casey C., San Mateo, CA, UNITED STATES

Urnov, Fyodor, Richmond, CA, UNITED STATES

PA Sangamo BioSciences, Inc., a Delaware Corporation, Richmond, CA (U.S. corporation)

PI US 2002164575 A1 20021107

AI US 2001-942090 A1 20010828 (9)

RLI Continuation-in-part of Ser. No. US 1999-395448, filed on 14 Sep 1999, PENDING

DT Utility

FS APPLICATION

LN.CNT 3687

INCL INCLM: 435/004.000

INCLS: 435/006.000

NCL NCLM: 435/004.000

NCLS: 435/006.000

IC [7]

ICM: C12Q001-00

ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 217 OF 297 USPATFULL on STN

AN 2002:288071 USPATFULL

TI Modulation of endogenous gene expression in cells

IN Case, Casey C., San Mateo, CA, UNITED STATES

Wolffe, Alan, UNITED STATES

Urnov, Fyodor, Richmond, CA, UNITED STATES

Lai, Albert, Richmond, CA, UNITED STATES

Snowden, Andrew, Richmond, CA, UNITED STATES

Tan, Siyuan, Alameda, CA, UNITED STATES

Gregory, Philip, El Cerrito, CA, UNITED STATES

PI US 2002160940 A1 20021031

AI US 2001-942087 A1 20010828 (9)

RLI Continuation-in-part of Ser. No. US 1999-229037, filed on 12 Jan 1999, PENDING

DT Utility

FS APPLICATION

LN.CNT 3966

INCL INCLM: 514/006.000

INCLS: 435/455.000

NCL NCLM: 514/006.000

NCLS: 435/455.000

IC [7]

ICM: A61K038-48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 218 OF 297 USPATFULL on STN

AN 2002:279998 USPATFULL

TI Genetically engineered herpes virus for the treatment of cardiovascular disease

IN Schwartz, Lewis B., Hinsdale, IL, UNITED STATES

Weichselbaum, Ralph R., Chicago, IL, UNITED STATES

Roizman, Bernard, Chicago, IL, UNITED STATES

PI US 2002155432 A1 20021024

AI US 2001-995475 A1 20011128 (9)

PRAI US 2000-253680P 20001128 (60)

DT Utility

FS APPLICATION

LN.CNT 4203

INCL INCLM: 435/005.000

INCLS: 435/320.100; 435/069.100; 424/199.100; 424/229.100; 424/205.100

NCL NCLM: 435/005.000

NCLS: 435/320.100; 435/069.100; 424/199.100; 424/229.100; 424/205.100

IC [7]

ICM: C12Q001-70

ICS: C12P021-06; A61K039-12; A61K039-245; A61K039-255; A61K039-265;

A61K039-27; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74

L4 ANSWER 219 OF 297 USPATFULL on STN
AN 2002:273329 USPATFULL
TI FRA -1 expression in brain cancer
IN Debinski, Waldemar, Hershey, PA, UNITED STATES
Gibo, Denise M., Hershey, PA, UNITED STATES
PI US 2002151457 A1 20021017
AI US 2002-75499 A1 20020212 (10)
PRAI US 2001-268089P 20010212 (60)
DT Utility
FS APPLICATION
LN.CNT 1865
INCL INCLM: 514/001.000
INCLS: 435/006.000
NCL NCLM: 514/001.000
NCLS: 435/006.000
IC [7]
ICM: A61K031-00
ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 297 USPATFULL on STN
AN 2002:272883 USPATFULL
TI Delivery vehicles and methods for using the same
IN Craig, Roger, Sandbach, UNITED KINGDOM
PI US 2002151004 A1 20021017
AI US 2001-785802 A1 20010216 (9)
RLI Continuation-in-part of Ser. No. US 2000-748789, filed on 22 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 2000-748063, filed on 22 Dec
2000, PENDING
PRAI GB 2000-3056 20000809
GB 2000-2848 20000724
DT Utility
FS APPLICATION
LN.CNT 2825
INCL INCLM: 435/173.100
INCLS: 424/093.700
NCL NCLM: 435/173.100
NCLS: 424/093.700
IC [7]
ICM: C12N013-00
ICS: C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 297 USPATFULL on STN
AN 2002:272442 USPATFULL
TI Selectively replicating viral vectors
IN Ramachandra, Muralidhara, San Diego, CA, UNITED STATES
Shabram, Paul W., Olivenhain, CA, UNITED STATES
PI US 2002150557 A1 20021017
AI US 2002-62216 A1 20020130 (10)
RLI Continuation-in-part of Ser. No. US 1999-416812, filed on 13 Oct 1999,
PENDING
PRAI US 1998-104399P 19981015 (60)
DT Utility
FS APPLICATION
LN.CNT 2723
INCL INCLM: 424/093.200
INCLS: 424/456.000; 435/320.100
NCL NCLM: 424/093.200
NCLS: 424/456.000; 435/320.100
IC [7]
ICM: A61K048-00
ICS: C12N015-861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 297 USPATFULL on STN
AN 2002:266423 USPATFULL
TI Peptides that modulate the interaction of B class ephrins and PDZ
domains
IN Lin, Danny, Scarborough, CANADA
Pawson, Anthony, Toronto, CANADA
Gish, Gerald, East York, CANADA
PI US 2002147306 A1 20021010
AI US 2001-862179 A1 20010521 (9)

US 1998-109158P 19981120 (60)
DT Utility
FS APPLICATION
LN.CNT 2332
INCL INCLM: 530/350.000
INCLS: 530/324.000
NCL NCLM: 530/350.000
NCLS: 530/324.000
IC [7]
ICM: C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 297 USPATFULL on STN
AN 2002:213835 USPATFULL
TI Targeted modification of chromatin structure
IN Wolffe, Alan P., Orinda, CA, UNITED STATES
Collingwood, Trevor, San Pablo, CA, UNITED STATES
PI US 2002115215 A1 20020822
AI US 2001-844508 A1 20010427 (9)
PRAI US 2000-200590P 20000428 (60)
US 2000-228523P 20000828 (60)
DT Utility
FS APPLICATION
LN.CNT 3444
INCL INCLM: 435/455.000
INCLS: 435/468.000; 435/006.000
NCL NCLM: 435/455.000
NCLS: 435/468.000; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 297 USPATFULL on STN
AN 2002:206204 USPATFULL
TI Gene repair involving in vivo excision of targeting DNA
IN Chouluka, Andre, Paris, FRANCE
Mulligan, Richard C., Lincoln, MA, UNITED STATES
PA The Children's Medical Center Corporation, Boston, MA (non-U.S.
corporation)
PI US 2002110898 A1 20020815
AI US 2001-922495 A1 20010803 (9)
RLI Continuation of Ser. No. WO 2000-US2949, filed on 3 Feb 2000, UNKNOWN
PRAI US 1999-118472P 19990203 (60)
DT Utility
FS APPLICATION
LN.CNT 1230
INCL INCLM: 435/252.300
NCL NCLM: 435/252.300
IC [7]
ICM: C12N001-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 225 OF 297 USPATFULL on STN
AN 2002:199105 USPATFULL
TI Gene repair involving the induction of double-stranded DNA cleavage at a
chromosomal target site
IN Chouluka, Andre, Paris, FRANCE
Mulligan, Richard C., Lincoln, MA, UNITED STATES
PA The Children's Medical Center, Boston, MA, UNITED STATES (non-U.S.
corporation)
PI US 2002107214 A1 20020808
AI US 2001-917295 A1 20010727 (9)
RLI Continuation of Ser. No. WO 2000-US3014, filed on 3 Feb 2000, UNKNOWN
PRAI US 1999-118669P 19990203 (60)
DT Utility
FS APPLICATION
LN.CNT 1128
INCL INCLM: 514/044.000
INCLS: 435/455.000
NCL NCLM: 514/044.000
NCLS: 435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87

L4 ANSWER 226 OF 297 USPATFULL on STN
 AN 2002:191204 USPATFULL
 TI CLASP-5 transmembrane protein
 IN Lu, Peter S., Mountain View, CA, UNITED STATES
 Garman, Jonathan D., San Jose, CA, UNITED STATES
 Candia, Albert F., III, Menlo Park, CA, UNITED STATES
 PI US 2002102267 A1 20020801
 AI US 2000-736960 A1 20001213 (9)
 PRAI US 2000-240508P 20001013 (60)
 US 2000-240503P 20001013 (60)
 US 2000-240539P 20001013 (60)
 US 2000-240543P 20001013 (60)
 US 2000-196267P 20000411 (60)
 US 2000-196527P 20000411 (60)
 US 2000-196528P 20000411 (60)
 US 2000-196460P 20000411 (60)
 US 2000-182296P 20000214 (60)
 US 2000-176195P 20000114 (60)
 US 1999-170453P 19991213 (60)
 US 1999-162498P 19991029 (60)
 US 1999-160860P 19991021 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4844
 INCL INCLM: 424/185.100
 INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
 NCL NCLM: 424/185.100
 NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
 IC [7]
 ICM: A61K039-00
 ICS: C07H021-04; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 297 USPATFULL on STN
 AN 2002:179178 USPATFULL
 TI Nuclear reprogramming using IWSI and related chromatin remodeling
 ATPases
 IN Wolffe, Alan P., UNITED STATES
 Wolffe, Elizabeth, UNITED STATES LR
 PI US 2002094968 A1 20020718
 AI US 2001-967868 A1 20010928 (9)
 PRAI US 2000-236409P 20000928 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1827
 INCL INCLM: 514/044.000
 INCLS: 435/455.000
 NCL NCLM: 514/044.000
 NCLS: 435/455.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-87
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 297 USPATFULL on STN
 AN 2002:178541 USPATFULL
 TI Targeting pluripotent stem cells to tissues
 IN Petersen, Bryon E., Gainesville, FL, UNITED STATES
 PI US 2002094327 A1 20020718
 AI US 2001-13015 A1 20011105 (10)
 PRAI US 2000-246028P 20001105 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1663
 INCL INCLM: 424/093.210
 INCLS: 435/370.000; 514/012.000
 NCL NCLM: 424/093.210
 NCLS: 435/370.000; 514/012.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 297 USPATFULL on STN

TI Dendritic cell co-stimulatory molecules
IN Pardoll, Drew M., Brookville, MD, UNITED STATES
Tsuchiya, Haruo, Baltimore, MD, UNITED STATES
Gorski, Kevin S., Baltimore, MD, UNITED STATES
Tseng, Su-Yi, Baltimore, MD, UNITED STATES
PI US 2002091246 A1 20020711
AI US 2001-794210 A1 20010228 (9)
PRAI US 2000-200580P 20000428 (60)
US 2000-240169P 20001013 (60)
DT Utility
FS APPLICATION
LN.CNT 3534
INCL INCLM: 536/023.200
INCLS: 435/320.100; 435/372.000; 435/069.300; 435/069.700
NCL NCLM: 536/023.200
NCLS: 435/320.100; 435/372.000; 435/069.300; 435/069.700
IC [7]
ICM: C07H021-04
ICS: C12P021-04; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 297 USPATFULL on STN
AN 2002:164764 USPATFULL
TI Clasp-3 transmembrane protein
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Garman, Jonathan D., San Jose, CA, UNITED STATES
Candia, Albert F., III, Menlo Park, CA, UNITED STATES
PI US 2002086382 A1 20020704
AI US 2000-737246 A1 20001213 (9)
PRAI US 2000-240508P 20001013 (60)
US 2000-240503P 20001013 (60)
US 2000-240539P 20001013 (60)
US 2000-240543P 20001013 (60)
US 2000-196267P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196460P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
DT Utility
FS APPLICATION
LN.CNT 5126
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12P021-02
ICS: C12N009-00; C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 297 USPATFULL on STN
AN 2002:157136 USPATFULL
TI Nucleic acid delivery
IN Conroy, Susan E., London, UNITED KINGDOM
Engler, Heidrun, San Diego, CA, UNITED STATES
Maneval, Daniel C., San Diego, CA, UNITED STATES
PI US 2002081736 A1 20020627
AI US 2001-3494 A1 20011101 (10)
PRAI US 2000-245539P 20001103 (60)
US 2001-287871P 20010430 (60)
DT Utility
FS APPLICATION
LN.CNT 1225
INCL INCLM: 435/455.000
INCLS: 514/044.000; 514/053.000; 514/058.000
NCL NCLM: 435/455.000
NCLS: 514/044.000; 514/053.000; 514/058.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87; A61K031-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 297 USPATFULL on STN
AN 2002:157004 USPATFULL
TI Databases of regulatory sequences; methods of making and using same
IN Wolffe, Alan, Orinda, CA, UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
Guschin, Dmitry, Richmond, CA, UNITED STATES
Collingwood, Trevor, San Pablo, CA, UNITED STATES
Li, Xiao-Yong, Richmond, CA, UNITED STATES
Johnstone, Brian, Benicia, CA, UNITED STATES
PI US 2002081603 A1 20020627
AI US 2001-844501 A1 20010427 (9)
PRAI US 2000-200590P 20000428 (60)
US 2000-214674P 20000627 (60)
US 2000-228556P 20000828 (60)
DT Utility
FS APPLICATION
LN.CNT 5742
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 297 USPATFULL on STN
AN 2002:133451 USPATFULL
TI Clasp-4 transmembrane protein
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Garman, Jonathan D., San Jose, CA, UNITED STATES
Candia, Albert F., III, Menlo Park, CA, UNITED STATES
PI US 2002068302 A1 20020606
AI US 2001-736969 A1 20010507 (9)
PRAI US 2000-240508P 20001013 (60)
DT Utility
FS APPLICATION
LN.CNT 5116
INCL INCLM: 435/007.100
INCLS: 530/350.000; 536/023.100
NCL NCLM: 435/007.100
NCLS: 530/350.000; 536/023.100
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 297 USPATFULL on STN
AN 2002:119316 USPATFULL
TI Delivery method for the tumor specific apoptosis inducing activity of
apoptin
IN Noteborn, Mathieu H.M., Leiderdrop, NETHERLANDS
Voorhoeve, Pieter M., Amesterdam, NETHERLANDS
Zhang, Ying-Hui, Leiden, NETHERLANDS
Leliveld, Sirik R., Leiden, NETHERLANDS
PI US 2002061296 A1 20020523
AI US 2001-949780 A1 20010910 (9)
PRAI EP 2000-203115 20000908
EP 2000-203147 20000928
US 2000-236117P 20000928 (60)
DT Utility
FS APPLICATION
LN.CNT 1601
INCL INCLM: 424/093.210
INCLS: 424/094.630; 435/226.000; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 424/093.210
NCLS: 424/094.630; 435/226.000; 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: A61K048-00
ICS: A61K038-48; C12N009-64; C12P021-02; C12N015-867; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 297 USPATFULL on STN
AN 2002:54991 USPATFULL
TI Interferon-suppressing placental lactogen peptides

PI US 2002032154 A1 20020314
AI US 2001-876478 A1 20010607 (9)
PRAI US 2000-210082P 20000607 (60)
DT Utility
FS APPLICATION
LN.CNT 1557
INCL INCLM: 514/012.000
INCLS: 435/184.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 530/350.000
IC [7]
ICM: A61K038-17
ICS: C12N009-99; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 297 USPATFULL on STN
AN 2002:3830 USPATFULL
TI Immunogenic ovarian cancer genes
IN Roden, Richard Bruce, Washington, DC, UNITED STATES
Naora, Honami, Baltimore, MD, UNITED STATES
PI US 2002001805 A1 20020103
AI US 2001-805177 A1 20010314 (9)
PRAI US 2000-189226P 20000314 (60)
US 2000-258452P 20001228 (60)
DT Utility
FS APPLICATION
LN.CNT 1953
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 297 USPATFULL on STN
AN 2002:332609 USPATFULL
TI Complex-forming proteins
IN Jerome, Valerie, Colbe, GERMANY, FEDERAL REPUBLIC OF
Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
PA Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)
PI US 6495346 B1 20021217
AI US 2000-481593 20000112 (9)
PRAI DE 1999-19900743 19990112
DT Utility
FS GRANTED
LN.CNT 2224
INCL INCLM: 435/069.700
INCLS: 435/069.500; 435/069.520; 424/085.100; 424/085.200; 536/023.400;
536/023.500; 536/023.510; 530/351.000
NCL NCLM: 435/069.700
NCLS: 424/085.100; 424/085.200; 435/069.500; 435/069.520; 530/351.000;
536/023.400; 536/023.500; 536/023.510
IC [7]
ICM: C12N015-62
ICS: A61K038-20; C07K014-54
EXF 435/6; 435/69.7; 435/69.5; 435/69.52; 536/23.4; 536/23.5; 530/351;
424/85.1; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 297 USPATFULL on STN
AN 2002:290772 USPATFULL
TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
IN Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmond, CA, United States
PA University Technology Corporation, Boulder, CO, United States (U.S.
corporation)

PI US 6475789 B1 20021105
AI US 1997-912951 19970814 (8)
RLI Continuation-in-part of Ser. No. US 1997-845050, filed on 9 May 1997,
now patented, Pat. No. US 5743518 Continuation-in-part of Ser. No. US
1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809
Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997,
now abandoned Continuation-in-part of Ser. No. US 1997-844419, filed on
18 Apr 1997, now abandoned Continuation-in-part of Ser. No. US
1996-724643, filed on 1 Oct 1996, now abandoned
DT Utility
FS GRANTED
LN.CNT 11405
INCL INCLM: 435/366.000
INCLS: 435/320.100; 435/069.100; 536/023.200; 424/094.100
NCL NCLM: 435/366.000
NCLS: 424/094.100; 435/069.100; 435/320.100; 536/023.200
IC [7]
ICM: C12N005-08
ICS: C12N015-12; C07H021-04; A61K038-43
EXF 435/366; 435/320; 435/69.1; 536/23.2; 429/94.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 297 USPATFULL on STN
AN 2002:268409 USPATFULL
TI Methods and compositions for reducing immune response
IN LaFace, Drake M., San Diego, CA, United States
Rahman, Amena, San Diego, CA, United States
Shabram, Paul W., Olivenhain, CA, United States
Tsai, Van T., San Diego, CA, United States
PA Canji, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6464976 B1 20021015
AI US 2000-653474 20000831 (9)
PRAI US 1999-152650P 19990907 (60)
DT Utility
FS GRANTED
LN.CNT 1437
INCL INCLM: 424/140.100
INCLS: 424/233.100; 424/131.100; 424/159.100; 424/278.100; 424/093.100;
435/007.100; 530/351.000; 514/885.000; 604/004.010; 604/005.010;
604/005.020
NCL NCLM: 424/140.100
NCLS: 424/093.100; 424/131.100; 424/159.100; 424/233.100; 424/278.100;
435/007.100; 514/885.000; 530/351.000; 604/004.010; 604/005.010;
604/005.020
IC [7]
ICM: A61K039-00
ICS: A61K045-00; A61K039-395; A61M037-00; G01N033-53
EXF 435/7.1; 424/140.1; 424/233.1; 424/131.1; 424/159.1; 424/278.1;
424/93.1; 530/351; 514/885; 604/4.01; 604/5.01; 604/5.02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 297 USPATFULL on STN
AN 2002:238860 USPATFULL
TI Regulated expression of recombinant proteins using RNA viruses
IN Jessee, Joel A., Mount Airy, MD, United States
Ciccarone, Valentina C., Gaithersburg, MD, United States
PA Invitrogen Corporation, Carlsbad, CA, United States (U.S. corporation)
PI US 6451579 B1 20020917
AI US 1999-361740 19990728 (9)
PRAI US 1998-94476P 19980729 (60)
DT Utility
FS GRANTED
LN.CNT 1243
INCL INCLM: 435/235.100
INCLS: 435/440.000; 435/455.000; 435/006.000; 435/320.100; 435/069.100;
435/015.000; 424/945.000; 514/044.000; 530/350.000; 530/435.000;
530/194.000
NCL NCLM: 435/235.100
NCLS: 424/094.500; 435/006.000; 435/015.000; 435/069.100; 435/320.100;
435/440.000; 435/455.000; 514/044.000; 530/350.000
IC [7]
ICM: C12N007-00
ICS: C12N009-12
EXF 435/440; 435/194; 435/455; 435/69.1; 435/6; 435/15; 435/320.1; 514/44;
424/99.5; 530/350

L4 ANSWER 241 OF 297 USPATFULL on STN
 AN 2002:238816 USPATFULL
 TI Methods using genetic package display for selecting internalizing
 IN ligands for gene delivery
 Larocca, David, Encinitas, CA, United States
 Baird, Andrew, San Diego, CA, United States
 Kassner, Paul, Hayward, CA, United States
 PA Selective Genetics, Inc., San Diego, CA, United States (U.S.
 corporation)
 PI US 6451527 B1 20020917
 AI US 1999-258689 19990226 (9)
 RLI Continuation-in-part of Ser. No. US 1998-193445, filed on 17 Nov 1998
 Continuation-in-part of Ser. No. US 1998-195379, filed on 17 Nov 1998
 Continuation-in-part of Ser. No. US 1998-141631, filed on 28 Aug 1998,
 now abandoned
 PRAI US 1997-57067P 19970829 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2048
 INCL INCLM: 435/006.000
 INCLS: 435/005.000; 435/235.100; 435/320.100; 435/DIG.002; 435/DIG.003;
 435/DIG.004; 435/DIG.014; 435/DIG.015; 435/DIG.017; 536/023.100
 NCL NCLM: 435/006.000
 NCLS: 435/005.000; 435/235.100; 435/320.100; 435/DIG.002; 435/DIG.003;
 435/DIG.004; 435/DIG.014; 435/DIG.015; 435/DIG.017; 536/023.100
 IC [7]
 ICM: C12Q001-68
 ICS: C12Q001-70; C12N015-00; C07H021-02
 EXF 435/7.1; 435/5; 435/6; 435/235.1; 435/320.1; 435/69.1; 435/DIG.1;
 435/DIG.2; 435/DIG.3; 435/DIG.4; 435/DIG.14; 435/DIG.15; 435/DIG.17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 297 USPATFULL on STN
 AN 2002:129535 USPATFULL
 TI Compositions and methods for treating Papillomavirus-infected cells
 IN Howley, Peter M., Wellesley, MA, United States
 Benson, John, Brookline, MA, United States
 Kasukawa, Hiroaki, Princeton, NJ, United States
 PA President and Fellows of Harvard College, Cambridge, MA, United States
 (U.S. corporation)
 PI US 6399075 B1 20020604
 AI US 1999-347504 19990702 (9)
 PRAI US 1998-91661P 19980702 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3332
 INCL INCLM: 424/204.100
 INCLS: 514/012.000; 530/350.000; 530/321.000; 530/325.000; 530/326.000;
 530/388.400; 536/023.740
 NCL NCLM: 424/204.100
 NCLS: 514/012.000; 530/321.000; 530/325.000; 530/326.000; 530/350.000;
 530/388.400; 536/023.740
 IC [7]
 ICM: A61K039-12
 ICS: A61K038-00
 EXF 424/204.1; 514/12; 530/350; 530/321; 530/325; 530/326; 530/388.4;
 536/23.74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 243 OF 297 USPATFULL on STN
 AN 2002:88268 USPATFULL
 TI Peptide-enhanced transfections
 IN Hawley-Nelson, Pamela, Silver Spring, MD, United States
 Lan, Jianqing, Germantown, MD, United States
 Shih, PoJen, Columbia, MD, United States
 Jessee, Joel A., Mt. Airy, MD, United States
 Schifferli, Kevin P., Germantown, MD, United States
 Gebeyehu, Gulilat, Silver Spring, MD, United States
 Ciccarone, Valentina C., Gaithersburg, MD, United States
 Evans, Krista L., Germantown, MD, United States
 PA Life Technologies, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 6376248 B1 20020423
 AI US 1998-39780 19980316 (9)
 RLI Continuation-in-part of Ser. No. US 1997-818200, filed on 14 Mar 1997,

DT Utility
FS GRANTED
LN.CNT 4698
INCL INCLM: 435/458.000
INCLS: 435/320.100; 435/235.100; 536/023.100
NCL NCLM: 435/458.000
NCLS: 435/235.100; 435/320.100; 536/023.100
IC [7]
ICM: C12N015-88
ICS: C12N007-00; C12N015-63; C12N015-11
EXF 435/235.1; 435/320.1; 435/458; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 244 OF 297 USPATFULL on STN
AN 2002:39765 USPATFULL
TI Interaction between ***cyclin*** D1 and steroid receptor
coactivators and users thereof in assays
IN Bernards, Rene, Alcoude, NETHERLANDS
Zwijssen, Renate, Utrecht, NETHERLANDS
PA Prolifix Limited, Abingdon, UNITED KINGDOM (non-U.S. corporation)
PI US 6350572 B1 20020226
AI US 1999-302305 19990430 (9)
RLI Continuation of Ser. No. WO 1999-GB440, filed on 12 Feb 1999
PRAI GB 1998-3035 19980212
GB 1998-18243 19980820

DT Utility
FS GRANTED
LN.CNT 1540
INCL INCLM: 435/004.000
INCLS: 435/007.100; 435/007.210; 435/007.200; 435/007.230; 435/007.800;
435/041.000; 435/069.100; 435/069.400; 435/069.700; 435/070.100;
435/070.300
NCL NCLM: 435/004.000
NCLS: 435/007.100; 435/007.200; 435/007.210; 435/007.230; 435/007.800;
435/041.000; 435/069.100; 435/069.400; 435/069.700; 435/070.100;
435/070.300
IC [7]
ICM: C12N015-09
ICS: C12N015-16; C12Q001-00; C12Q001-02
EXF 435/4; 435/7.1; 435/7.2; 435/7.21; 435/7.23; 435/7.8; 435/41; 435/69.1;
435/69.4; 435/69.7; 435/70.1; 435/70.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 245 OF 297 MEDLINE on STN
AN 2003024076 MEDLINE
DN PubMed ID: 12530063
TI Efficient translocation and apoptosis induction by adenovirus encoded
VP22 -p53 fusion protein in human tumor cells in vitro.
AU Roy Illa; Holle Lori; Song Wendy; Holle Eric; Wagner Thomas; Yu Xianzhong
CS Department of Biological Science, Clemson University, Clemson, South
Carolina 29634, USA.
SO Anticancer research, (2002 Nov-Dec) 22 (6A) 3185-9.
Journal code: 8102988. ISSN: 0250-7005.
CY Greece
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 20030118
Last Updated on STN: 20030202
Entered Medline: 20030131

L4 ANSWER 246 OF 297 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V.
on STN DUPLICATE
AN 2002258759 ESBIOBASE
TI Protein transduction: A novel tool for tissue regeneration
AU Cardoso M.C.; Leonhardt H.
CS M.C. Cardoso, Max Delbrück Center Mol. Med., D-13125 Berlin, Germany.
SO Biological Chemistry, (01 OCT 2002), 383/10 (1593-1599), 46 reference(s)
CODEN: BICHP3 ISSN: 1431-6730
DT Journal; Article
CY Germany, Federal Republic of
LA English
SL English

STN
 AN 2002:90665 BIOSIS
 DN PREV200200090665
 TI A novel approach to induce cell cycle reentry in terminally differentiated muscle cells.
 AU Derer, Wolfgang; Easwaran, Hariharan P.; Leonhardt, Heinrich; Cardoso, M. Cristina [Reprint author]
 CS Max Delbrück Center for Molecular Medicine, Wiltbergstr. 50, D-13125, Berlin, Germany
 SO FASEB Journal, (January, 2002) Vol. 16, No. 1, pp. 132-133. print.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DT Article
 LA English
 ED Entered STN: 24 Jan 2002
 Last Updated on STN: 25 Feb 2002

L4 ANSWER 248 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN DUPLICATE 35
 AN 2002-12233 BIOTECHDS
 TI New recombinant, modified adenovirus vectors for regulating transgene expression in tumor cells, useful in gene therapy, particularly for treating cancers, e.g. cervical, lung, liver or breast; adeno virus vector-mediated gene transfer and expression in cancer cell for recombinant protein production and cancer gene therapy
 AU LIEBER A; STEINWAERDER D S; CARLSON C A; MI J
 PA UNIV WASHINGTON
 PI WO 2001083796 8 Nov 2001
 AI WO 2000-US14428 3 May 2000
 PRAI US 2000-202367 3 May 2000
 DT Patent
 LA English
 OS WPI: 2002-240307 [29]

L4 ANSWER 249 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 36
 AN 2001:45029 CAPLUS
 DN 134:91095
 TI Method for tissue regeneration using fusion proteins
 IN Leonhardt, Heinrich; Cardoso, Cristina M.
 PA Max-Delbrueck-Centrum fuer Molekulare Medizin, Germany
 SO Ger. Offen., 4 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19933089	A1	20010118	DE 1999-19933089	19990715
	WO 2001005418	A2	20010125	WO 2000-DE2258	20000712
	WO 2001005418	A3	20010719		
	W: JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1198240	A2	20020424	EP 2000-954316	20000712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	JP 2003504411	T2	20030204	JP 2001-510472	20000712
PRAI	DE 1999-19933089	A	19990715		
	WO 2000-DE2258	W	20000712		

L4 ANSWER 250 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:115309 CAPLUS
 DN 134:158512
 TI Multiple gene-containing vectors for gene therapy of tumors
 IN Tiemann, Frank
 PA Hepavec A.-G. fur Gentherapie, Germany
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001011063	A2	20010215	WO 2000-DE2726	20000810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 10039844 A1 20010419 DE 2000-10039844 20000810
 PRAI DE 1999-19937308 A 19990810

L4 ANSWER 251 OF 297 USPATFULL on STN
 AN 2001:212421 USPATFULL
 TI Compound containing a labile disulfide bond
 IN Wolff, Jon A., Madison, WI, United States
 Monahan, Sean D., Madison, WI, United States
 Budker, Vladimir G., Middleton, WI, United States
 Slattum, Paul M., Madison, WI, United States
 Rozema, David B., Madison, WI, United States
 PI US 2001044417 A1 20011122
 AI US 2001-779791 A1 20010208 (9)
 RLI Continuation-in-part of Ser. No. US 1999-312351, filed on 14 May 1999,
 PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 2264
 INCL INCLM: 514/044.000
 INCLS: 514/002.000; 530/350.000; 536/023.100
 NCL NCLM: 514/044.000
 NCLS: 514/002.000; 530/350.000; 536/023.100
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-00; C07H021-04; C07K014-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 252 OF 297 USPATFULL on STN
 AN 2001:88094 USPATFULL
 TI Use of a modified baculovirus containing exogenous nucleic acid for the
 manufacture of a medicament for delivering said nucleic acid to the
 hepatocytes
 IN McGarvey, Michael J., London, Great Britain
 Thomas, Howard C., London, Great Britain
 PA IMPERIAL COLLEGE INNOVATIONS LIMITED (non-U.S. corporation)
 PI US 2001000228 A1 20010412
 AI US 2000-729856 A1 20001206 (9)
 RLI Continuation of Ser. No. US 1999-428532, filed on 28 Oct 1999, ABANDONED
 PRAI GB 1997-8698 19970429
 WO 1998-GB1249 19980429
 DT Utility
 FS APPLICATION
 LN.CNT 530
 INCL INCLM: 424/093.210
 INCLS: 514/044.000
 NCL NCLM: 424/093.210
 NCLS: 514/044.000
 IC [7]
 ICM: A61K031-70
 ICS: A01N043-04; A61K048-00; A01N063-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 253 OF 297 USPATFULL on STN
 AN 2001:197161 USPATFULL
 TI Tumor necrosis factor related receptor, TR6
 IN Deen, Keith C., Glenmore, PA, United States
 Young, Peter R., Lawrenceville, NJ, United States
 Marshall, Lisa A., Wyndmoor, PA, United States
 Roshak, Amy K., East Norriton, PA, United States
 Tan, Kong B., Philadelphia, PA, United States
 Truneh, Alemseged, West Chester, PA, United States
 PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.
 corporation)
 PI US 6313269 B1 20011106
 AI US 1999-333593 19990615 (9)
 RLI Continuation-in-part of Ser. No. US 1997-916625, filed on 22 Aug 1997
 Continuation-in-part of Ser. No. US 1997-853684, filed on 9 May 1997,
 now abandoned

DT Utility
FS GRANTED
LN.CNT 1423
INCL INCLM: 530/350.000
INCLS: 435/069.100
NCL NCLM: 530/350.000
NCLS: 435/069.100
IC [7]
ICM: C07K014-715
ICS: C12N015-12
EXF 530/350; 530/351; 530/402; 435/69.1; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 254 OF 297 USPATFULL on STN
AN 2001:97423 USPATFULL
TI Materials and methods for intracellular transport and their uses
IN O'Hare, Peter Francis Joseph, Oxted, United Kingdom
Elliott, Gillian Daphne, Oxted, United Kingdom
PA Marie Curie Cancer Care, London, United Kingdom (non-U.S. corporation)
PI US 6251398 B1 20010626
AI US 1999-395344 19990913 (9)
RLI Continuation of Ser. No. US 1998-12126, filed on 22 Jan 1998, now
patented, Pat. No. US 6017735
PRAI GB 1997-1363 19970123
GB 1997-16398 19970801

DT Utility
FS GRANTED
LN.CNT 1076
INCL INCLM: 424/186.100
INCLS: 424/192.100; 424/204.100; 424/208.100; 424/248.100; 424/263.100;
530/350.000; 530/826.000; 536/023.400; 435/235.100; 435/325.000;
435/317.100; 435/252.300
NCL NCLM: 424/186.100
NCLS: 424/192.100; 424/204.100; 424/208.100; 424/248.100; 424/263.100;
435/235.100; 435/252.300; 435/317.100; 435/325.000; 530/350.000;
530/826.000; 536/023.400
IC [7]
ICM: A61K039-00
ICS: C12N015-62; C07K019-00
EXF 424/186.1; 424/192.1; 424/204.1; 424/208.1; 424/248.1; 424/263.1;
530/350; 530/826; 536/23.4; 435/235.1; 435/325; 435/69.7; 435/317.1;
435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 297 USPATFULL on STN
AN 2001:59379 USPATFULL
TI Anti-pathogen system and methods of use thereof
IN Dowdy, Steven F., Clayton, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 6221355 B1 20010424
AI US 1998-208966 19981210 (9)
PRAI US 1998-82402P 19980420 (60)
US 1997-69012P 19971210 (60)

DT Utility
FS Granted
LN.CNT 3168
INCL INCLM: 424/192.100
INCLS: 424/204.100; 424/208.100; 536/023.400; 530/387.300; 530/388.300
NCL NCLM: 424/192.100
NCLS: 424/204.100; 424/208.100; 530/387.300; 530/388.300; 536/023.400
IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-21; C07H021-04; C12P021-08
EXF 536/23.4; 530/387.3; 530/388.3; 424/192.1; 424/204.1; 424/208.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 297 USPATFULL on STN
AN 2001:18285 USPATFULL
TI Transport proteins and their uses
IN O'Hare, Peter Francis Joseph, Oxted, United Kingdom
Elliott, Gillian Daphne, Oxted, United Kingdom
PA Marie Curie Cancer Care, London, United Kingdom (non-U.S. corporation)
PI US 6184038 B1 20010206
WO 9705265 19970213
AI US 1998-11073 19980126 (9)

PRAI GB 1995-15568 19950728
GB 1996-1570 19960126
DT Utility
FS Granted
LN.CNT 901
INCL INCLM: 435/455.000
INCLS: 435/468.000; 435/471.000; 530/300.000; 530/350.000
NCL NCLM: 435/455.000
NCLS: 435/468.000; 435/471.000; 530/300.000; 530/350.000
IC [7]
ICM: C12N015-87
ICS: C07K014-03
EXF 530/300; 530/350; 435/325; 435/243; 435/410; 435/455; 435/408; 435/471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 257 OF 297 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-418224 [44] WPIDS
DNC C2001-126495
TI Inhibiting cancer cell proliferation by exposing cells to a composition of fusion proteins comprising ***VP22*** polypeptides coupled to cell cycle progression regulators, and further exposing cells to cell death stimulators.
DC B04 D16
IN BREWIS, N D; NORMAND, N M; O'HARE, P F J; PHELAN, A; OHARE, P F J
PA (PHOG-N) PHOGEN LTD; (BREW-I) BREWIS N D; (NORM-I) NORMAND N M; (OHAR-I) O'HARE P F J; (PHEL-I) PHELAN A
CYC 95
PI WO 2001047960 A1 20010705 (200144)* EN 23 C07K014-035
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001022079 A 20010709 (200164) C07K014-035
EP 1240190 A1 20020918 (200269) EN C07K014-035
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
US 2002155988 A1 20021024 (200273) A01N037-18
JP 2003519159 W 20030617 (200349) 24 A61K047-48
MX 2002006168 A1 20030101 (200373) A61K047-48
US 6734167 B2 20040511 (200431)# A61K038-00
US 2004142900 A1 20040722 (200449) A61K048-00
ADT WO 2001047960 A1 WO 2000-GB4965 20001221; AU 2001022079 A AU 2001-22079
20001221; EP 1240190 A1 EP 2000-985678 20001221; WO 2000-GB4965 20001221;
US 2002155988 A1 US 2000-747772 20001220; JP 2003519159 W WO 2000-GB4965
20001221, JP 2001-549430 20001221; MX 2002006168 A1 WO 2000-GB4965
20001221, MX 2002-6168 20020620; US 6734167 B2 US 2000-747772 20001220; US
2004142900 A1 Cont of US 2000-747772 20001220, US 2004-789113 20040226
FDT AU 2001022079 A Based on WO 2001047960; EP 1240190 A1 Based on WO
2001047960; JP 2003519159 W Based on WO 2001047960; MX 2002006168 A1 Based
on WO 2001047960; US 2004142900 A1 Cont of US 6734167
PRAI GB 1999-30519 19991224
IC ICM A01N037-18; A61K038-00; A61K047-48; A61K048-00; C07K014-035
ICS A61K031-7088; A61P009-10; A61P017-02; A61P017-06; A61P035-00;
C12N015-85; G01N033-574

L4 ANSWER 258 OF 297 CANCERLIT on STN DUPLICATE 37
AN 2002073801 CANCERLIT
DN 21398561 PubMed ID: 11507218
TI Intratumoral spread and increased efficacy of a p53- ***VP22*** fusion protein expressed by a recombinant adenovirus.
AU Wills K N; Atencio I A; Avanzini J B; Neuteboom S; Phelan A; Philopena J; Sutjipto S; Vaillancourt M T; Wen S F; Ralston R O; Johnson D E
CS Canji, Inc., San Diego, California 92121, USA.. ken.wills@canji.com
SO JOURNAL OF VIROLOGY, (2001 Sep) 75 (18) 8733-41.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001462483
EM 200109

L4 ANSWER 259 OF 297 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2002:261533 BIOSIS
DN PREV200200261533
TI Tob increases the threshold of T cell activation and functions as a
negative regulator of cell cycle progression and cytokine transcription.
AU Tzachanis, Dimitrios [Reprint author]; Freeman, Gordon J. [Reprint
author]; Hirano, Naoto [Reprint author]; van Puijenbroek, Andreas A. F. L.
[Reprint author]; Delfs, Micahel W.; Berezovskaya, Alla [Reprint author];
Nadler, Lee M. [Reprint author]; Boussiotis, Vassiliki A. [Reprint author]
CS Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA, USA
SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 818a. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology,
Part 1. Orlando, Florida, USA. December 07-11, 2001. American Society of
Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 1 May 2002
Last Updated on STN: 1 May 2002

L4 ANSWER 260 OF 297 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2001:959291 SCISEARCH
GA The Genuine Article (R) Number: 496WR
TI A novel approach to induce cell cycle reentry in terminally differentiated
muscle cells
AU Derer W; Easwaran H P; Leonhardt H; Cardoso M C (Reprint)
CS Franz Volhard Clin, Wiltbergstr 50, D-13125 Berlin, Germany (Reprint); Max
Delbruck Ctr Mol Med, D-13125 Berlin, Germany
CYA Germany
SO FASEB JOURNAL, (NOV 2001) Vol. 15, No. 13, pp. U83-U94.
Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD
20814-3998 USA.
ISSN: 0892-6638.
DT Article; Journal
LA English
REC Reference Count: 21
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 261 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 38
AN 2000:98338 CAPLUS
DN 132:117530
TI Cdk inhibitors as inhibitors of herpesvirus gene expression, replication
and pathogenesis
IN Schang, Luis M.; Schaffer, Priscilla A.; Jordan, Robert
PA The Trustees of the University of Pennsylvania, USA
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006170	A1	20000210	WO 1999-US16252	19990716
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9951116	A1	20000221	AU 1999-51116	19990716
	US 2003049602	A1	20030313	US 2000-905689	20001206
	US 2003060457	A1	20030327	US 2000-905695	20001206
	US 2003099944	A1	20030529	US 2000-905687	20001206
PRAI	US 1998-94805P	P	19980731		
	US 1999-131264P	P	19990427		
	US 1999-140926P	P	19990624		
	WO 1999-US16252	W	19990716		
	US 2000-656592	A2	20000907		
	US 2000-951058	A2	20000912		

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 03272334 IFIPAT;IFIUDB;IFICDB
 TI MATERIALS AND METHODS FOR INTRACELLULAR TRANSPORT AND THEIR USES; A
 FUSION POLYPEPTIDE HAVING A HERPES VIRUS VIRION PROTEIN AND A SECOND
 PROTEIN SELECTED FROM CELL CYCLE CONTROL, SUICIDE PROTEIN, ANTIGENIC
 SEQUENCES, IMMUNOMODULATING OR THERAPEUTIC PROTEIN;
 ANTIPROLIFERATIVE/ANTICARCINOGENIC AGENTS
 IN Elliott Gillian Daphne (GB); O'Hare Peter Francis Joseph (GB)
 PA Curie, Marie Cancer Care GB (52237)
 PI US 6017735 A 20000125 (CITED IN 002 LATER PATENTS)
 AI US 1998-12126 19980122
 PRAI GB 1997-1363 19970123
 GB 1997-16398 19970801
 FI US 6017735 20000125
 DT Utility; CERTIFICATE OF CORRECTION
 CDAT 13 Aug 2002
 FS CHEMICAL
 GRANTED
 MRN 009059 MFN: 0506
 CLMN 19
 GI 6 Drawing Sheet(s), 10 Figure(s).

L4 ANSWER 263 OF 297 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2000-08342 BIOTECHDS
 TI New vector useful for increasing transfection efficiencies comprises a
 nucleic acid sequence encoding a transport protein and at least one
 nucleic acid sequence to be transported;
 Herpes simplex virus ***VP22***, green fluorescent protein and tet
 repressor fusion protein gene transfer and expression in animal cell
 by lipofection or electroporation

AU Sczakiel G
 PA Mueller-Bore and Partner
 LO Heidelberg, Germany.
 PI DE 1045420 13 Apr 2000
 AI DE 1998-1045420 2 Oct 1998
 PRAI DE 1998-1045420 2 Oct 1998
 DT Patent
 LA German
 OS WPI: 2000-294045 [26]

L4 ANSWER 264 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:401851 CAPLUS
 DN 133:53685
 TI Protein transduction system and methods of use thereof
 IN Dowdy, Steven F.
 PA Washington University, USA
 SO PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000034308	A2	20000615	WO 1999-US29289	19991210
	WO 2000034308	A3	20001019		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000021728	A1	20000626	AU 2000-21728	19991210
	EP 1137664	A2	20011004	EP 1999-966101	19991210
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002531113	T2	20020924	JP 2000-586751	19991210
PRAI	US 1998-111701P	P	19981210		
	WO 1999-US29289	W	19991210		
OS	MARPAT 133:53685				

L4 ANSWER 265 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:241537 CAPLUS
 DN 132:261385

IN vectors encoding proteins that transport the transforming DNA to the nucleus
 PA Szczakiel, Georg
 PA Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts, Germany
 SO PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020617	A1	20000413	WO 1999-EP7228	19990929
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19845420	A1	20000413	DE 1998-19845420	19981002
	DE 19845420	C2	20001116		
	AU 9959825	A1	20000426	AU 1999-59825	19990929
PRAI	DE 1998-19845420	A	19981002		
	WO 1999-EP7228	W	19990929		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 266 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:738773 CAPLUS
 DN 133:291142
 TI Control of cell cycle/cell growth with NF-.kappa.B inhibitors and methods for assessment of chemotherapy and for screening for cell cycle inhibitors
 IN Kaltschmidt, Barbara; Kaltschmidt, Christian; Hehner, Steffen; Droege, Wulf; Schmitz, Lienhard
 PA Germany
 SO Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19917084	A1	20001019	DE 1999-19917084	19990415
PRAI	DE 1999-19917084		19990415		

L4 ANSWER 267 OF 297 USPATFULL on STN
 AN 2000:174804 USPATFULL
 TI Telomerase catalytic subunit
 IN Cech, Thomas R., Boulder, CO, United States
 Lingner, Joachim, Boulder, CO, United States
 PA University Technology Corporation, Boulder, CO, United States (U.S. corporation)
 Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
 PI US 6166178 20001226
 AI US 1997-974549 19971119 (8)
 RLI Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996
 PRAI WO 1997-US17618 19971001
 WO 1997-US17885 19971001
 DT Utility
 FS Granted
 LN.CNT 23874
 INCL INCLM: 530/324.000
 INCLS: 530/827.000; 530/828.000; 536/023.200; 536/023.500

NCLS: 530/827.000; 530/828.000; 536/023.200; 536/023.500
 IC [7]
 ICM: A61K038-00
 ICS: C07K005-00; C07K007-00; C07K016-00
 EXF 530/324; 530/827; 530/828; 536/23.2; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 268 OF 297 USPATFULL on STN
 AN 2000:87733 USPATFULL
 TI Recombinant bovine herpesvirus type 1 vaccines
 IN Zamb, Timothy, Setauket, NY, United States
 Liang, Xiaoping, Saskatoon, Canada
 Babiuk, Lorne A., Saskatoon, Canada
 PA University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)
 PI US 6086902 20000711
 AI US 1994-303861 19940909 (8)
 RLI Continuation-in-part of Ser. No. US 1993-51448, filed on 19 Apr 1993,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 2955
 INCL INCLM: 424/299.100
 INCLS: 424/204.100; 424/205.100
 NCL NCLM: 424/209.100
 NCLS: 424/204.100; 424/205.100
 IC [7]
 ICM: A01N037-18
 EXF 424/197.1; 424/201.1; 424/202.1; 424/229.1; 424/243.1; 424/204.1;
 424/205.1; 424/299.1; 435/69.1; 435/172.1; 435/252.3; 514/320.1; 514/44;
 536/23.72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 269 OF 297 USPATFULL on STN
 AN 2000:87731 USPATFULL
 TI Methods and compositions for using membrane-penetrating proteins to
 carry materials across cell membranes
 IN Draper, Rockford, Plano, TX, United States
 PA Board of Regents, The University of Texas Systems, Austin, TX, United
 States (U.S. corporation)
 PI US 6086900 20000711
 AI US 1998-47148 19980324 (9)
 PRAI US 1997-42056P 19970326 (60)
 DT Utility
 FS Granted
 LN.CNT 2729
 INCL INCLM: 424/282.100
 INCLS: 514/002.000; 514/044.000; 435/455.000; 435/320.100; 435/358.000;
 435/357.000; 435/367.000; 435/372.200; 435/372.300; 530/350.000;
 530/387.100; 536/023.100; 536/023.400; 536/023.500; 536/023.700
 NCL NCLM: 424/282.100
 NCLS: 435/320.100; 435/357.000; 435/358.000; 435/367.000; 435/372.200;
 435/372.300; 435/455.000; 514/002.000; 514/044.000; 530/350.000;
 530/387.100; 536/023.100; 536/023.400; 536/023.500; 536/023.700
 IC [7]
 ICM: A61K039-44
 ICS: C12N005-10; C07K017-02
 EXF 435/320.1; 435/69.1; 435/455; 435/358; 435/357; 435/367; 435/372.2;
 435/372.3; 530/350; 530/387.1; 424/282.1; 514/2; 514/44; 536/23.1;
 536/23.4; 536/23.5; 536/23.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 270 OF 297 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2000-665115 [64] WPIDS
 DNC C2000-201518
 TI Fusion proteins with cell immortalization and telomerase specific activity
 are useful for increasing replicative capacity of normally quiescent cells
 such as somatic cells to produce cells suitable for cell therapy.
 DC B04 D16
 IN BAETGE, E E; DUPRAZ, P; THORENS, B; WONG, S; HUNZIKER, T; LIMAT, A
 PA (MODE-N) MODEX THERAPEUTIQUES SA; (BAET-I) BAETGE E E; (DUPR-I) DUPRAZ P;
 (THOR-I) THORENS B; (WONG-I) WONG S; (EPIT-N) EPITECH SA
 CYC 93
 PI WO 2000061617 A2 20001019 (200064)* EN 40 C07K014-035
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW

EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
 LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
 SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000043429 A 20001114 (200108) C07K014-035
 EP 1175436 A2 20020130 (200216) EN C07K014-035
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 US 6358739 B1 20020319 (200224) C12N005-08
 US 2002076787 A1 20020620 (200244) C12N015-867
 US 6451601 B1 20020917 (200264) C12N005-08
 JP 2002541786 W 20021210 (200301) 53 C12N015-09
 US 6730513 B1 20040504 (200430) C12N005-00

ADT WO 2000061617 A2 WO 2000-US9775 20000412; AU 2000043429 A AU 2000-43429
 20000412; EP 1175436 A2 EP 2000-923274 20000412, WO 2000-US9775 20000412;
 US 6358739 B1 Provisional US 1999-128893P 19990412, US 2000-546483
 20000410; US 2002076787 A1 Provisional US 1999-128893P 19990412, CIP of US
 2000-546483 20000410, US 2001-823177 20010329; US 6451601 B1 Provisional
 US 1999-128893P 19990412, CIP of US 2000-546483 20000410, US 2001-823177
 20010329; JP 2002541786 W JP 2000-611558 20000412, WO 2000-US9775
 20000412; US 6730513 B1 CIP of US 1999-358181 19990720, US 2000-546269
 20000410

FDT AU 2000043429 A Based on WO 2000061617; EP 1175436 A2 Based on WO
 2000061617; JP 2002541786 W Based on WO 2000061617; US 6730513 B1 CIP of
 US 6548058

PRAI US 2000-546269 20000410; US 1999-128893P 19990412;
 US 2000-546483 20000410; US 2001-823177 20010329;
 US 1999-358181 19990720

IC ICM C07K014-035; C12N005-00; C12N005-08; C12N015-09; C12N015-867
 ICS A61K048-00; A61P035-00; C07K014-03; C07K014-155; C07K014-16;
 C07K014-82; C07K019-00; C12N001-15; C12N001-19; C12N001-21;
 C12N005-06; C12N005-10; C12N009-22; C12N015-10; C12N015-62;
 C12N015-79

L4 ANSWER 271 OF 297 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN

AN 2001:323812 BIOSIS

DN PREV200100323812

TI Downregulation of p27kip1 by IL-7 is mandatory for induction of bcl-2,
 promotion of viability and cell cycle progression in T cell acute
 lymphoblastic leukemia cells.

AU Barata, Joao T. [Reprint author]; Cardoso, Angelo A. [Reprint author];
 Keenan, Thomas [Reprint author]; Sallan, Steven; Nadler, Lee M. [Reprint
 author]; Boussiotis, Vassiliki A. [Reprint author]

CS Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 462a. print.
 Meeting Info.: 42nd Annual Meeting of the American Society of Hematology.
 San Francisco, California, USA. December 01-05, 2000. American Society of
 Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 11 Jul 2001

Last Updated on STN: 19 Feb 2002

L4 ANSWER 272 OF 297 USPATFULL on STN

AN 1999:155500 USPATFULL

TI Herpesvirus pre-(viral DNA replication) enveloped particles

IN Dargan, Derrick James, Glasgow, United Kingdom

Patel, Arvind Hirabhai, Motherwell, United Kingdom

Subak-Sharpe, John Herbert, Glasgow, United Kingdom

PA Medical Research Council, London, United Kingdom (non-U.S. corporation)

PI US 5994116 19991130

WO 9520049 19950727

AI US 1996-676323 19960719 (8)

WO 1995-GB156 19950125

19960719 PCT 371 date

19960719 PCT 102(e) date

PRAI GB 1994-1333 19940125

DT Utility

FS Granted

LN.CNT 904

INCL INCLM: 435/236.000

INCLS: 435/237.000; 435/238.000; 435/239.000; 424/231.100

NCL NCLM: 435/236.000

NCLS: 424/231.100; 435/237.000; 435/238.000; 435/239.000

ICM: C12N007-04
EXF 435/236; 435/261; 424/229.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 273 OF 297 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:527442 CAPLUS
DN 129:132838
TI Fusion proteins containing herpesvirus ***VP22*** for intracellular
and intercellular transport and their uses
IN O'Hare, Peter Francis Joseph; Elliott, Gillian Daphne
PA Marie Curie Cancer Care, UK
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832866	A1	19980730	WO 1998-GB207	19980123
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6017735	A	20000125	US 1998-12126	19980122
	AU 9856749	A1	19980818	AU 1998-56749	19980123
	AU 735830	B2	20010719		
	EP 961829	A1	19991208	EP 1998-900953	19980123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001508304	T2	20010626	JP 1998-531733	19980123
	US 6251398	B1	20010626	US 1999-395344	19990913
	US 2002106378	A1	20020808	US 2001-800433	20010305
	AU 759858	B2	20030501	AU 2001-81504	20011019
PRAI	GB 1997-1363	A	19970123		
	GB 1997-16398	A	19970801		
	US 1998-12126	A1	19980122		
	AU 1998-56749	A3	19980123		
	WO 1998-GB207	W	19980123		
	US 1999-395344	A1	19990913		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 274 OF 297 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004371099 BIOENG
DN 4424908
TI Transduction of full-length TAT fusion proteins into mammalian cells:
TAT-p27 super(Kip1) induces cell migration
AU Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF*
CS Howard Hughes Medical Institute and Division of Molecular Oncology, Depts of Pathology and Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA, [mailto:dowdy@pathology.wustl.edu]
SO Nature Medicine [Nat. Med.]. Vol. 4, no. 12, pp. 1449-1452. Dec 1998.
ISSN: 1078-8956
DT Journal
LA English
OS Medical and Pharmaceutical Biotechnology Abstracts; Oncogenes & Growth Factors Abstracts

L4 ANSWER 275 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ADA37365 peptide DGENE
TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
PI WO 2003054002 A1 20030703 33p
AI WO 2002-CU10 20021204
PRAI CU 2001-309 20011220

LA Spanish
 OS 2003-514183 [48]
 DESC ***SV40*** large T antigen nuclear localisation signal.

L4 ANSWER 276 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37363 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site as target molecule for inhibitory peptides.

L4 ANSWER 277 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37361 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #10.

L4 ANSWER 278 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37357 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #6.

L4 ANSWER 279 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37354 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #3.

L4 ANSWER 280 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37360 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting

phosphorylation site of casein kinase II. -

IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B

PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.

PI WO 2003054002 A1 20030703 33p

AI WO 2002-CU10 20021204

PRAI CU 2001-309 20011220

DT Patent

LA Spanish

OS 2003-514183 [48]

DESC CKII phosphorylation site inhibitory binding peptide #9.

L4 ANSWER 281 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN ADA37358 peptide DGENE

TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.

IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B

PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.

PI WO 2003054002 A1 20030703 33p

AI WO 2002-CU10 20021204

PRAI CU 2001-309 20011220

DT Patent

LA Spanish

OS 2003-514183 [48]

DESC CKII phosphorylation site inhibitory binding peptide #7.

L4 ANSWER 282 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN ADA37355 peptide DGENE

TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.

IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B

PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.

PI WO 2003054002 A1 20030703 33p

AI WO 2002-CU10 20021204

PRAI CU 2001-309 20011220

DT Patent

LA Spanish

OS 2003-514183 [48]

DESC CKII phosphorylation site inhibitory binding peptide #4.

L4 ANSWER 283 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN ADA37352 peptide DGENE

TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.

IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B

PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.

PI WO 2003054002 A1 20030703 33p

AI WO 2002-CU10 20021204

PRAI CU 2001-309 20011220

DT Patent

LA Spanish

OS 2003-514183 [48]

DESC CKII phosphorylation site inhibitory binding peptide #1.

L4 ANSWER 284 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN ADA37359 peptide DGENE

TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.

IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B

PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.

PI WO 2003054002 A1 20030703 33p

AI WO 2002-CU10 20021204

DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #8.

L4 ANSWER 285 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37353 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #2.

L4 ANSWER 286 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37364 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC HIV Tat1 intracellular penetration peptide.

L4 ANSWER 287 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37362 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #11.

L4 ANSWER 288 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ADA37356 peptide DGENE
 TI New peptides and related expression vectors, useful for inhibiting tumors, especially where caused by human papilloma virus, bind to the phosphorylation site of casein kinase II.
 IN Perea Rodriguez S E; Reyes Acosta O; Santiago Vispo N F; Puchades Izaguirre Y; Silva Rodriguez R; Moro Soria A; Santos Savio A; Gonzalez Lopez L J; Gonzalez Barrios B
 PA (INGG-N) CENT ING GENETICA & BIOTECNOLOGIA.
 PI WO 2003054002 A1 20030703 33p
 AI WO 2002-CU10 20021204
 PRAI CU 2001-309 20011220
 DT Patent
 LA Spanish
 OS 2003-514183 [48]
 DESC CKII phosphorylation site inhibitory binding peptide #5.

L4 ANSWER 289 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABG75506 Peptide DGENE

intracellular delivery of a therapeutic agent to a target site, by loading a cell with an agent-MTS conjugate, which comprises a membrane translocation sequence -

IN Craig R
PA (CRAI-I) CRAIG R.
PI US 2002151004 A1 20021017 43p
AI US 2001-785802 20010216
PRAI GB 2000-2848 20000724
GB 2000-3056 20000809
US 2000-748063 20001222
US 2000-748789 20001222
DT Patent
LA English
OS 2003-182503 [18]
DESC Signal-sequence-based peptide I.

L4 ANSWER 290 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY96575 Protein DGENE
TI New method for increasing the proliferative capacity of cell lines comprises administering agents reversibly activating telomerase activity and reversibly inactivating Rb/INK4 and/or p53 pathways useful in treating age related diseases
IN Hannon G J; Beach D H
PA (GENE-N) GENETICA INC.
PI WO 2000031238 A2 20000602 123p
AI WO 1999-US27907 19991124
PRAI US 1998-109891 19981125
US 1999-120549 19990217
DT Patent
LA English
OS 2000-400055 [34]
CR N-PSDB: AAA29396
DESC HSV-1 ***VP22*** polypeptide C-terminal domain.

L4 ANSWER 291 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY96574 Protein DGENE
TI New method for increasing the proliferative capacity of cell lines comprises administering agents reversibly activating telomerase activity and reversibly inactivating Rb/INK4 and/or p53 pathways useful in treating age related diseases
IN Hannon G J; Beach D H
PA (GENE-N) GENETICA INC.
PI WO 2000031238 A2 20000602 123p
AI WO 1999-US27907 19991124
PRAI US 1998-109891 19981125
US 1999-120549 19990217
DT Patent
LA English
OS 2000-400055 [34]
CR N-PSDB: AAA29395
DESC HSV-1 ***VP22*** polypeptide.

L4 ANSWER 292 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW95100 peptide DGENE
TI Fusion and chimaeric proteins including ***cyclin*** -dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI WO 9906540 A2 19990211 88p
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR N-PSDB: AAX26228
DESC HIV-1 ***VP22*** polypeptide C-terminal domain.

L4 ANSWER 293 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW95099 Protein DGENE
TI Fusion and chimaeric proteins including ***cyclin*** -dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration

PA (MITO-N) MITOTIX INC.
 PI WO 9906540 A2 19990211 88p
 AI WO 1998-US15759 19980729
 PRAI US 1997-902572 19970729
 DT Patent
 LA English
 OS 1999-153770 [13]
 CR N-PSDB: AAX26227
 DESC HIV-1 ***VP22*** polypeptide.

L4 ANSWER 294 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAA29396 DNA DGENE
 TI New method for increasing the proliferative capacity of cell lines comprises administering agents reversibly activating telomerase activity and reversibly inactivating Rb/INK4 and/or p53 pathways useful in treating age related diseases
 IN Hannon G J; Beach D H
 PA (GENE-N) GENETICA INC.
 PI WO 2000031238 A2 20000602 123p
 AI WO 1999-US27907 19991124
 PRAI US 1998-109891 19981125
 US 1999-120549 19990217
 DT Patent
 LA English
 OS 2000-400055 [34]
 CR P-PSDB: AAY96575
 DESC HSV-1 ***VP22*** polypeptide C-terminal domain coding sequence.

L4 ANSWER 295 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAA29395 DNA DGENE
 TI New method for increasing the proliferative capacity of cell lines comprises administering agents reversibly activating telomerase activity and reversibly inactivating Rb/INK4 and/or p53 pathways useful in treating age related diseases
 IN Hannon G J; Beach D H
 PA (GENE-N) GENETICA INC.
 PI WO 2000031238 A2 20000602 123p
 AI WO 1999-US27907 19991124
 PRAI US 1998-109891 19981125
 US 1999-120549 19990217
 DT Patent
 LA English
 OS 2000-400055 [34]
 CR P-PSDB: AAY96574
 DESC HSV-1 ***VP22*** polypeptide coding sequence.

L4 ANSWER 296 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAX26227 DNA DGENE
 TI Fusion and chimaeric proteins including ***cyclin*** -dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
 IN Beach D H; Gyuris J; Lamphere L
 PA (MITO-N) MITOTIX INC.
 PI WO 9906540 A2 19990211 88p
 AI WO 1998-US15759 19980729
 PRAI US 1997-902572 19970729
 DT Patent
 LA English
 OS 1999-153770 [13]
 CR P-PSDB: AAW95099
 DESC HIV-1 ***VP22*** polypeptide encoding DNA.

L4 ANSWER 297 OF 297 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAX26228 DNA DGENE
 TI Fusion and chimaeric proteins including ***cyclin*** -dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
 IN Beach D H; Gyuris J; Lamphere L
 PA (MITO-N) MITOTIX INC.
 PI WO 9906540 A2 19990211 88p
 AI WO 1998-US15759 19980729
 PRAI US 1997-902572 19970729
 DT Patent

OS 1999-153770 [13]
CR P-PSDB: AAW95100
DESC HIV-1 ***VP22*** polypeptide C-terminal domain encoding DNA.
STN INTERNATIONAL LOGOFF AT 16:39:45 ON 15 SEP 2004